Benzoyl peroxide (Dibenzoyl peroxide) [C14H10O4]

Page 1

Query Query

Results

Date

1 substances in Reaxys

2018-02-22 00h:00m:27s (EST)

O O

1. Query

O O

Search as: As drawn AND (IDE.XRN=984320)

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

1/162

2018-02-22 00:03:45


Reaxys ID 984320 View in Reaxys

1/1 CAS Registry Number: 94-36-0 Chemical Name: dibenzoyl peroxide; Dibenzoyl peroxide; dibenzoylperoxide; BENZOYL PEROXIDE Linear Structure Formula: [C6H5C(O)O]2 Molecular Formula: C14H10O4 Molecular Weight: 242.231 Type of Substance: isocyclic InChI Key: OMPJBNCRMGITSC-UHFFFAOYSA-N Note:

O O

O

O

Substance Label (36) Label References BPO

Sueishi, Yoshimi; Miyake, Yuzo; Bulletin of the Chemical Society of Japan; vol. 70; nb. 2; (1997); p. 397 403, View in Reaxys; Phanstiel IV; Wang; Powell; Ospina; Leeson; Journal of Organic Chemistry; vol. 64; nb. 3; (1999); p. 803 - 806, View in Reaxys; Ho, Zwei-Chang; Livant, Peter; Lott, William B.; Webb, Thomas R.; Journal of Organic Chemistry; vol. 64; nb. 22; (1999); p. 8226 - 8235, View in Reaxys; Yang, Zhixiang; Kitano, Yoshikazu; Chiba, Kazuhiro; Shibata, Naohiro; Kurokawa, Hiroshi; Doi, Yohei; Arakawa, Yoshichika; Tada, Masahiro; Bioorganic and Medicinal Chemistry; vol. 9; nb. 2; (2001); p. 347 - 356, View in Reaxys; Guo, Hongyan; Naser, Saleh A.; Ghobrial, George; Phanstiel IV, Otto; Journal of Medicinal Chemistry; vol. 45; nb. 10; (2002); p. 2056 - 2063, View in Reaxys; Andruzzi, Luisa; Chiellini, Emo; Galli, Giancarlo; Li, Xuefa; Kang, Seok H.; Ober, Christopher K.; Journal of Materials Chemistry; vol. 12; nb. 6; (2002); p. 1684 - 1692, View in Reaxys; Sueishi; Yoshioka; Takemoto; Kotake; Zeitschrift fur Physikalische Chemie; vol. 216; nb. 11; (2002); p. 1353 - 1360, View in Reaxys; Nemchik, Anne; Badescu, Valentina; Phanstiel IV, Otto; Tetrahedron; vol. 59; nb. 24; (2003); p. 4315 - 4325, View in Reaxys; Higaki, Yuji; Otsuka, Hideyuki; Endo, Takeshi; Takahara, Atsushi; Macromolecules; vol. 36; nb. 5; (2003); p. 1494 1499, View in Reaxys; Moorhoff, Cornelis M.; Braybrook, Carl; Journal of Chemical Research, Miniprint; nb. 3; (2003); p. 339 - 361, View in Reaxys; Luo, Ning; Metters, Andrew T.; Hutchison, J. Brian; Bowman, Christopher N.; Anseth, Kristi S.; Macromolecules; vol. 36; nb. 18; (2003); p. 6739 - 6745, View in Reaxys; McNulty, James; Capretta, Alfredo; Laritchev, Vladimir; Dyck, Jeff; Robertson, Al J.; Angewandte Chemie - International Edition; vol. 42; nb. 34; (2003); p. 4051 - 4054, View in Reaxys; Gardner, Richard A.; Ghobrial, George; Naser, Saleh A.; Phanstiel IV, Otto; Journal of Medicinal Chemistry; vol. 47; nb. 20; (2004); p. 4933 - 4940, View in Reaxys; Li, Dejin; Sheng, Xia; Zhao, Bin; Journal of the American Chemical Society; vol. 127; nb. 17; (2005); p. 6248 - 6256, View in Reaxys; Galli; Martinelli; Chiellini; Ober; Glisenti; Molecular Crystals and Liquid Crystals; vol. 441; (2005); p. 211 - 226, View in Reaxys; Ghani, Mohmad Asri Abd; Abdallah, Dalia; Kazmaier, Peter M.; Keoshkerian, Barkev; Buncel, Erwin; Canadian Journal of Chemistry; vol. 82; nb. 9; (2004); p. 1403 - 1412, View in Reaxys; He, Tao; Li, Dejin; Sheng, Xia; Zhao, Bin; Macromolecules; vol. 37; nb. 9; (2004); p. 3128 - 3135, View in Reaxys; Achilias, Dimitris S.; Sideridou, Irini D.; Macromolecules; vol. 37; nb. 11; (2004); p. 4254 - 4265, View in Reaxys; Sessions, Laura B.; Miinea, Liliana A.; Ericson, Kjell D.; Glueck, David S.; Grubbs, Robert B.; Macromolecules; vol. 38; nb. 6; (2005); p. 2116 - 2121, View in Reaxys; Bhasin, Gayatri; Kauser, Hina; Athar, Mohammad; Archives of Toxicology; vol. 78; nb. 3; (2004); p. 139 - 146, View in Reaxys; Hsueh, Mao-Lin; Huang, Bor-Hunn; Wu, Jincai; Lin, Chu-Chieh; Macromolecules; vol. 38; nb. 23; (2005); p. 9482 - 9487, View in Reaxys; Fennell, Kelley A.; Miller, Marvin J.; Organic Letters; vol. 9; nb. 9; (2007); p. 1683 - 1685, View in Reaxys; Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys; Arora, Jasbir Singh; Kaur, Navneet; Phanstiel IV, Otto; Journal of Organic Chemistry; vol. 73; nb. 16; (2008); p. 6182 6186, View in Reaxys; Ansong, Omari E.; Jansen, Susan; Wei, Yen; Pomrink, Gregory; Lu, Hui; Li, Shuxi; Guo, Yi; Journal of Materials Chemistry; vol. 17; nb. 42; (2007); p. 4499 - 4507, View in Reaxys; Furmick, Julie K.; Kaneko, Ichiro; Walsh, Angela N.; Yang, Joanna; Bhogal, Jaskaran S.; Gray, Geoffrey M.; Baso, Juan C.; Browder, Drew O.; Prentice, Jessica L.S.; Montano, Luis A.; Huynh, Chanh C.; Marcus, Lisa M.; Tsosie, Dorian G.; Kwon, Jungeun S.; Quezada, Alexis; Reyes, Nicole M.; Lemming, Brittney; Saini, Puneet; vanderVaart, Arjan; Groy, Thomas L.; Marshall, Pamela A.; Jurutka, Peter W.; Wagner, Carl E.; ChemMedChem; vol. 7; nb. 9; (2012); p. 1551 - 1566, View in Reaxys; Sakaguchi, Toshikazu; Sato, Miki; Hashimoto, Tamotsu; Polymer (United Kingdom); vol. 54; nb. 9; (2013); p. 2272 - 2277, View in Reaxys; Mashiach, Roi; Meijler, Michael M.; Organic Letters; vol. 15; nb. 7; (2013); p. 1702 - 1705, View in Reaxys; Kuo, Cheng-Yu; Huang, Yu-Chen; Hsiow, Chuen-Yo; Yang, Yu-Wen; Huang, Ching-I; Rwei, Syang-Peng; Wang, Hsing-Lin; Wang, Leeyih; Macromolecules; vol. 46; nb. 15; (2013); p. 5985 5997, View in Reaxys; Patent; DIGNITY SCIENCES LIMITED; COUGHLAN, Dave; DOWNES, Bill; CLIMAX, John; MANKU, Mehar; WO2013/124479; (2013); (A1) English, View in Reaxys; Tsuchiya, Daisuke; Kawagoe, Yuhsuke; Moriyama, Katsuhiko; Togo, Hideo; Organic Letters; vol. 15; nb. 16; (2013); p. 4194 4197, View in Reaxys; Kaiser, Manuel; Leitner, Sebastian P.; Hirtenlehner, Christa; List, Manuela; Gerisch, Alexander; Monkowius, Uwe; Dalton Transactions; vol. 42; nb. 41; (2013); p. 14749 - 14756, View in Reaxys; Shahrisa, Aziz; Safa, Kazem Dindar; Esmati, Somayeh; Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy; vol. 117; (2014); p. 614 - 621, View in Reaxys; Desbois, Andrew P.; Lawlor, Keelan C.; Marine Drugs; vol. 11; nb. 11; (2013); p. 4544 - 4557, View in Reaxys; Peng, HuiQing; Xu, Jiang-Fei; Chen, Yu-Zhe; Wu, Li-Zhu; Tung, Chen-Ho; Yang, Qing-Zheng; Chemical Communications; vol. 50; nb. 11; (2014); p. 1334 - 1337, View in Reaxys; Patent; NOVARTIS AG; BEHNKE, Dirk; CARCACHE, David; ERTL, Peter; KOLLER, Manuel; ORAIN, David; WO2014/30128; (2014); (A1) English, View in Reaxys; Singleton, Michael L.; Castellucci, Nicola; Massip, Stephane; Kauffmann, Brice; Fer-

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

2/162

2018-02-22 00:03:45


rand, Yann; Huc, Ivan; Journal of Organic Chemistry; vol. 79; nb. 5; (2014); p. 2115 - 2122, View in Reaxys; Qiu, Di; Meng, He; Jin, Liang; Tang, Shengbo; Wang, Shuai; Mo, Fangyang; Zhang, Yan; Wang, Jianbo; Organic Syntheses; vol. 91; (2014); p. 106 - 115, View in Reaxys; Qu, Wei; Zhu, Xingqi; Chen, Jiahui; Niu, Lin; Liang, Dehai; Fan, Xinghe; Shen, Zhihao; Zhou, Qifeng; Macromolecules; vol. 47; nb. 8; (2014); p. 2727 - 2735, View in Reaxys; Wang, Jianhong; Gan, Ying; Li, Shaobin; Luo, Tianwei; Zhang, Yahong; Zhao, Jin; Medicinal Chemistry Research; vol. 23; nb. 4; (2014); p. 2106 - 2112, View in Reaxys; Yuan, Chan'E; Zhang, Ming Qiu; Rong, Min Zhi; Journal of Materials Chemistry A; vol. 2; nb. 18; (2014); p. 6558 - 6566, View in Reaxys; He, Minghui; Jiang, Shun; Xu, Ruixin; Yang, Jianwen; Zeng, Zhaohua; Chen, Guangxue; Journal of Polymer Science, Part A: Polymer Chemistry; vol. 52; nb. 11; (2014); p. 1560 - 1569, View in Reaxys; Gao, Min; Wang, Zhijian; Jia, Xinru; Supramolecular Chemistry; vol. 26; nb. 5-6; (2014); p. 435 - 441, View in Reaxys; Tang, Shi; Zhou, Dong; Wang, Ying-Chun; European Journal of Organic Chemistry; vol. 2014; nb. 17; (2014); p. 3656 - 3661, View in Reaxys; Zhang, Zhi-Jing; Quan, Xue-Jing; Ren, Zhi-Hui; Wang, Yao-Yu; Guan, Zheng-Hui; Organic Letters; vol. 16; nb. 12; (2014); p. 3292 - 3295, View in Reaxys; Gao, Yuting; Qu, Yi; Jiang, Tao; Zhang, Hao; He, Nannan; Li, Bo; Wu, Junchen; Hua, Jianli; Journal of Materials Chemistry C; vol. 2; nb. 31; (2014); p. 6353 - 6361, View in Reaxys; Peng, HuiQing; Sun, Cai-Li; Xu, Jiang-Fei; Niu, Li-Ya; Chen, Yu-Zhe; Wu, Li-Zhu; Tung, Chen-Ho; Yang, QingZheng; Chemistry--A European Journal; vol. 20; nb. 37; (2014); p. 11699 - 11702,4, View in Reaxys; Storch, Jan; Zadny, Jaroslav; Strasak, Tomas; Kubala, Martin; Sykora, Jan; Dusek, Michal; Cirkva, Vladimir; Matejka, Pavel; Krbal, Milos; Vacek, Jan; Chemistry - A European Journal; vol. 21; nb. 6; (2015); p. 2343 2347, View in Reaxys; Chen, Zhaolai; Liu, Fangyuan; Zeng, Qingsen; Cheng, Zhongkai; Du, Xiaohang; Jin, Gan; Zhang, Hao; Yang, Bai; Journal of Materials Chemistry A; vol. 3; nb. 20; (2015); p. 10969 - 10975, View in Reaxys; Yin, Yan-Bing; Wang, Hui-Song; Yang, Yu-Lin; Fan, Rui-Qing; Dong, Guo-Hua; Wei, LiGuo; Chinese Chemical Letters; vol. 27; nb. 4; (2016); p. 613 - 618, View in Reaxys; Xu, Yuan-Yuan; Qian, An-Ran; Cao, Xu-Feng; Ling, Chen-Yu; Cao, Yong-Bing; Wang, Rui-Lian; Li, Yi-Su; Yang, Yu-She; Chinese Chemical Letters; vol. 27; nb. 5; (2016); p. 703 - 706, View in Reaxys; Li, Shen; Song, Run-Jiang; Wang, Dong-Hui; Tian, Xue; Shao, Xu-Sheng; Li, Zhong; Chinese Chemical Letters; vol. 27; nb. 5; (2016); p. 635 - 639, View in Reaxys; Li, Qian; Zhai, Yangyang; Luo, Wen; Zhu, Zixin; Zhang, Xin; Xie, Songqiang; Hong, Chen; Wang, Yuxia; Su, Yabin; Zhao, Jin; Wang, Chaojie; European Journal of Medicinal Chemistry; vol. 121; (2016); p. 110 - 119, View in Reaxys; Guan; Jia; Zhang; Ma; Lu; Lai; Lei; Dyes and Pigments; vol. 136; (2017); p. 873 - 880, View in Reaxys; Patent; Samsung Display Co., Ltd.; Jin, Haizhen; Han, Xiangxuan; Jin, Rongguo; Jin, Zhongyou; Huang, Xihuan; Jin, Henggen; (168 pag.); CN105481829; (2016); (A) Chinese, View in Reaxys; Manikandan, Chitrarasu; Ganesan, Kilivelu; Journal of Heterocyclic Chemistry; vol. 54; nb. 1; (2017); p. 503 - 508, View in Reaxys; Wang, Xiaobin; Huang, Wenqian; Wang, Qingyan; Liu, Chen; Wang, Chaopeng; Yang, Guiyan; Zhao, Chunjiang; Journal of Molecular Structure; vol. 1138; (2017); p. 6 - 11, View in Reaxys; Pan, Chongqing; Zhu, Zixi; Zhang, Mingkai; Gu, Zhenhua; Angewandte Chemie - International Edition; vol. 56; nb. 17; (2017); p. 4777 - 4781; Angew. Chem.; vol. 129; nb. 59; (2017); p. 4855 - 4859,5, View in Reaxys; Fujino, Shota; Yamaji, Minoru; Okamoto, Hideki; Mutai, Toshiki; Yoshikawa, Isao; Houjou, Hirohiko; Tani, Fumito; Photochemical and Photobiological Sciences; vol. 16; nb. 6; (2017); p. 925 - 934, View in Reaxys; Patent; DR. REDDY'S LABORATORIES LTD; PATIL, Sushil Kumar; SONI, Rajeev; VAISHNAV, Kaushalesh Kumar; (43 pag.); WO2017/109761; (2017); (A1) English, View in Reaxys; Patent; IMMUNE SENSOR, LLC; THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM; ZHONG, Boyu; SUN, Lijun; SHI, Heping; LI, Jing; CHEN, Chuo; CHEN, Zhijian; (270 pag.); WO2017/176812; (2017); (A1) English, View in Reaxys; Zhao, Baodong; Zhao, Weidong; Yu, Liujian; Li, Jie; Zhao, Yuming; Wang, Tao; New Journal of Chemistry; vol. 41; nb. 21; (2017); p. 13156 - 13165, View in Reaxys; Yadav, Arvind Kumar; Singh, Krishna Nand; New Journal of Chemistry; vol. 41; nb. 24; (2017); p. 14914 - 14917, View in Reaxys; Yu, Fei; Wang, Ting; Zhou, Huan; Li, Yajun; Zhang, Xinhao; Bao, Hongli; Organic Letters; vol. 19; nb. 24; (2017); p. 6538 - 6541, View in Reaxys 2a

Qian, Cheng; Lin, Dongen; Deng, Yuanfu; Zhang, Xiao-Qi; Jiang, Huanfeng; Miao, Guang; Tang, Xihao; Zeng, Wei; Organic and Biomolecular Chemistry; vol. 12; nb. 31; (2014); p. 5866 - 5875, View in Reaxys; Li, Dengke; Xu, Ning; Zhang, Yicheng; Wang, Lei; Chemical Communications; vol. 50; nb. 94; (2014); p. 14862 - 14865, View in Reaxys; Pan, Changduo; Zhang, Honglin; Han, Jie; Cheng, Yixiang; Zhu, Chengjian; Chemical Communications; vol. 51; nb. 18; (2015); p. 3786 - 3788, View in Reaxys; Terent'ev, Alexander O.; Vil', Vera A.; Gorlov, Evgenii S.; Nikishin, Gennady I.; Pivnitsky, Kasimir K.; Adam, Waldemar; Journal of Organic Chemistry; vol. 81; nb. 3; (2016); p. 810 - 823, View in Reaxys; Zhu, Hui; Teng, Fan; Pan, Changduo; Cheng, Jiang; Yu, Jin-Tao; Tetrahedron Letters; vol. 57; nb. 22; (2016); p. 2372 - 2374, View in Reaxys; Qian, Bo; Xiong, Haigen; Zhu, Nengbo; Ye, Changqing; Jian, Wujun; Bao, Hongli; Tetrahedron Letters; vol. 57; nb. 30; (2016); p. 3400 - 3403, View in Reaxys; Sun, Meng; Wang, Zhe; Wang, Jiaxin; Guo, Peiyu; Chen, Xiangxiang; Li, Ya-Min; Organic and Biomolecular Chemistry; vol. 14; nb. 45; (2016); p. 10585 - 10588, View in Reaxys; Zhu, Nengbo; Qian, Bo; Xiong, Haigen; Bao, Hongli; Tetrahedron Letters; vol. 58; nb. 43; (2017); p. 4125 - 4128, View in Reaxys

2

Patel, Darshan C.; Breitbach, Zachary S.; Woods, Ross M.; Lim, Yeeun; Wang, Andy; Foss, Frank W.; Armstrong, Daniel W.; Journal of Organic Chemistry; vol. 81; nb. 3; (2016); p. 1295 - 1299, View in Reaxys; Sharma; Utreja; Bedi; Asian Journal of Chemistry; vol. 28; nb. 10; (2016); p. 2153 - 2158, View in Reaxys; Kanemitsu, Takuya; Sato, Miho; Yoshida, Miyuki; Ozasa, Eisuke; Miyazaki, Michiko; Odanaka, Yuki; Nagata, Kazuhiro; Itoh, Takashi; Organic Letters; vol. 18; nb. 21; (2016); p. 5484 - 5487, View in Reaxys; Piras, Enrico; Secci, Francesco; Caboni, Pierluigi; Casula, Maria Francesca; Frongia, Angelo; RSC Advances; vol. 7; nb. 78; (2017); p. 49215 - 49219, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

3/162

2018-02-22 00:03:45


1a

Chen, Meng; Li, Yang; Tang, Hong; Ding, Hao; Wang, Kai; Yang, Lingen; Li, Cuiting; Gao, Meng; Lei, Aiwen; Organic Letters; vol. 19; nb. 12; (2017); p. 3147 - 3150, View in Reaxys

dbp

Ravat, Prince; Hinkelmann, Rahel; Steinebrunner, David; Prescimone, Alessandro; Bodoky, Ina; Juríček, Michal; Organic Letters; vol. 19; nb. 14; (2017); p. 3707 - 3710, View in Reaxys

1o

Pan, Changduo; Zhu, Jiawei; Chen, Rongzhen; Yu, Jin-Tao; Organic and Biomolecular Chemistry; vol. 15; nb. 31; (2017); p. 6467 - 6469, View in Reaxys

14

He, Benzhao; Wu, Yongwei; Qin, Anjun; Tang, Ben Zhong; Macromolecules; vol. 50; nb. 15; (2017); p. 5719 - 5728, View in Reaxys

1c

Zhu, Nengbo; Wang, Ting; Ge, Liang; Li, Yajun; Zhang, Xinhao; Bao, Hongli; Organic Letters; vol. 19; nb. 18; (2017); p. 4718 - 4721, View in Reaxys

2i

Li, Yougui; Han, Yulong; Xiong, Haigen; Zhu, Nengbo; Qian, Bo; Ye, Changqing; Kantchev, Eric Assen B.; Bao, Hongli; Organic Letters; vol. 18; nb. 3; (2016); p. 392 - 395, View in Reaxys

(PhCOO)2

Terentjeva, Svetlana; Muceniece, Dzintra; Petushkova, Jekaterina; Lusis, Viesturs; Journal of Chemical Research; vol. 40; nb. 4; (2016); p. 224 - 227, View in Reaxys

In.

Bahia, Samara Ben B. B.; Reis, Wallace J.; Jardim, Guilherme A. M.; Souto, Francielly T.; De Simone, Carlos A.; Gatto, Claudia C.; Menna-Barreto, Rubem F. S.; De Castro, Solange L.; Cavalcanti, Bruno C.; Pessoa, Claudia; Araujo, Maria H.; Da Silva Júnior, Eufrânio N.; MedChemComm; vol. 7; nb. 8; (2016); p. 1555 - 1563, View in Reaxys

9a

Yedage, Subhash L.; Bhanage, Bhalchandra M.; Green Chemistry; vol. 18; nb. 20; (2016); p. 5635 - 5642, View in Reaxys

BP

Opeida; Turovskii; Maksyuta; Russian Journal of Organic Chemistry; vol. 36; nb. 11; (2000); p. 1646 1649, View in Reaxys; Valacchi, Giuseppe; Rimbach, Gerald; Saliou, Claude; Weber, Stefan U; Packer, Lester; Toxicology; vol. 165; nb. 2-3; (2001); p. 225 - 234, View in Reaxys; Mosnacek, Jaroslav; Weiss, Richard G.; Lukac, Ivan; Macromolecules; vol. 35; nb. 10; (2002); p. 3870 - 3875, View in Reaxys; MacManus-Spencer, Laura A.; Edhlund, Betsy L.; McNeill, Kristopher; Journal of Organic Chemistry; vol. 71; nb. 2; (2006); p. 796 - 799, View in Reaxys; Waller; Dreher; Behnam; Ford; Lee; Tiet; Weinstein; Maibach; Skin Pharmacology and Physiology; vol. 19; nb. 5; (2006); p. 283 - 289, View in Reaxys; Shoinbekova; Nikitina; Moldagazyeva; Mukhitdinova; Ergozhin; Russian Journal of Applied Chemistry; vol. 78; nb. 12; (2005); p. 2010 - 2013, View in Reaxys; Islamova; Puzin; Kraikin; Fatykhov; Dzhemilev; Monakov; Russian Journal of Applied Chemistry; vol. 79; nb. 9; (2006); p. 1509 - 1513, View in Reaxys; Patent; CADILA HEALTHCARE LIMITED; Mittal, Ravindra; Roy, Sunilendu Bhushan; Kothari, Jay Shantilal; Sheikh, Shafiq; Patel, Jitendra Dasharathlal; Pancholi, Jinesh Suresh; US2013/337016; (2013); (A1) English, View in Reaxys; Serebryakova, Maria K.; Solomonov, Alexey V.; Rumyantsev, Evgeniy V.; Ivanov, Sergei P.; International Journal of Chemical Kinetics; vol. 47; nb. 1; (2015); p. 27 - 35, View in Reaxys; Murinov, Yu. I.; Grabovskiy, S. A.; Kuramshina, A. R.; Antipin, A. V.; Kabal'Nova, N. N.; Russian Journal of General Chemistry; vol. 85; nb. 1; (2015); p. 123 - 125; Zhurnal Obshchei Khimii; vol. 85; nb. 1; (2015); p. 132 134,3, View in Reaxys; Nasibullin; Safiullin; Sigaeva; Yakupova; Kolesov; Kinetics and Catalysis; vol. 56; nb. 1; (2015); p. 71 - 75; Kinet. Katal.; vol. 56; nb. 1; (2015); p. 77 - 81,5, View in Reaxys; Patent; Swenholt, Karen C.; US2015/320794; (2015); (A1) English, View in Reaxys

(PhCO&2%)&2%

Kojima, Hiroyuki; Takahata, Chisato; Lemin, David; Takahashi, Masato; Kumamoto, Takuya; Nakanishi, Waka; Suzuki, Noriyuki; Ishikawa, Tsutomu; Helvetica Chimica Acta; vol. 96; nb. 3; (2013); p. 379 388, View in Reaxys; Kisin-Finfer, Einat; Shabat, Doron; Bioorganic and Medicinal Chemistry; vol. 21; nb. 12; (2013); p. 3602 - 3608, View in Reaxys; Stopka, Tobias; Marzo, Leyre; Zurro, Mercedes; Janich, Simon; Würthwein, Ernst-Ulrich; Daniliuc, Constantin G.; Alemán, José; Mancheño, Olga García; Angewandte Chemie - International Edition; vol. 54; nb. 17; (2015); p. 5049 - 5053; Angew. Chem.; vol. 127; nb. 17; (2015); p. 5137 - 5141,5, View in Reaxys

(PhCOO)&2%

Braga, Saulo F.P.; Alves, Erika V.P.; Ferreira, Rafaela S.; Fradico, Jordana R.B.; Lage, Paula S.; Duarte, Mariana C.; Ribeiro, Tatiana G.; Junior, Policarpo A.S.; Romanha, Alvaro J.; Tonini, Maiko L.; Steindel, Mario; Coelho, Eduardo F.; De Oliveira, Renata B.; European Journal of Medicinal Chemistry; vol. 71; (2014); p. 282 - 289, View in Reaxys; Zhang, Xi-Sha; Zhang, Yun-Fei; Li, Zhao-Wei; Luo, Fei-Xian; Shi, Zhang-Jie; Angewandte Chemie - International Edition; vol. 54; nb. 18; (2015); p. 5478 - 5482; Angew. Chem.; vol. 127; nb. 18; (2015); p. 5568 - 5572,5, View in Reaxys

BzOOBz

Reeves, Jonathan T.; Lorenc, Chris; Camara, Kaddy; Li, Zhibin; Lee, Heewon; Busacca, Carl A.; Senanayake, Chris H.; Journal of Organic Chemistry; vol. 79; nb. 12; (2014); p. 5895 - 5902, View in Reaxys; Moore, Jane N.; Laskay, Nicholas M.; Duque, Kevin S.; Kelley, Steven P.; Rogers, Robin D.; Shaughnessy, Kevin H.; Journal of Organometallic Chemistry; vol. 777; (2015); p. 16 - 24, View in Reaxys

BPO; 3

Wang, Dehong; Xu, Changming; Zhang, Long; Luo, Sanzhon; Organic Letters; vol. 17; nb. 3; (2015); p. 576 - 579, View in Reaxys

DBP

Rickhaus, Michel; Bannwart, Linda Maria; Neuburger, Markus; Gsellinger, Heiko; Zimmermann, Kaspar; Häussinger, Daniel; Mayor, Marcel; Angewandte Chemie - International Edition; vol. 53; nb. 52; (2014); p. 14587 - 14591; Angew. Chem.; vol. 126; nb. 52; (2014); p. 14816 - 14820,5, View in Reaxys; See-

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

4/162

2018-02-22 00:03:45


tharamsingh; Ramesh, Remya; Dange, Santoshkumar S.; Khairnar, Pankaj V.; Singhal, Smita; Upadhyay, Dilip; Veeraraghavan, Sridhar; Viswanadha, Srikant; Vakkalanka, Swaroop; Reddy, D. Srinivasa; ACS Medicinal Chemistry Letters; vol. 6; nb. 11; (2015); p. 1105 - 1110, View in Reaxys 12

Zhu, Rong; Buchwald, Stephen L.; Journal of the American Chemical Society; vol. 137; nb. 25; (2015); p. 8069 - 8077, View in Reaxys

(PhCO2)2

Sefkow, Michael; Hoefle, Gerhard; Heterocycles; vol. 48; nb. 12; (1998); p. 2485 - 2488, View in Reaxys; Bottle, Steven E.; Micallef, Aaron S.; Organic and Biomolecular Chemistry; vol. 1; nb. 14; (2003); p. 2581 2584, View in Reaxys; Quek, Ser Kiang; Lyapkalo, Ilya M.; Huynh, Han Vinh; Synthesis; nb. 9; (2006); p. 1423 - 1426, View in Reaxys; Patent; NOGRA PHARMA LIMITED; HOMMES, Daan; VERHAAR, Auke; VAN DEN BRINK, Gijs; VITI, Francesa; WO2013/178816; (2013); (A1) English, View in Reaxys; Garcia-Rubin, Silvia; Gonzalez-Rodriguez, Carlos; Garcia-Yebra, Cristina; Varela, Jesus A.; Esteruelas, Miguel A.; Saa, Carlos; Angewandte Chemie - International Edition; vol. 53; nb. 7; (2014); p. 1841 - 1844; Angew. Chem.; vol. 53-126; nb. 7; (2014); p. 1872 - 1875, View in Reaxys

(BzO)&2%

Li, Xun; Jain, Nareshkumar; Russell, Ronald K.; Ma, Robert; Branum, Shawn; Xu, Jiayi; Sui, Zhihua; Organic Process Research and Development; vol. 10; nb. 2; (2006); p. 354 - 360, View in Reaxys; Bugera, Maksym Ya.; Tarasenko, Karen V.; Kukhar, Valery P.; Röschenthaler, Gerd-Volker; Gerus, Igor I.; Synthesis (Germany); vol. 45; nb. 22; (2013); p. 3157 - 3163; Art.No: SS-2013-T0354-OP, View in Reaxys; Zheng, Jun; You, Shu-Li; Angewandte Chemie - International Edition; vol. 53; nb. 48; (2014); p. 13244 13247; Angew. Chem.; vol. 126; nb. 48; (2014); p. 13460 - 13463,4, View in Reaxys

(PhCO)2O2

Wang, Fang; Sun, Jun-Rong; Huang, Mei-Yan; Wang, Hui-Ying; Sun, Ping-Hua; Lin, Jing; Chen, WeiMin; European Journal of Medicinal Chemistry; vol. 72; (2014); p. 35 - 45, View in Reaxys

2b

Chen, Zhi-Yuan; Ye, Chang-Qing; Zhu, Hui; Zeng, Xing-Ping; Yuan, Jian-Jun; Chemistry - A European Journal; vol. 20; nb. 15; (2014); p. 4237 - 4241, View in Reaxys

Bz&2%O&2%

Hong, Jun Bae; Davidson, James P.; Jin, Qingwu; Lee, Gary R.; Matchett, Michael; O'Brien, Erin; Welch, Michael; Bingenheimer, Bill; Sarma, Keshab; Organic Process Research and Development; vol. 18; nb. 1; (2014); p. 228 - 238, View in Reaxys; Kotha, Sambasivarao; Meshram, Milind; Synthesis (Germany); vol. 46; nb. 11; (2014); p. 1525 - 1531; Art.No: SS-2014-Z0002-OP, View in Reaxys

E-BPO

Patent; SOL-GEL TECHNOLOGIES LTD.; SERTCHOOK, Hanan; TOLEDANO, Ofer; BAR-SIMANTOV, Haim; WO2014/83557; (2014); (A1) English, View in Reaxys

DBPO

Reichardt, Christian; Schroeder, Joerg; Voehringer, Peter; Schwarzer, Dirk; Physical Chemistry Chemical Physics; vol. 10; nb. 12; (2008); p. 1662 - 1668, View in Reaxys; Lennartz, Petra; Raabe, Gerhard; Bolm, Carsten; Advanced Synthesis and Catalysis; vol. 354; nb. 17; (2012); p. 3237 - 3249, View in Reaxys; Schmidt, Bernd M.; Topolinski, Berit; Yamada, Mihoko; Higashibayashi, Shuhei; Shionoya, Mitsuhiko; Sakurai, Hidehiro; Lentz, Dieter; Chemistry - A European Journal; vol. 19; nb. 41; (2013); p. 13872 13880, View in Reaxys

(PhCO)&2%O&2 %

Zhang, Xin; Li, Ridong; Qiao, Kang; Ge, Zemei; Zhang, Liangren; Cheng, Tieming; Li, Runtao; Archiv der Pharmazie; vol. 346; nb. 1; (2013); p. 44 - 52, View in Reaxys

Bz&2%O&3%

Reber, Keith P.; Tilley, S. David; Carson, Cheryl A.; Sorensen, Erik J.; Journal of Organic Chemistry; vol. 78; nb. 19; (2013); p. 9584 - 9607, View in Reaxys

(BzO)2

Yang, Dexi; Micalizio, Glenn C.; Journal of the American Chemical Society; vol. 134; nb. 37; (2012); p. 15237 - 15240, View in Reaxys

PS-36

Patent; RHODIA CHIMIE; US2008/287562; (2008); (A1) English, View in Reaxys

Bz2O2

Clark, Andrew J.; Deeth, Robert J.; Samuel, Christopher J.; Wongtap, Hathaichanuk; Synlett; nb. 4; (1999); p. 444 - 446, View in Reaxys; Nowak, Ireneusz; Rogers, Lillian M.; Rogers, Robin D.; Thrasher, Joseph S.; Journal of Fluorine Chemistry; vol. 99; nb. 1; (1999); p. 73 - 81, View in Reaxys; Clark, Andrew J.; Al-Faiyz, Yassair S.S.; Broadhurst, Michael J.; Patel, Divya; Peacock, Joanne L.; Journal of the Chemical Society, Perkin Transactions 1; nb. 7; (2000); p. 1117 - 1127, View in Reaxys; Jang, Yeong-Jiunn; Wu, Jhenyi; Lin, Yung-Feng; Yao, Ching-Fa; Tetrahedron; vol. 60; nb. 31; (2004); p. 6565 - 6574, View in Reaxys

I

Turovskii; Opeida; Kushch; Russian Journal of Organic Chemistry; vol. 39; nb. 5; (2003); p. 642 - 645, View in Reaxys

18

Ahn, Chuljin; Correia, Reuben; DeShong, Philip; Journal of Organic Chemistry; vol. 67; nb. 6; (2002); p. 1751 - 1753, View in Reaxys

4

Adam, Waldemar; Grimm, Guenther N.; Saha-Moeller, Chantu R.; Dall'Acqua, Francesco; Miolo, Gorgia; Vedaldi, Daniela; Chemical Research in Toxicology; vol. 11; nb. 9; (1998); p. 1089 - 1097, View in Reaxys; Martinez, Alicia; Urios, Amparo; Blanco, Manuel; Mutation Research - Genetic Toxicology and Environmental Mutagenesis; vol. 467; nb. 1; (2000); p. 41 - 53, View in Reaxys

BZP

Babich; Zuckerbraun; Wurzburger; Rubin; Borenfreund; Blau; Toxicology; vol. 106; nb. 1-3; (1996); p. 187 - 196, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

5/162

2018-02-22 00:03:45


BzPO

Matsui; Mintz; DeLeo; Skin Pharmacology; vol. 8; nb. 3; (1995); p. 130 - 138, View in Reaxys

Patent-Specific Data (7) Prophetic ComLocation in Patent References pound Page/Page column

Patent; DOW AGROSCIENCES LLC; Lowe, Christian T.; Trullinger, Tony K.; Hunter, Ricky; US2012/220453; (2012); (A1) English, View in Reaxys; Patent; Odorisio, Paul; Andrews, Stephen M.; Thompson, Thomas F.; Wu, Si; Thanki, Paragkumar; Rane, Deepak M.; Joseph, Delina; Wang, Jianzhao; US2013/35451; (2013); (A1) English, View in Reaxys; Patent; BioMarin Pharmaceutical, Inc.; Wang, Bing; Chu, Daniel; US2013/53365; (2013); (A1) English, View in Reaxys; Patent; HANMI SCIENCE CO., LTD.; CATHOLIC UNIVERSITY INDUSTRY ACADEMIC COOPERATION FOUNDATION; KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY; Son, Jung Beom; Jung, Seung Hyun; Choi, Wha ll; Jung, Young Hee; Choi, Jae Yul; Song, Ji Yeon; Lee, Kyu Hang; Lee, Jae Chul; Kim, Eun Young; Ahn, Young Gil; Kim, Maeng Sup; Choi, Hwan Geun; Sim, Tae Bo; Ham, Young Jin; Park, Dong-sik; Kim, Hwan; Kim, Dong-Wook; US2013/53370; (2013); (A1) English, View in Reaxys; Patent; EISAI RandD MANAGEMENT CO., LTD.; YOSHIDA, Ichiro; OKABE, Tadashi; MATSUMOTO, Yasunobu; WATANABE, Nobuhisa; ONIZAWA, Yuji; OHASHI, Yoshiaki; HARADA, Hitoshi; US2013/65925; (2013); (A1) English, View in Reaxys; Patent; Gruenenthal GmbH; FRANK, Robert; Bahrenberg, Gregor; Christoph, Thomas; Lesch, Bernhard; Lee, Jeewoo; US2013/79320; (2013); (A1) English, View in Reaxys; Patent; GALDERMA RESEARCH and DEVELOPMENT; Rodeville, Nicolas; Pascal, Jean-Claude; Bouix-Peter, Claire; US2013/79544; (2013); (A1) English, View in Reaxys; Patent; Incyte Corporation; Huang, Taisheng; Feng, Hao; Kong, Lingquan; Wang, Anlai; Ye, Hai Fen; US2013/96144; (2013); (A1) English, View in Reaxys; Patent; Curis, Inc.; Bao, Rudi; Lai, Chengjung; Qian, Changgeng; US2013/102595; (2013); (A1) English, View in Reaxys; Patent; PFIZER INC.; DOROSKI, Matthew David; MADERNA, Andreas; O'DONNELL, Christopher John; SUBRAMANYAM, Chakrapani; VETELINO, Beth; DUSHIN, Russell George; STROP, Pavel; GRAZIANI, Edmund Idris; US2013/129753; (2013); (A1) English, View in Reaxys; Patent; The Regents of the University of Colorado, a body corporated; Wang, Xiang; Xu, Wenqing; US2013/137720; (2013); (A1) English, View in Reaxys; Patent; EISAI RandD MANAGEMENT CO., LTD.; Norimine, Yoshihiko; Takeda, Kunitoshi; Hagiwara, Koji; Suzuki, Yuichi; Ishihara, Yuki; Sato, Nobuaki; US2013/143907; (2013); (A1) English, View in Reaxys; Patent; Conn, P. Jeffrey; Lindsley, Craig W.; Stauffer, Shaun R.; Bartolomé-Nebreda, José Manuel; MacDonald, Gregor James; Conde-Ceide, Susana; Jones, Carrie K.; Luz Martín-Martín, María; Tong, Han Min; US2013/245043; (2013); (A1) English, View in Reaxys; Patent; RVX Therapeutics Inc.; McLure, Kevin G.; Young, Peter R.; US2013/281399; (2013); (A1) English, View in Reaxys; Patent; Babaoglu, Kerim; Brizgys, Gediminas; Cha, Jake; Chen, Xiaowu; Guo, Hongyan; Halcomb, Randall L.; Han, Xiaochun; Huang, Richard; Liu, Hongtao; McFadden, Ryan; Mitchell, Michael L.; Qi, Yingmei; Roethle, Paul A.; Xu, Lianhong; Yang, Hong; US2013/281433; (2013); (A1) English, View in Reaxys; Patent; NOVARTIS AG; Cotesta, Simona; Furet, Pascal; Guagnano, Vito; Holzer, Philipp; Kallen, Joerg; Mah, Robert; Masuya, Keiichi; Schlapbach, Achim; Stutz, Stefan; Vaupel, Andrea; US2013/317024; (2013); (A1) English, View in Reaxys; Patent; NOVARTIS AG; Bock, Mark Gary; Gaul, Christoph; Gummadi, Venkateshwar Rao; Moebitz, Henrik; Sengupta, Saumitra; US2014/45872; (2014); (A1) English, View in Reaxys; Patent; Gavai, Ashvinikumar V.; DeLucca, George V.; O'Malley, Daniel; Gill, Patrice; Quesnelle, Claude A.; Fink, Brian E.; Zhao, Yufen; Lee, Francis Y.; US2014/87992; (2014); (A1) English, View in Reaxys; Patent; Arrington, Kenneth L.; Burgey, Christopher; Gilfillan, Robert; Han, Yongxin; Patel, Mehul; Li, Chun Sing; Li, Yaozong; Luo, Yunfu; Lei, Zhiyu; US2014/100231; (2014); (A1) English, View in Reaxys; Patent; LEWIS, Richard T.; ALLEN, Jennifer R.; CHENG, Yuan; CHOQUETTE, Deborah; EPSTEIN, Oleg; GUZMAN-PEREZ, Angel; HARRINGTON, Paul E.; HUA, Zihao; HUNGATE, Randall W.; HUMAN, Jason Brooks; JUDD, Ted; LIU, Qingyian; LOPEZ, Patricia; MINATTI, Ana Elena; OLIVIERI, Philip; ROMERO, Karina; RUMFELT, Shannon; RZASA, Robert M.; SCHENKEL, Laurie; STELLWAGEN, John; WHITE, Ryan; XUE, Qiufen; ZHENG, Xiao; ZHONG, Wenge; US2014/107109; (2014); (A1) English, View in Reaxys; Patent; CHIESI FARMACEUTICI S.p.A.; Armani, Elisabetta; Amari, Gabriele; Riccaboni, Mauro; Rizzi, Andrea; Baker-Glenn, Charles; Blackaby, Wesley; Van de Poel, Herve'; Whittaker, Ben; US2014/155427; (2014); (A1) English, View in Reaxys; Patent; Chiesi Farmaceutici S.p.A.; RANCATI, Fabio; Linney, Ian; Knight, Chris; Schmidt, Wolfgang; US2014/163066; (2014); (A1) English, View in Reaxys; Patent; Borealis AG; Resconi, Luigi; Castro, Pascal; Virkkunen, Ville; Izmer, Vyatcheslav V; Kononovich, Dimitry S.; Kulyabin, Pavel Sergeevich; Voskoboynikov, Alexander Z.; EP2746301; (2014); (A1) English, View in Reaxys; Patent; Meiji Seika Pharma Co., Ltd.; NAKANISHI Nozomu; FUKUDA Yoshimasa; KITSUDA Shigeki; OHNO Ikuya; EP2749555; (2014); (A1) English, View in Reaxys; Pat-

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

6/162

2018-02-22 00:03:45


ent; THE REGENTS OF THE UNIVERSITY OF MICHIGAN; Wang, Shaomeng; Chen, Jianfang; McEachern, Donna; Bai, Longchuan; Liu, Liu; Sun, Duxin; Li, Xiaoqin; Aguilar, Angelo; US2014/199234; (2014); (A1) English, View in Reaxys; Patent; Eisai RandD Management Co., Ltd.; YOSHIDA Ichiro; OKABE Tadashi; MATSUMOTO Yasunobu; WATANABE Nobuhisa; OHASHI Yoshiaki; ONIZAWA Yuji; HARADA Hitoshi; EP2757103; (2014); (A1) English, View in Reaxys; Patent; Maisch, Tim; Späth, Andreas; US2014/212459; (2014); (A1) English, View in Reaxys; Patent; Dow AgroSciences LLC; Eckelbarger, Joseph D.; Epp, Jeffrey B.; Fischer, Lindsey G.; Lowe, Christian T.; Petkus, Jeff; Roth, Joshua; Satchivi, Norbert M.; Schmitzer, Paul R.; Siddall, Thomas L.; US2014/274701; (2014); (A1) English, View in Reaxys; Patent; DIC CORPORATION; Tojo, Kenta; Takeuchi, Kiyofumi; Osawa, Masashi; Kaneoya, Masakazu; Kusumoto, Tetsuo; US2014/275577; (2014); (A1) English, View in Reaxys; Patent; Beijing Medisan Technology Co. Ltd.; WANG, Mingxin; LIU, Jinai; YANG, Fan; WANG, Ailing; SUN, Jiguo; WANG, Yan; CUI, Jin; JI, Lei; EP2784077; (2014); (A1) English, View in Reaxys; Patent; Council of Scientific and Industrial Research; Reddy, Dumbala Srinivasa; Balamkundu, Seetharam Singh; Ramesh, Remya; US2014/296133; (2014); (A1) English, View in Reaxys; Patent; CandC RESEARCH LABORATORIES; Ho, Pil Su; Yoon, Dong Oh; Han, Sun Young; Lee, Won Il; Kim, Jung Sook; Park, Woul Seong; Ahn, Sung Oh; Kim, Hye Jung; US2014/315888; (2014); (A1) English, View in Reaxys; Patent; KBP Biosciences Co., Ltd.; ZHANG, Yan; ZHANG, Min; LO, HoYin; (52 pag.); EP2781508; (2014); (A1) English, View in Reaxys; Patent; UNIVERSITA DEGLI STUDI DI FERRARA; Balzarini, Jan; Dehaen, Wim; Thomas, Joice; Liekens, Sandra; Romagnoli, Romeo; Baraldi, Pier Giovanni; US2015/126559; (2015); (A1) English, View in Reaxys; Patent; BAYER PHARMA AKTIENGESELLSCHAFT; Fürstner, Chantal; Ackerstaff, Jens; Straub, Alexander; Meier, Heinrich; Tinel, Hanna; Zimmermann, Katja; Tersteegen, Adrian; Zubov, Dmitry; Kast, Raimund; Schamberger, Jens; Schäfer, Martina; Börngen, Kirsten; US2015/148340; (2015); (A1) English, View in Reaxys; Patent; CHIESI FARMACEUTICI S.p.A.; Biagetti, Matteo; Capelli, Anna Maria; Accetta, Alessandro; Carzaniga, Laura; US2015/166549; (2015); (A1) English, View in Reaxys; Patent; Lantheus Medical Imaging, Inc.; Cesati, Richard R.; Radeke, Heike S.; Pandey, Suresh K.; Purohit, Ajay; Robinson, Simon P.; US2015/196672; (2015); (A1) English, View in Reaxys Claim

Patent; Norac Pharma; US2012/64135; (2012); (A1) English, View in Reaxys; Patent; PEKING UNIVERSITY; US2012/184768; (2012); (A1) English, View in Reaxys; Patent; Peking University; EP2481742; (2012); (A1) English, View in Reaxys; Patent; Glenmark Generics Limited; US2012/252897; (2012); (A1) English, View in Reaxys Patent; SYNTOPIX LIMITED; WO2006/100495; (2006); (A1) English, View in Reaxys Patent; Dainippon Sumitomo Pharma Co., Ltd.; AstraZeneca AB; EP1728792; (2006); (A1) English, View in Reaxys Patent; BP CORPORATION NORTH AMERICA INC.; WO2003/91195; (2003); (A1) English, View in Reaxys

prophetic product

Patent; The Procter and Gamble Company; US6338855; (2002); (B1) English, View in Reaxys; Patent; Yu, Ruey J.; Van Scott, Eugene J.; US6335023; (2002); (B1) English, View in Reaxys

prophetic catalyst

Patent; Eastman Chemical Company; US6348623; (2002); (B2) English, View in Reaxys

Druglikeness (1) 1 of 1

LogP

3.32

H Bond Donors

0

H Bond Acceptors

4

Rotatable Bonds

5

TPSA

52.6

Lipinski Number

4

Veber Number

2

Highest Clinical Phase (1) Highest Clinical Phase Marketed Related Structure (2) Related Structure References

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

7/162

2018-02-22 00:03:45


Lee; Minoura; Journal of the Chemical Society, Faraday Transactions 1: Physical Chemistry in Condensed Phases; vol. 74; (1978); p. 1726,1729,1731-1733, View in Reaxys Constitution.

Willstaetter; Hauenstein; Chemische Berichte; vol. 42; (1909); p. 1850, View in Reaxys

Catalyst Investigation (3) 1 of 3

Investigated characteris- Catalytic activity tic(s) Kotha, Sambasivarao; Meshram, Milind; Synthesis (Germany); vol. 46; nb. 11; (2014); p. 1525 - 1531; Art.No: SS-2014-Z0002-OP, View in Reaxys; Wang, Yaxin; Li, Guo-Xing; Yang, Guohui; He, Gang; Chen, Gong; Chemical Science; vol. 7; nb. 4; (2016); p. 2679 - 2683, View in Reaxys; Gobbi, Silvia; Hu, Qingzhong; Zimmer, Christina; Engel, Matthias; Belluti, Federica; Rampa, Angela; Hartmann, Rolf W.; Bisi, Alessandra; Journal of Medicinal Chemistry; vol. 59; nb. 6; (2016); p. 2468 - 2477, View in Reaxys

2 of 3

Investigated characteris- Catalytic activity tic(s) Type of reaction (Catalyst Investigation)

Annulation

Pan, Changduo; Huang, Bifan; Hu, Weiming; Feng, Xiaomei; Yu, Jin-Tao; Journal of Organic Chemistry; vol. 81; nb. 5; (2016); p. 2087 - 2093, View in Reaxys 3 of 3

Investigated characteris- Catalytic activity tic(s) Location

Paragraph 0071

Patent; Gao Tingmei; Gao, Tingmei; (9 pag.); CN105481767; (2016); (A) Chinese, View in Reaxys Derivative (3) Comment (Derivative) Mol.Komplex 1:1 mit Piperidin in DMF; K (9-24grad, potentiometrisch)

References Vartapetyan et al.; Russian Journal of Physical Chemistry; vol. 47; (1973); p. 774; ; p. 1351, View in Reaxys

Komplex (1:1) mit Vartapetyan; Khachatryan; Uchenye Zapiski, Erevanskii Gosudarstvennyi Universitet; vol. 2; (1973); p. 1,4-Dipiperid-yl-2- 50,51-54; Chem.Abstr.; vol. 81; nb. 151933e; Chem. Zentralbl.; 1974, Nr.8, B119B, View in Reaxys Me-buten-2 K(Stab.): Spektrophotometr., nur i.Orig. bei 9-20grad -> ΔH(Standard), ΔS(Standard), vorausgesetzt Bindung von -OO- zu freien El.Paaren des Piperidins Komplex (1:1) mit Vartapetyan; Khachatryan; Uchenye Zapiski, Erevanskii Gosudarstvennyi Universitet; vol. 2; (1973); p. 1-Piperid-yl-250,51-54; Chem.Abstr.; vol. 81; nb. 151933e; Chem. Zentralbl.; 1974, Nr.8, B119B, View in Reaxys Cl-3-Me-5-MeObuten-2 K(Stab.): Spektrophotometr., nur i.Orig. bei 9-20grad -> ΔH(Standard), ΔS(Standard), vorausgesetzt Bindung von -OO- zu freien El.Paaren des Piperidins Melting Point (38) 1 of 38

Melting Point [°C]

107.84

Solvent (Melting Point)

methanol

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

8/162

2018-02-22 00:03:45


Nasibullin; Safiullin; Sigaeva; Yakupova; Kolesov; Kinetics and Catalysis; vol. 56; nb. 1; (2015); p. 71 - 75; Kinet. Katal.; vol. 56; nb. 1; (2015); p. 77 - 81,5, View in Reaxys 2 of 38

Melting Point [°C]

108

Solvent (Melting Point)

methanol

Comment (Melting Point)

Decomposition

Islamova; Puzin; Kraikin; Fatykhov; Dzhemilev; Monakov; Russian Journal of Applied Chemistry; vol. 79; nb. 9; (2006); p. 1509 - 1513, View in Reaxys 3 of 38

Melting Point [°C]

106 - 108

Solvent (Melting Point)

methanol

Shoinbekova; Nikitina; Moldagazyeva; Mukhitdinova; Ergozhin; Russian Journal of Applied Chemistry; vol. 78; nb. 12; (2005); p. 2010 - 2013, View in Reaxys 4 of 38

Melting Point [°C]

108

Solvent (Melting Point)

methanol

Yumagulova; Kolesov; Monakov; Russian Journal of Applied Chemistry; vol. 78; nb. 2; (2005); p. 291 - 294, View in Reaxys 5 of 38

Melting Point [°C]

104

Solvent (Melting Point)

ethanol

Achilias, Dimitris S.; Sideridou, Irini D.; Macromolecules; vol. 37; nb. 11; (2004); p. 4254 - 4265, View in Reaxys 6 of 38

Melting Point [°C]

107

Solvent (Melting Point)

methanol

Puzin, Yu.I.; Leplyanin, G.V.; Kozheparova, E.A.; Tolstikov, G.A.; Doklady Chemistry; vol. 320; nb. 1-3; (1991); p. 251 - 253; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 320; nb. 2; (1991); p. 349 - 352, View in Reaxys; Puzin, Yu. I.; Leplyanin, G.V.; Muslikhov, R.R.; Tolstikov, G.A.; Doklady Chemistry; vol. 320; nb. 1-3; (1991); p. 277 - 281; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 320; nb. 3; (1991); p. 638 - 642, View in Reaxys; Puzin, Yu. I.; Leplyanin, G. V.; Spirikhin, L. V.; Parmenova, I. P.; Muslukhov, R. M.; Tolstikov, G. A.; Doklady Chemistry; vol. 279; (1984); p. 422 - 426; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 279; nb. 3; (1984); p. 646 - 650, View in Reaxys 7 of 38

Melting Point [°C]

106 - 107

Solvent (Melting Point)

CHCl3; methanol

Comment (Melting Point)

Decomposition

Auricchio, Sergio; Citterio, Attilio; Sebastiano, Roberto; Journal of Organic Chemistry; vol. 55; nb. 26; (1990); p. 6312 - 6316, View in Reaxys 8 of 38

Melting Point [°C]

107.5

Solvent (Melting Point)

methanol

Puzin, Yu. I.; Leplyanin, G. V.; Rafikov, S. R.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); vol. 33; (1984); p. 1892 - 1895; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; nb. 9; (1984); p. 2073 - 2076, View in Reaxys 9 of 38

Melting Point [°C]

105 - 106

Tanner et al.; Canadian Journal of Chemistry; vol. 48; (1970); p. 1492,1496, View in Reaxys; Bolton et al.; Journal of Fluorine Chemistry; vol. 4; (1974); p. 363,364-368, View in Reaxys; Bolton et al.; Journal of Fluorine Chemistry; vol. 11; (1978); p. 591,593, 599, View in Reaxys; El'nitskii, A. P.; Serrano, K. F.; Poluyan, O. S.; Journal of Organic Chemistry USSR (English Translation); vol. 19; nb. 8; (1983); p. 1565 - 1566; Zhurnal Organicheskoi Khimii; vol. 19; nb. 8; (1983); p. 1764, View in Reaxys 10 of 38

Melting Point [°C]

106 - 108

Baeyer; Villiger; Chemische Berichte; vol. 33; (1900); p. 1581, View in Reaxys; Rakhimov, A. I.; Androsyuk, E. R.; Shelyazhenko, S. V.; Yagupol'skii, L. M.; Journal of Organic Chemistry USSR (English Translation); (1981); p. 1470 - 1475; Zhurnal Organicheskoi Khimii; vol. 17; nb. 8; (1981); p. 1652 - 1657, View in Reaxys 11 of 38

Melting Point [°C]

104 - 106

Ogata, Yoshiro; Tomizawa, Kohtaro; Furuta, Kyoji; Kato, Hiroshi; Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999); (1981); p. 110 - 112, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

9/162

2018-02-22 00:03:45


12 of 38

Melting Point [°C]

106

Razuvaev et al.; J. Gen. Chem. USSR (Engl. Transl.); vol. 40; (1970); p. 1804,1789,1791,1792,1793, View in Reaxys; Voronkov et al.; Soobshcheniya Akademii Nauk Gruzinskoi SSR; vol. 93; nb. 1; (1979); p. 61,62,63,64, View in Reaxys 13 of 38

Melting Point [°C]

104

Kiparisova,E.G.; Rabinovich,I.B.; Doklady Chemistry; vol. 199; (1971); p. 675 - 677; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 199; nb. 5; (1971); p. 1075 - 1077, View in Reaxys; Prileshajew; Zhurnal Russkago Fiziko-Khimicheskago Obshchestva; vol. 42; (1910); p. 1409; Chem. Zentralbl.; vol. 82; nb. I; (1911); p. 1280, View in Reaxys; Rychly; Andrasik; Staudner; Beniska; Journal of Luminescence; vol. 11; nb. 3-4; (1976); p. 173 - 183, View in Reaxys 14 of 38

Melting Point [°C]

105 - 107

Swern et al.; Analytical Chemistry; vol. 41; (1969); p. 412, View in Reaxys; Johnson; Tetrahedron Letters; (1976); p. 331, View in Reaxys 15 of 38

Melting Point [°C]

103

Fichter; Schnider; Helvetica Chimica Acta; vol. 13; (1930); p. 1428,1430, 1433, View in Reaxys; Karawya; Ghourab; Egyptian Journal of Pharmaceutical Sciences; vol. 16; (1975); p. 35,36, View in Reaxys; Yousufzai et al.; Pakistan Journal of Scientific and Industrial Research; vol. 15; (1972); p. 148, View in Reaxys 16 of 38

Melting Point [°C]

108

Borsig et al.; Collection of Czechoslovak Chemical Communications; vol. 40; (1975); p. 3845, View in Reaxys 17 of 38

Melting Point [°C]

105.5

Burn et al.; Journal of the Chemical Society; (1963); p. 1527,1531, View in Reaxys; Gill; Williams; Journal of the Chemical Society; (1965); p. 7127,7130, View in Reaxys; Bolton et al.; Journal of Fluorine Chemistry; vol. 4; (1974); p. 363,364-368, View in Reaxys; Gill; Williams; Journal of the Chemical Society; (1965); p. 995,999, View in Reaxys; Gill; Williams; Journal of the Chemical Society [Section] B: Physical Organic; (1966); p. 880,881,882, View in Reaxys; Lewis; Williams; Journal of the Chemical Society [Section] B: Physical Organic; (1969); p. 120, View in Reaxys 18 of 38

Melting Point [°C]

107 - 108

Berre; Bergue; Bulletin de la Societe Chimique de France; (1966); p. 2368,2373, View in Reaxys; Otsuka et al.; Journal of the American Chemical Society; vol. 94; (1972); p. 3761,3767, View in Reaxys 19 of 38

Melting Point [°C]

106 - 107

Kuhnert-Brandstaetter et al.; Scientia Pharmaceutica; vol. 38; (1970); p. 154,156,162, View in Reaxys 20 of 38

Melting Point [°C]

101.5 - 102

Solvent (Melting Point)

ethanol

Mikhailov; Nenkov; Izvestiya na Otdelenieto za Khimicheski Nauki (Bulgarska Akademiya na Naukite); vol. 2; (1969); p. 103,109, View in Reaxys 21 of 38

Melting Point [°C]

108

Solvent (Melting Point)

CHCl3; methanol

Hashimoto et al.; Kogyo Kagaku Zasshi; vol. 72; (1969); p. 2277,2278-2280; Chem.Abstr.; vol. 72; nb. 42508; (1970), View in Reaxys 22 of 38

Melting Point [°C]

96.85 - 99.85

Lazar; Ambrovic; Chemicke Zvesti; vol. 23; (1969); p. 881,883,885,886,889, View in Reaxys 23 of 38

Melting Point [°C]

105

Marvel; Nichols; Journal of Organic Chemistry; vol. 6; (1941); p. 296,299, View in Reaxys; Cadogan et al.; Journal of the Chemical Society; (1965); p. 3939,3941, View in Reaxys; Sprecher; Nativ; Tetrahedron Letters; (1968); p. 4405, View in Reaxys 24 of 38

Melting Point [°C]

103.5

Sax; McMullan; Acta Crystallographica; vol. 22; (1967); p. 281,284, 286, View in Reaxys 25 of 38

Melting Point [°C]

105

Solvent (Melting Point)

CHCl3; methanol

Huyser; Kim; Journal of Organic Chemistry; vol. 32; (1967); p. 618,619, 620, View in Reaxys; Ol'dekop; El'nizkii; J. Gen. Chem. USSR (Engl. Transl.); vol. 34; (1964); p. 3478,3520, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

10/162

2018-02-22 00:03:45


26 of 38

Melting Point [°C]

104 - 105

Staab,H.A. et al.; Chemische Berichte; vol. 98; (1965); p. 1122 - 1127, View in Reaxys; Vanino; Herzer; Archiv der Pharmazie (Weinheim, Germany); vol. 253; (1915); p. 434, View in Reaxys 27 of 38

Melting Point [°C]

106

Solvent (Melting Point)

methanol; CHCl3

Hasegawa et al.; Bulletin of the Chemical Society of Japan; vol. 36; (1963); p. 522, View in Reaxys 28 of 38

Melting Point [°C]

105 - 105.5

Solvent (Melting Point)

CHCl3; methanol

Greene,F.D.; Kazan,J.; Journal of Organic Chemistry; vol. 28; (1963); p. 2168 - 2171, View in Reaxys 29 of 38

Melting Point [°C]

105 - 106

Solvent (Melting Point)

CCl4; methanol

Greene,F.D.; Kazan,J.; Journal of Organic Chemistry; vol. 28; (1963); p. 2168 - 2171, View in Reaxys 30 of 38

Melting Point [°C]

101 - 101.5

Milowskaja et al.; J. Gen. Chem. USSR (Engl. Transl.); vol. 32; (1962); p. 621,612; Chem.Abstr.; vol. 58; nb. 445; (1963), View in Reaxys 31 of 38

Melting Point [°C]

103 - 104

Solvent (Melting Point)

CHCl3; methanol

Lawesson et al.; Arkiv foer Kemi; vol. 17; (1961); p. 429,433, View in Reaxys 32 of 38

Melting Point [°C]

110

Kirmse; Horner; Chemische Berichte; vol. 89; (1956); p. 836,840, View in Reaxys 33 of 38

Comment (Melting Point)

Decomposition.at:110 degreeC.Explosionspunkt.

Dickey et al.; Industrial and Engineering Chemistry; vol. 41; (1949); p. 1674, View in Reaxys 34 of 38

Solvent (Melting Point)

CHCl3

Fichter; Schnider; Helvetica Chimica Acta; vol. 13; (1930); p. 1428,1430, 1433, View in Reaxys 35 of 38

Comment (Melting Point)

Decomposition.at:107 degreeC.Explosionspunkt.

Fichter; Helvetica Chimica Acta; vol. 13; (1930); p. 92,96, View in Reaxys 36 of 38

Comment (Melting Point)

Decomposition.at:104 degreeC. - :105 degreeC.Explosionspunkt.

Fichter; Schnider; Helvetica Chimica Acta; vol. 13; (1930); p. 1428,1430, 1433, View in Reaxys 37 of 38

Melting Point [°C]

110

Comment (Melting Point)

bei raschem Erhitzen.

Baeyer; Villiger; Chemische Berichte; vol. 33; (1900); p. 1581, View in Reaxys 38 of 38

Melting Point [°C]

103.5

Solvent (Melting Point)

diethyl ether

Comment (Melting Point)

Decomposition.

Brodie; Jahresbericht ueber die Fortschritte der Chemie und Verwandter Theile Anderer Wissenschaften; (1863); p. 317, View in Reaxys; Brodie; Journal of the Chemical Society; vol. 17; (1864); p. 269; Ann. d. Physik; vol. 121; (1864); p. 377, View in Reaxys Density (2) 1 of 2

Type (Density)

crystallographic

Vary; McBride; Molecular Crystals and Liquid Crystals (1969-1991); vol. 52; (1979); p. 133,134,136,140, View in Reaxys; Sax; McMullan; Acta Crystallographica; vol. 22; (1967); p. 281,284, 286, View in Reaxys 2 of 2

Density [g·cm-3]

1.334

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

11/162

2018-02-22 00:03:45


Type (Density)

crystallographic

Kasatotschkin; Perlina; Ablesowa; Doklady Akademii Nauk SSSR; S.S.S.R.; vol. 47; (1945); p. 36,37, View in Reaxys Adsorption (MCS) (3) 1 of 3

Description (Adsorption (MCS))

Adsorption

Solvent (Adsorption (MCS))

acetonitrile

Partner (Adsorption (MCS))

poly(dimethylsiloxane) modified with Si(OC2H5)4 and VO(acetylacetonate)2(pyrazole)*tris(1-pyrazolyl)methane

Silva, Telma F.S.; Leod, Tatiana C.O. Mac; Martins, Luisa M.D.R.S.; Guedes Da Silva, M. Fatima C.; Schiavon, Marco A.; Pombeiro, Armando J.L.; Journal of Molecular Catalysis A: Chemical; vol. 367; (2013); p. 52 - 60, View in Reaxys 2 of 3

Description (Adsorption (MCS))

Adsorption

Solvent (Adsorption (MCS))

acetonitrile

Partner (Adsorption (MCS))

poly(dimethylsiloxane) modified with Si(OC2H5)4 and VOCl2(2,2,2-tris(1-pyrazolyl)ethanol)

Silva, Telma F.S.; Leod, Tatiana C.O. Mac; Martins, Luisa M.D.R.S.; Guedes Da Silva, M. Fatima C.; Schiavon, Marco A.; Pombeiro, Armando J.L.; Journal of Molecular Catalysis A: Chemical; vol. 367; (2013); p. 52 - 60, View in Reaxys 3 of 3

Description (Adsorption (MCS))

Adsorption

Mar'in; Shlyapnikov; Doklady Physical Chemistry; vol. 219; (1974); p. 1205,1206, 1207; ; p. 1409, View in Reaxys; Sokolova; Boichinova; J. Appl. Chem. USSR (Engl. Transl.); vol. 43; (1970); p. 798,802, View in Reaxys Association (MCS) (13) 1 of 13

Description (Association Stability constant of the complex with ... (MCS)) Solvent (Association (MCS))

various solvents

Partner (Association (MCS))

β‐cyclodextrin

Xie, Hui; Wang, Huai You; Ma, Li Ying; Xiao, Yan; Han, Juan; Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy; vol. 62; nb. 1-3; (2005); p. 197 - 202, View in Reaxys 2 of 13

Description (Association UV/VIS spectrum of the complex (MCS)) Solvent (Association (MCS))

various solvents

Comment (Association (MCS))

concentration dependence

Partner (Association (MCS))

β‐cyclodextrin

Xie, Hui; Wang, Huai You; Ma, Li Ying; Xiao, Yan; Han, Juan; Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy; vol. 62; nb. 1-3; (2005); p. 197 - 202, View in Reaxys 3 of 13

Description (Association IR spectrum of the complex (MCS)) Solvent (Association (MCS))

toluene

Comment (Association (MCS))

solvent dependence. Object(s) of Study: time dependence. Object(s) of Study: concentration dependence

Partner (Association (MCS))

hydrogenated diamond powder

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

12/162

2018-02-22 00:03:45


Tsubota, Toshiki; Hirabayashi, Osamu; Ida, Shintaro; Nagaoka, Shoji; Nagata, Masanori; Matsumoto, Yasumichi; Physical Chemistry Chemical Physics; vol. 4; nb. 5; (2002); p. 806 - 811, View in Reaxys 4 of 13

Description (Association NMR spectrum of the complex (MCS)) Solvent (Association (MCS))

various solvent(s)

Temperature (Association (MCS)) [°C]

21.85

Partner (Association (MCS))

C96H108N12O16

Koerner, Steffi K.; Tucci, Fabio C.; Rudkevich, Dmitry M.; Heinz, Thomas; Rebek Jr., Julius; Chemistry - A European Journal; vol. 6; nb. 1; (2000); p. 187 - 195, View in Reaxys 5 of 13

Description (Association UV/VIS spectrum of the complex (MCS)) Solvent (Association (MCS))

H2O

Temperature (Association (MCS)) [°C]

20

Partner (Association (MCS))

cetylpyridinium chloride; KI3

Lunar; Rubio; Perez-Bendito; Journal of Pharmaceutical Sciences; vol. 83; nb. 3; (1994); p. 407 - 409, View in Reaxys 6 of 13

Description (Association IR spectrum of the complex (MCS)) Solvent (Association (MCS))

CCl4

Partner (Association (MCS))

bis(amylthio)bis(phenyl)methane

Puzin, Yu. I.; Leplyanin, G. V.; Tolstikov, G. A.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); vol. 37; (1988); p. 1586 - 1588; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; nb. 8; (1988); p. 1780 - 1782, View in Reaxys 7 of 13

Description (Association IR spectrum of the complex (MCS)) Solvent (Association (MCS))

CCl4

Partner (Association (MCS))

2,2-bis(amylthio)propane

Puzin, Yu. I.; Leplyanin, G. V.; Tolstikov, G. A.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); vol. 37; (1988); p. 1586 - 1588; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; nb. 8; (1988); p. 1780 - 1782, View in Reaxys 8 of 13

Description (Association NMR spectrum of the complex (MCS)) Solvent (Association (MCS))

CDCl3

Temperature (Association (MCS)) [°C]

24.9 - 59.9

Partner (Association (MCS))

bis(amylthio)bis(phenyl)methane

Puzin, Yu. I.; Leplyanin, G. V.; Tolstikov, G. A.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); vol. 37; (1988); p. 1586 - 1588; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; nb. 8; (1988); p. 1780 - 1782, View in Reaxys 9 of 13

Description (Association NMR spectrum of the complex (MCS))

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

13/162

2018-02-22 00:03:45


Solvent (Association (MCS))

CD2Cl2

Partner (Association (MCS))

pyridine; InI

Peppe, Clovis; Tuck, Dennis G.; Canadian Journal of Chemistry; vol. 62; (1984); p. 2798 - 2802, View in Reaxys 10 of 13

Description (Association IR spectrum of the complex (MCS)) Solvent (Association (MCS))

CCl4

Temperature (Association (MCS)) [°C]

25

Partner (Association (MCS))

formaldehyde S,S'-diamylomercaptal

Puzin, Yu. I.; Leplyanin, G. V.; Rafikov, S. R.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); vol. 33; (1984); p. 1892 - 1895; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; nb. 9; (1984); p. 2073 - 2076, View in Reaxys 11 of 13

Description (Association NMR spectrum of the complex (MCS)) Solvent (Association (MCS))

CDCl3

Temperature (Association (MCS)) [°C]

24.9

Partner (Association (MCS))

formaldehyde S,S'-diamylomercaptal

Puzin, Yu. I.; Leplyanin, G. V.; Spirikhin, L. V.; Parmenova, I. P.; Muslukhov, R. M.; Tolstikov, G. A.; Doklady Chemistry; vol. 279; (1984); p. 422 - 426; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 279; nb. 3; (1984); p. 646 - 650, View in Reaxys 12 of 13

Description (Association NMR spectrum of the complex (MCS)) Solvent (Association (MCS))

CDCl3

Temperature (Association (MCS)) [°C]

24.9

Partner (Association (MCS))

1-(1-Pentylsulfanyl-ethylsulfanyl)-pentane

Puzin, Yu. I.; Leplyanin, G. V.; Spirikhin, L. V.; Parmenova, I. P.; Muslukhov, R. M.; Tolstikov, G. A.; Doklady Chemistry; vol. 279; (1984); p. 422 - 426; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 279; nb. 3; (1984); p. 646 - 650, View in Reaxys 13 of 13

Description (Association NMR spectrum of the complex (MCS)) Solvent (Association (MCS))

CDCl3

Temperature (Association (MCS)) [°C]

24.9

Partner (Association (MCS))

1-(bis(pentylthio)methyl)benzene

Puzin, Yu. I.; Leplyanin, G. V.; Spirikhin, L. V.; Parmenova, I. P.; Muslukhov, R. M.; Tolstikov, G. A.; Doklady Chemistry; vol. 279; (1984); p. 422 - 426; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 279; nb. 3; (1984); p. 646 - 650, View in Reaxys Chromatographic Data (1) Chromatographic References data TLC (Thin layer chromatography)

McDonald, Stacey L.; Hendrick, Charles E.; Bitting, Katie J.; Wang, Qiu; Organic Syntheses; vol. 92; (2016); p. 356 - 372, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

14/162

2018-02-22 00:03:45


Conformation (2) Object of Investi- References gation Energy difference between the conformers

Kikuchi et al.; Bulletin of the Chemical Society of Japan; vol. 51; (1978); p. 11,13, View in Reaxys

Conformation

Jehlicka et al.; Collection of Czechoslovak Chemical Communications; vol. 40; (1975); p. 3004,3005,3006, View in Reaxys; Fayat; Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques; vol. 265; (1967); p. 1406, View in Reaxys

Crystal Phase (5) Description (Crys- Comment (Crystal References tal Phase) Phase) Crystal structure determination

Vary; McBride; Molecular Crystals and Liquid Crystals (1969-1991); vol. 52; (1979); p. 133,134,136,140, View in Reaxys; Sax; McMullan; Acta Crystallographica; vol. 22; (1967); p. 281,284, 286, View in Reaxys; Jeffrey et al.; Journal of the American Chemical Society; vol. 86; (1964); p. 949, View in Reaxys

Solid state structure properties

Vary; McBride; Molecular Crystals and Liquid Crystals (1969-1991); vol. 52; (1979); p. 133,134,136,140, View in Reaxys

Crystal morphology

Morsi et al.; Journal of the Chemical Society, Faraday Transactions 1: Physical Chemistry in Condensed Phases; vol. 71; (1975); p. 1857,1858 - 1863, View in Reaxys; Sax; McMullan; Acta Crystallographica; vol. 22; (1967); p. 281,284, 286, View in Reaxys

Crystal structure determination

.

Sax; McMullan; Acta Crystallographica; vol. 22; (1967); p. 281,284, 286, View in Reaxys

Crystal structure determination

a=8.91 Angstroem, b=9.45 Angstroem, c=14.33 Angstroem, n=4.

Kasatotschkin; Perlina; Ablesowa; Doklady Akademii Nauk SSSR; S.S.S.R.; vol. 47; (1945); p. 36,37, View in Reaxys

Crystal Property Description (2) Colour & Other Location Properties

References

white

Paragraph 0014; 0016; 0018

Patent; Jiangsu Sinobiopharma Co., Ltd.; Huang, Lequn; Chen, Quan; (6 pag.); CN106349139; (2017); (A) Chinese, View in Reaxys

yellow

Paragraph 159

Patent; CONCERT PHARMACEUTICALS, INC.; TUNG, Roger, D.; WO2014/110322; (2014); (A2) English, View in Reaxys

Crystal System (1) Crystal System References rhombic

Kasatotschkin; Perlina; Ablesowa; Doklady Akademii Nauk SSSR; S.S.S.R.; vol. 47; (1945); p. 36,37, View in Reaxys

Decomposition (1) 1 of 1

Rykov; Buchachenko; Doklady Physical Chemistry; vol. 184-189; (1969); p. 233; Doklady Akademii Nauk SSSR; vol. 185; (1969); p. 870, View in Reaxys; Rychly; Andrasik; Staudner; Beniska; Journal of Luminescence; vol. 11; nb. 3-4; (1976); p. 173 - 183, View in Reaxys; Melik-Ogandzhanyan et al.; Kinetics and Catalysis; vol. 15; (1974); p. 509, View in Reaxys; Vary; McBride; Molecular Crystals and Liquid Crystals (1969-1991); vol. 52; (1979); p. 133,134,136,140, View in Reaxys

Dissociation Energy (1) References Kiparisova,E.G.; Rabinovich,I.B.; Doklady Chemistry; vol. 199; (1971); p. 675 - 677; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 199; nb. 5; (1971); p. 1075 - 1077, View in Reaxys Electrical Data (1) 1 of 1

Description (Electrical Data)

Piezoelectricity

Comment (Electrical Da- Dibenzoylperoxid ist piezoelektrisch. ta) Hettich; Steinmetz; Zeitschrift fuer Physik; vol. 76; (1932); p. 688,699, View in Reaxys Electrical Moment (3)

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

15/162

2018-02-22 00:03:45


1 of 3

Description (Electrical Moment)

Dipole moment

Jehlicka et al.; Collection of Czechoslovak Chemical Communications; vol. 40; (1975); p. 3004,3005,3006, View in Reaxys 2 of 3

Description (Electrical Moment)

Dipole moment

Moment (Electrical Moment) [D]

1.6

Method (Electrical Moment)

Dielectric constant (ε)

Solvent (Electrical Moment)

benzene

Lobunez et al.; Journal of the American Chemical Society; vol. 80; (1958); p. 3505,3506, View in Reaxys 3 of 3

Description (Electrical Moment)

Dipole moment

Moment (Electrical Moment) [D]

1.58

Method (Electrical Moment)

Dielectric constant (ε)

Solvent (Electrical Moment)

benzene

Oesper; Smyth; Journal of the American Chemical Society; vol. 64; (1942); p. 768,769, View in Reaxys Electrochemical Behaviour (1) Description (Elec- References trochemical Behaviour) Polarography

Fleet et al.; Journal of Electroanalytical Chemistry and Interfacial Electrochemistry; vol. 22; (1969); p. 63, View in Reaxys; Kuta; Quackenbush; Analytical Chemistry; vol. 32; (1960); p. 1069,1070, View in Reaxys; Antonowskii et al.; J. Gen. Chem. USSR (Engl. Transl.); vol. 39; (1969); p. 268,250, View in Reaxys

Electrochemical Characteristics (4) 1 of 4

Description (Electrochemical Characteristics)

polarographic half-wave potential

Kovbuz, M. A.; Gorbachevskaya, K. R.; Artym, I. I.; J. Gen. Chem. USSR (Engl. Transl.); vol. 55; nb. 4; (1985); p. 817 - 820,729 - 732, View in Reaxys 2 of 4

Description (Electrochemical Characteristics)

polarographic half-wave potential

Comment (Electrochem- in Methanol und Benzol. ical Characteristics) Willits et al.; Analytical Chemistry; vol. 24; (1952); p. 785,789, View in Reaxys; Bernard; Annales de Chimie (Cachan, France); vol. <12> 10; (1955); p. 315,324, 328, 333, 338, View in Reaxys; Besugly; Dimitriewa; Zhurnal Prikladnoi Khimii (Sankt-Peterburg, Russian Federation); vol. 31; (1958); p. 298,302; engl. Ausg. S. 283, 285; Zavod. Labor.; vol. 24; (1958); p. 941,945; Chem.Abstr.; (1960); p. 11539, View in Reaxys 3 of 4

Description (Electrochemical Characteristics)

polarographic half-wave potential

Comment (Electrochem- in wss. Aethanol. ical Characteristics) Giguere; Lamontagne; Canadian Journal of Chemistry; vol. 29; (1951); p. 54,56, View in Reaxys 4 of 4

Description (Electrochemical Characteristics)

polarographic current/voltage curve

Lewis; Quackenbush; De Vries; Analytical Chemistry; vol. 21; (1949); p. 762,765, View in Reaxys Electron Binding (1)

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

16/162

2018-02-22 00:03:45


Description (Elec- References tron Binding) Electron affinity

Cabildo et al.; Anales de Quimica (1968-1979); vol. 73; (1977); p. 330, View in Reaxys; Kurov, G. N.; Svyatkina, L. I.; Gaintseva, L. L.; Naumova, I. P.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); vol. 34; (1985); p. 2542 - 2546; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; nb. 12; (1985); p. 2746 - 2749, View in Reaxys

Energy Data (MCS) (5) 1 of 5

Description (Energy Data (MCS))

Enthalpy of solution

Solvent (Energy Data (MCS))

dichloroethane

Rogowin; Nikolajewa; Zhurnal Fizicheskoi Khimii; vol. 20; (1946); p. 753; Chem.Abstr.; (1947); p. 334, View in Reaxys 2 of 5

Description (Energy Data (MCS))

Enthalpy of solution

Solvent (Energy Data (MCS))

benzene

Rogowin; Nikolajewa; Zhurnal Fizicheskoi Khimii; vol. 20; (1946); p. 753; Chem.Abstr.; (1947); p. 334, View in Reaxys 3 of 5

Description (Energy Data (MCS))

Enthalpy of solution

Solvent (Energy Data (MCS))

ethyl acetate

Rogowin; Nikolajewa; Zhurnal Fizicheskoi Khimii; vol. 20; (1946); p. 753; Chem.Abstr.; (1947); p. 334, View in Reaxys 4 of 5

Description (Energy Data (MCS))

Enthalpy of solution

Solvent (Energy Data (MCS))

vinyl acetate

Rogowin; Nikolajewa; Zhurnal Fizicheskoi Khimii; vol. 20; (1946); p. 753; Chem.Abstr.; (1947); p. 334, View in Reaxys 5 of 5

Description (Energy Data (MCS))

Enthalpy of solution

Solvent (Energy Data (MCS))

2-methyl-prop-2-enoic acid methyl ester

Rogowin; Nikolajewa; Zhurnal Fizicheskoi Khimii; vol. 20; (1946); p. 753; Chem.Abstr.; (1947); p. 334, View in Reaxys Enthalpy of Combustion (2) Enthalpy of Com- Comment (Enbustion [Jmol-1] thalpy of Combustion)

References

Kiparisova,E.G.; Rabinovich,I.B.; Doklady Chemistry; vol. 199; (1971); p. 675 - 677; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 199; nb. 5; (1971); p. 1075 - 1077, View in Reaxys -6.55025E+06

Standard.

Enthalpy of Formation (2) Enthalpy of ForComment (Enmation [Jmol-1] thalpy of Formation)

Breitenbach; Derkosch; Monatshefte fuer Chemie; vol. 82; (1951); p. 177; Monatshefte fuer Chemie; vol. 81; (1950); p. 689,694, View in Reaxys References

Kiparisova,E.G.; Rabinovich,I.B.; Doklady Chemistry; vol. 199; (1971); p. 675 - 677; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 199; nb. 5; (1971); p. 1075 - 1077, View in Reaxys; Corson et al.; Journal of Chemical Thermodynamics; vol. 7; (1975); p. 993,994,995, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

17/162

2018-02-22 00:03:45


-391466

Standard.

Breitenbach; Derkosch; Monatshefte fuer Chemie; vol. 82; (1951); p. 177; Monatshefte fuer Chemie; vol. 81; (1950); p. 689,694, View in Reaxys; Breitenbach; Derkosch; Monatshefte fuer Chemie; vol. 81; (1950); p. 689,694, View in Reaxys

Enthalpy of Sublimation (1) References Corson et al.; Journal of Chemical Thermodynamics; vol. 7; (1975); p. 993,994,995, View in Reaxys Further Information (25) Description (Fur- References ther Information) Further information

Melik-Ogandzhanyan et al.; Kinetics and Catalysis; vol. 15; (1974); p. 509, View in Reaxys

Further information

Vartapetyan et al.; Russian Journal of Physical Chemistry; vol. 47; (1973); p. 774; ; p. 1351, View in Reaxys

Further information

Vartapetyan; Khachatryan; Uchenye Zapiski, Erevanskii Gosudarstvennyi Universitet; vol. 2; (1973); p. 50,51-54; Chem.Abstr.; vol. 81; nb. 151933e; Chem. Zentralbl.; 1974, Nr.8, B119B, View in Reaxys

Further information

Byrne et al.; Journal of Chemical and Engineering Data; vol. 17; (1972); p. 507, View in Reaxys

Further information

Fahrenholtz; Trozzolo; Journal of the American Chemical Society; vol. 93; (1971); p. 251, View in Reaxys

Further information

Gream,G.E. et al.; Australian Journal of Chemistry; vol. 22; (1969); p. 1229 - 1247, View in Reaxys

Further information

Antonovskii,V.L. et al.; J. Gen. Chem. USSR (Engl. Transl.); vol. 39; nb. 3; (1969); p. 518 - 522,488 - 491, View in Reaxys

Further information

Stepovik et al.; J. Gen. Chem. USSR (Engl. Transl.); vol. 39; (1969); p. 2043,1996, View in Reaxys

Further information

Livingston; Leonhardt; Journal of Physical Chemistry; vol. 72; (1968); p. 2254, View in Reaxys

Further information

Milowskaja et al.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); (1967); p. 1053; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; (1967); p. 1093, View in Reaxys

Further information

Tvuzard; van Tiggeln; Bulletin des Societes Chimiques Belges; vol. 76; (1967); p. 444,448, 450, View in Reaxys

Further information

Jakobsen et al.; Arkiv foer Kemi; vol. 24; (1965); p. 519,526, View in Reaxys

Further information

Shono et al.; Bulletin of the Chemical Society of Japan; vol. 37; (1964); p. 635, View in Reaxys

Further information

Banerjee; Budke; Analytical Chemistry; vol. 36; (1964); p. 792,794, View in Reaxys

Further information

Patent; Pfizer; Chas and Co.; Inc.; US3438882; (1964); Chem.Abstr.; vol. 71; nb. 12843f; (1969), View in Reaxys

Further information

Trosman; Bagdasar'jan; Russian Journal of Physical Chemistry; vol. 38; (1964); p. 73; Zhurnal Fizicheskoi Khimii; vol. 38; (1964); p. 141, View in Reaxys

Further information

Romanzew; Lewin; J. Anal. Chem. USSR (Engl. Transl.); vol. 18; (1963); p. 1109,957, View in Reaxys

Further information

Beckwith; Evans; Proceedings of the Chemical Society, London; (1962); p. 63, View in Reaxys

Further information

Pobiner; Analytical Chemistry; vol. 33; (1961); p. 1423, View in Reaxys

Further information

Dugan; Analytical Chemistry; vol. 33; (1961); p. 1630, View in Reaxys

Further information

Dugan; Analytical Chemistry; vol. 33; (1961); p. 696,697, 698, View in Reaxys

Further information

Bellamy et al.; Zeitschrift fuer Elektrochemie; vol. 64; (1960); p. 563, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

18/162

2018-02-22 00:03:45


Further information

Dolgoplosk et al.; Vopr. Khim. Kinet., Katal. Reakts. Sposobn., Dokl. Vses. Soveshch.; (1955); p. 810,812; Chem.Abstr.; vol. 50; nb. 9318a; (1956), View in Reaxys

Behaviour as catalyst

Andreson, C. A.; Miller, C. E.; J. Am. pharm. Assoc. sci. Edit.; vol. 37; (1948); p. 204 - 205 ; (from Gmelin), View in Reaxys

Behaviour as catalyst

vol. S: MVol.B3; 33, page 1599 - 1601 ; (from Gmelin), View in Reaxys

Interatomic Distances and Angles (3) Description Comment (Intera- References tomic Distances and Angles) Electron distribution

Kikuchi et al.; Bulletin of the Chemical Society of Japan; vol. 51; (1978); p. 11,13, View in Reaxys

Interatomic distances and angles

Sax; McMullan; Acta Crystallographica; vol. 22; (1967); p. 281,284, 286, View in Reaxys

Interatomic distances and angles

aus dem Roentgen-Diagramm ermittelt.

Kasatotschkin; Perlina; Ablesowa; Doklady Akademii Nauk SSSR; vol. 47; (1945); p. 37; Doklady Akademii Nauk SSSR; vol. 47; (1945); p. 36, View in Reaxys

Liquid/Liquid Systems (MCS) (4) 1 of 4

Description (Liquid/ Liquid Systems (MCS))

Distribution between solvent 1 + 2

Solvent (Liquid/Liquid Systems (MCS))

benzene; H2O

Temperature (Liquid/ Liquid Systems (MCS)) [°C]

25

Jurshenko; Gromowa; Chaizer; Zhurnal Obshchei Khimii; vol. 16; (1946); p. 1505,1508; Chem.Abstr.; (1947); p. 5746, View in Reaxys 2 of 4

Description (Liquid/ Liquid Systems (MCS))

Distribution between solvent 1 + 2

Solvent (Liquid/Liquid Systems (MCS))

H2O

Temperature (Liquid/ Liquid Systems (MCS)) [°C]

60

Jurshenko; Gromowa; Chaizer; Zhurnal Obshchei Khimii; vol. 16; (1946); p. 1505,1508; Chem.Abstr.; (1947); p. 5746, View in Reaxys 3 of 4

Description (Liquid/ Liquid Systems (MCS))

Distribution between solvent 1 + 2

Solvent (Liquid/Liquid Systems (MCS))

aq. NaOH

Temperature (Liquid/ Liquid Systems (MCS)) [°C]

25

Jurshenko; Gromowa; Chaizer; Zhurnal Obshchei Khimii; vol. 16; (1946); p. 1505,1508; Chem.Abstr.; (1947); p. 5746, View in Reaxys 4 of 4

Description (Liquid/ Liquid Systems (MCS))

Distribution between solvent 1 + 2

Solvent (Liquid/Liquid Systems (MCS))

aq. NaOH

Temperature (Liquid/ Liquid Systems (MCS)) [°C]

60

Jurshenko; Gromowa; Chaizer; Zhurnal Obshchei Khimii; vol. 16; (1946); p. 1505,1508; Chem.Abstr.; (1947); p. 5746, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

19/162

2018-02-22 00:03:45


Liquid/Solid Systems (MCS) (3) 1 of 3

Description (Liquid/Solid Melting points Systems (MCS)) Partner (Liquid/Solid Systems (MCS))

bis(2-methylbenzoyl) peroxide; benzoyl(o-toluoyl)peroxide

Moorhoff, Cornelis M.; Braybrook, Carl; Journal of Chemical Research, Miniprint; nb. 3; (2003); p. 339 - 361, View in Reaxys 2 of 3

Description (Liquid/Solid Eutectic Systems (MCS)) Kuhnert-Brandstaetter et al.; Scientia Pharmaceutica; vol. 38; (1970); p. 154,156,162, View in Reaxys

3 of 3

Description (Liquid/Solid Melting diagram Systems (MCS)) Comment (Liquid/Solid Systems (MCS))

Eutektikum.

Partner (Liquid/Solid Systems (MCS))

phenacylacetophenone

Grimm; Guenther; Tittus; Zeitschrift fuer Physikalische Chemie (Leipzig); vol. <B> 14; (1931); p. 169,208, View in Reaxys Molecular Deformation (1) Description (MoReferences lecular Deformation) Force constants

Ivanchev et al.; Russian Journal of Physical Chemistry; vol. 39; (1965); p. 1009; ; p. 1900, View in Reaxys

Optics (2) Description (Optics)

Comment (Optics)

Crystal refractive indices Magnetorotation

References McBride; Gisler; Molecular Crystals and Liquid Crystals (1969-1991); vol. 52; (1979); p. 121,125-127, View in Reaxys

λ: 578 nm.

Other Thermochemical Data (4) Description (Oth- Comment (Other er Thermochemi- Thermochemical cal Data) Data)

Gallais; Wolf; Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences; vol. 236; (1953); p. 2236, View in Reaxys References

Thermodynamic properties

Rychly; Andrasik; Staudner; Beniska; Journal of Luminescence; vol. 11; nb. 3-4; (1976); p. 173 - 183, View in Reaxys; Mikovic; Lazar; Thermochimica Acta; vol. 2; (1971); p. 321, View in Reaxys

Heat of combustion at constant volume

Corson et al.; Journal of Chemical Thermodynamics; vol. 7; (1975); p. 993,994,995, View in Reaxys

Heat of combustion at constant volume

1552 kcal/Mol.

Anonymus; Jber. chem.-tech. Reichsanst.; vol. 4; (1924); p. 92, View in Reaxys

Heat of combustion at constant volume

1553.4 kcal/Mol.

Roth; Lasse; Zeitschrift fuer Elektrochemie und Angewandte Physikalische Chemie; vol. 30; (1924); p. 609 Anm., View in Reaxys; Roth in Landolt-Boernst.; H, 1598, View in Reaxys

Solubility (MCS) (1) 1 of 1

Temperature (Solubility (MCS)) [°C]

15

Solvent (Solubility (MCS))

CS2

Comment (Solubility (MCS))

1 part(s) of substance.dissolves in:39.5 parts of solvent.

Brodie; Jahresbericht ueber die Fortschritte der Chemie und Verwandter Theile Anderer Wissenschaften; (1863); p. 317, View in Reaxys; Brodie; Journal of the Chemical Society; vol. 17; (1864); p. 269; Ann. d. Physik; vol. 121; (1864); p. 377, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

20/162

2018-02-22 00:03:45


Space Group (2) Space Group

References Sax; McMullan; Acta Crystallographica; vol. 22; (1967); p. 281,284, 286, View in Reaxys; Jeffrey et al.; Journal of the American Chemical Society; vol. 86; (1964); p. 949, View in Reaxys

47; 47

Kasatotschkin; Perlina; Ablesowa; Doklady Akademii Nauk SSSR; S.S.S.R.; vol. 47; (1945); p. 36,37, View in Reaxys

NMR Spectroscopy (21) 1 of 21

Description (NMR Spec- Spectrum troscopy) Nucleus (NMR Spectroscopy)

1H

Solvents (NMR Spectro- dimethylsulfoxide-d6 scopy) Location

supporting information

Song, Young-Kyu; Lee, Kwang-Hun; Hong, Woo-Sung; Cho, Sung-Youl; Yu, Hwan-Chul; Chung, Chan-Moon; Journal of Materials Chemistry; vol. 22; nb. 4; (2012); p. 1380 - 1386, View in Reaxys 2 of 21

Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)

13C

Solvents (NMR Spectro- CDCl3 scopy) Frequency (NMR Spectroscopy) [MHz]

50

Moorhoff, Cornelis M.; Braybrook, Carl; Journal of Chemical Research, Miniprint; nb. 3; (2003); p. 339 - 361, View in Reaxys 3 of 21

Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)

17O

Solvents (NMR Spectro- CH2Cl2 scopy) Frequency (NMR Spectroscopy) [MHz]

59.4

Comment (NMR Spectroscopy)

ambient temperature

Ho, Zwei-Chang; Livant, Peter; Lott, William B.; Webb, Thomas R.; Journal of Organic Chemistry; vol. 64; nb. 22; (1999); p. 8226 - 8235, View in Reaxys 4 of 21

Description (NMR Spec- Linewidth of NMR absorption troscopy) Nucleus (NMR Spectroscopy)

17O

Ho, Zwei-Chang; Livant, Peter; Lott, William B.; Webb, Thomas R.; Journal of Organic Chemistry; vol. 64; nb. 22; (1999); p. 8226 - 8235, View in Reaxys 5 of 21

Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)

17O

Solvents (NMR Spectro- acetone-d6 scopy) Temperature (NMR Spectroscopy) [°C]

29.9

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

21/162

2018-02-22 00:03:45


Antolini, Luciano; Benassi, Rois; Ghelli, Stefano; Folli, Ugo; Sbardellati, Silvia; Taddei, Ferdinando; Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999); nb. 11; (1992); p. 1907 1913, View in Reaxys 6 of 21

Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)

17O

Solvents (NMR Spectro- benzene-d6; benzene scopy) Temperature (NMR Spectroscopy) [°C]

29.9

Antolini, Luciano; Benassi, Rois; Ghelli, Stefano; Folli, Ugo; Sbardellati, Silvia; Taddei, Ferdinando; Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999); nb. 11; (1992); p. 1907 1913, View in Reaxys 7 of 21

Description (NMR Spec- Linewidth of NMR absorption troscopy) Antolini, Luciano; Benassi, Rois; Ghelli, Stefano; Folli, Ugo; Sbardellati, Silvia; Taddei, Ferdinando; Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999); nb. 11; (1992); p. 1907 1913, View in Reaxys

8 of 21

Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)

13C

Puzin, Yu. I.; Leplyanin, G.V.; Muslikhov, R.R.; Tolstikov, G.A.; Doklady Chemistry; vol. 320; nb. 1-3; (1991); p. 277 - 281; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 320; nb. 3; (1991); p. 638 - 642, View in Reaxys 9 of 21

Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)

1H

Solvents (NMR Spectro- benzene scopy) Sadykov, R. A.; Shishlov, N. M.; Journal of Organometallic Chemistry; vol. 369; (1989); p. 1 - 8, View in Reaxys 10 of 21

Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)

13C

Solvents (NMR Spectro- dioxane scopy) Sadykov, R. A.; Shishlov, N. M.; Journal of Organometallic Chemistry; vol. 369; (1989); p. 1 - 8, View in Reaxys 11 of 21

Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)

13C

Solvents (NMR Spectro- CDCl3 scopy) Cheng, C. P.; Lin, S. C.; Shaw, Guan-Su; Journal of Magnetic Resonance (1969-1992); vol. 69; nb. 1; (1986); p. 58 - 67, View in Reaxys 12 of 21

Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)

17O

Solvents (NMR Spectro- CDCl3 scopy)

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

22/162

2018-02-22 00:03:45


Cheng, C. P.; Lin, S. C.; Shaw, Guan-Su; Journal of Magnetic Resonance (1969-1992); vol. 69; nb. 1; (1986); p. 58 - 67, View in Reaxys 13 of 21

Description (NMR Spec- Spectrum troscopy) Nucleus (NMR Spectroscopy)

1H

Solvents (NMR Spectro- CCl4 scopy) Temperature (NMR Spectroscopy) [°C]

25

Puzin, Yu. I.; Leplyanin, G. V.; Rafikov, S. R.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); vol. 33; (1984); p. 1892 - 1895; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; nb. 9; (1984); p. 2073 - 2076, View in Reaxys 14 of 21

Description (NMR Spec- Spectrum troscopy) Nucleus (NMR Spectroscopy)

13C

Solvents (NMR Spectro- CDCl3 scopy) Temperature (NMR Spectroscopy) [°C]

24.9

Puzin, Yu. I.; Leplyanin, G. V.; Spirikhin, L. V.; Parmenova, I. P.; Muslukhov, R. M.; Tolstikov, G. A.; Doklady Chemistry; vol. 279; (1984); p. 422 - 426; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 279; nb. 3; (1984); p. 646 - 650, View in Reaxys 15 of 21

Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)

13C

Solvents (NMR Spectro- 1,2-dichloro-ethane scopy) Takeuchi, Ken'ichi; Murai, Osamu; Matsui, Shin; Inoue, Takeshi; Kitagawa, Toshikazu; Okamoto, Kunio; Journal of the Chemical Society, Perkin Transactions 2: Physical Organic Chemistry (1972-1999); nb. 9; (1983); p. 1301 1310, View in Reaxys 16 of 21

Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)

13C

Solvents (NMR Spectro- acetone scopy) Temperature (NMR Spectroscopy) [°C]

30

Aganov, A. V.; Antonovskii, V. L.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); vol. 31; nb. 2; (1982); p. 247 - 250; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; nb. 2; (1982); p. 271 - 275, View in Reaxys 17 of 21

Description (NMR Spec- Chemical shifts troscopy) Nucleus (NMR Spectroscopy)

13C

Solvents (NMR Spectro- CDCl3 scopy) Temperature (NMR Spectroscopy) [°C]

-10

Budinger, P. A.; Mooney, J. R.; Grasselli, J. G.; Fay, P. S.; Guttman, A. T.; Analytical Chemistry; vol. 53; nb. 6; (1981); p. 884 - 889, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

23/162

2018-02-22 00:03:45


18 of 21

Description (NMR Spec- CIDNP troscopy) Kaptein et al.; Journal of the Chemical Society, Chemical Communications; (1975); p. 568, View in Reaxys; Levin et al.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); (1970); p. 1593; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; (1970); p. 1680, View in Reaxys; Rykov et al.; Spectroscopy Letters; vol. 3; (1970); p. 55, View in Reaxys; Blank; Fischer; Helvetica Chimica Acta; vol. 54; (1971); p. 905,907,908,911, View in Reaxys; Schaeublin et al.; Journal of Magnetic Resonance (1969-1992); vol. 27; (1977); p. 273,294-299, View in Reaxys; Schwerzel et al.; Chemical Physics Letters; vol. 29; (1974); p. 106, View in Reaxys; Buchachenko et al.; Doklady Chemistry; vol. 190; (1970); p. 101; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 190; (1970); p. 839, View in Reaxys; Rykov et al.; Journal of Structural Chemistry; vol. 10; (1969); p. 814; ; p. 928, View in Reaxys

19 of 21

Description (NMR Spec- NMR troscopy) Swern et al.; Analytical Chemistry; vol. 41; (1969); p. 412, View in Reaxys; Kaptein et al.; Journal of the Chemical Society [Section] D: Chemical Communications; (1970); p. 1687, View in Reaxys

20 of 21

Description (NMR Spec- Spectrum troscopy) Fischer; Accounts of Chemical Research; vol. 2; (1969); p. 110,111, View in Reaxys

21 of 21

Description (NMR Spec- Spectrum troscopy) Comment (NMR Spectroscopy)

1H

Bargon et al.; Zeitschrift fuer Naturforschung, Teil A: Astrophysik, Physik und Physikalische Chemie; vol. 22; (1967); p. 1551, View in Reaxys IR Spectroscopy (19) 1 of 19

Description (IR Spectroscopy)

ATR (attenuated total reflectance); Bands; Spectrum

Bronze-Uhle, Erika S.; Batagin-Neto, Augusto; Xavier, Pedro H. P.; Fernandes, Nicole I.; De Azevedo, Eduardo R.; Graeff, Carlos F. O.; Journal of Molecular Structure; vol. 1047; (2013); p. 102 - 108, View in Reaxys 2 of 19

Description (IR Spectroscopy)

Bands

Solvent (IR Spectroscopy)

CD3CN

Reichardt, Christian; Schroeder, Joerg; Voehringer, Peter; Schwarzer, Dirk; Physical Chemistry Chemical Physics; vol. 10; nb. 12; (2008); p. 1662 - 1668, View in Reaxys 3 of 19

Description (IR Spectroscopy)

Spectrum

Solvent (IR Spectroscopy)

CD3CN

Reichardt, Christian; Schroeder, Joerg; Voehringer, Peter; Schwarzer, Dirk; Physical Chemistry Chemical Physics; vol. 10; nb. 12; (2008); p. 1662 - 1668, View in Reaxys 4 of 19

Description (IR Spectroscopy)

Bands

Solvent (IR Spectroscopy)

acetonitrile

Turovskii; Opeida; Kushch; Russian Journal of Organic Chemistry; vol. 39; nb. 5; (2003); p. 642 - 645, View in Reaxys 5 of 19

Description (IR Spectroscopy)

Spectrum

Temperature (IR Spectroscopy) [°C]

91

Comment (IR Spectroscopy)

polymer matrix. Object(s) of Study: ambient temperature

Mosnacek, Jaroslav; Weiss, Richard G.; Lukac, Ivan; Macromolecules; vol. 35; nb. 10; (2002); p. 3870 - 3875, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

24/162

2018-02-22 00:03:45


6 of 19

Description (IR Spectroscopy)

Spectrum

Solvent (IR Spectroscopy)

acetonitrile

Temperature (IR Spectroscopy) [°C]

25

Opeida; Turovskii; Maksyuta; Russian Journal of Organic Chemistry; vol. 36; nb. 11; (2000); p. 1646 - 1649, View in Reaxys 7 of 19

Description (IR Spectroscopy)

Spectrum

Solvent (IR Spectroscopy)

KBr

Comment (IR Spectroscopy)

2000 - 500 cm**(-1)

Vacque; Sombret; Huvenne; Legrand; Suc; Spectrochimica Acta - Part A Molecular Spectroscopy; vol. 53; nb. 1; (1997); p. 55 - 66, View in Reaxys 8 of 19

Description (IR Spectroscopy)

Spectrum

Solvent (IR Spectroscopy)

KBr

Comment (IR Spectroscopy)

4000 - 2700 cm**(-1)

Grinevich, Oleg; Snavely; Chemical Physics Letters; vol. 267; nb. 3-4; (1997); p. 313 - 317, View in Reaxys 9 of 19

Description (IR Spectroscopy)

Spectrum

Solvent (IR Spectroscopy)

KBr

Comment (IR Spectroscopy)

2000 - 1400 cm**(-1)

Owen, David J.; O'Donnell, Jennifer; Schutt, Wendy; Morrow, Jeffrey; Li, Yuzhuo; Journal of Organic Chemistry; vol. 58; nb. 23; (1993); p. 6203 - 6207, View in Reaxys 10 of 19

Description (IR Spectroscopy)

Spectrum

Solvent (IR Spectroscopy)

acetonitrile

Comment (IR Spectroscopy)

1800 - 1600 cm**(-1)

Chikhacheva, I. P.; Stavrova, S. D.; Efremova, E. P.; Pravednikov, A. N.; Kazakova, V. M.; et al.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); vol. 34; (1985); p. 1848 1850; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; nb. 9; (1985); p. 2003 - 2006, View in Reaxys 11 of 19

Description (IR Spectroscopy)

Bands

Solvent (IR Spectroscopy)

CCl4

Comment (IR Spectroscopy)

1770 cm**(-1)

Puzin, Yu. I.; Leplyanin, G. V.; Rafikov, S. R.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); vol. 33; (1984); p. 1892 - 1895; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; nb. 9; (1984); p. 2073 - 2076, View in Reaxys; Puzin, Yu. I.; Leplyanin, G. V.; Spirikhin, L. V.; Parmenova, I. P.; Muslukhov, R. M.; Tolstikov, G. A.; Doklady Chemistry; vol. 279; (1984); p. 422 - 426; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 279; nb. 3; (1984); p. 646 - 650, View in Reaxys 12 of 19

Description (IR Spectroscopy)

Bands

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

25/162

2018-02-22 00:03:45


Solvent (IR Spectroscopy)

paraffin

Comment (IR Spectroscopy)

1781 - 1757 cm**(-1)

Budinger, P. A.; Mooney, J. R.; Grasselli, J. G.; Fay, P. S.; Guttman, A. T.; Analytical Chemistry; vol. 53; nb. 6; (1981); p. 884 - 889, View in Reaxys 13 of 19

Description (IR Spectroscopy)

Bands

Comment (IR Spectroscopy)

1788 - 1760 cm**(-1)

Rakhimov, A. I.; Androsyuk, E. R.; Shelyazhenko, S. V.; Yagupol'skii, L. M.; Journal of Organic Chemistry USSR (English Translation); (1981); p. 1470 - 1475; Zhurnal Organicheskoi Khimii; vol. 17; nb. 8; (1981); p. 1652 - 1657, View in Reaxys 14 of 19

Description (IR Spectroscopy)

Bands

Sorba et al.; Tetrahedron; vol. 35; (1979); p. 1509,1510,1513,1514,1516, View in Reaxys; Fayat; Comptes Rendus des Seances de l'Academie des Sciences, Serie C: Sciences Chimiques; vol. 265; (1967); p. 1406, View in Reaxys 15 of 19

Description (IR Spectroscopy)

IR

Kul'nevich; Borisova; Journal of Applied Spectroscopy; vol. 14; (1971); p. 480; ; p. 648, View in Reaxys; Ivanchev et al.; Russian Journal of Physical Chemistry; vol. 39; (1965); p. 1009; ; p. 1900, View in Reaxys; Anisimow et al.; J. Anal. Chem. USSR (Engl. Transl.); vol. 21; (1966); p. 113,96, View in Reaxys; Alekseeva et al.; J. Gen. Chem. USSR (Engl. Transl.); vol. 42; (1972); p. 1860,1843, View in Reaxys; Chalfont et al.; Journal of the Chemical Society [Section] B: Physical Organic; (1971); p. 233,242, View in Reaxys; Fayat; Foucaud; Bulletin de la Societe Chimique de France; (1971); p. 3747, View in Reaxys; Filliatre et al.; Bulletin de la Societe Chimique de France; vol. <II>; (1979); p. 473,477, View in Reaxys; Gladyshev et al.; Doklady Physical Chemistry; vol. 166-171; (1966); p. 372; vol. 168; p. 1093, View in Reaxys 16 of 19

Description (IR Spectroscopy)

Spectrum

Milowskaja et al.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); (1967); p. 1053; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; (1967); p. 1093, View in Reaxys 17 of 19

Description (IR Spectroscopy)

Spectrum

Solvent (IR Spectroscopy)

CS2

Comment (IR Spectroscopy)

5000 - 667 cm**(-1)

Shreve et al.; Analytical Chemistry; vol. 23; (1951); p. 282,283, View in Reaxys 18 of 19

Description (IR Spectroscopy)

Spectrum

Solvent (IR Spectroscopy)

CCl4

Comment (IR Spectroscopy)

2000 - 1429 cm**(-1)

Davison; Journal of the Chemical Society; (1951); p. 2456,2459, View in Reaxys 19 of 19

Description (IR Spectroscopy)

Spectrum

Solvent (IR Spectroscopy)

CCl4

Comment (IR Spectroscopy)

2000 - 833 cm**(-1)

Barnes; Liddel; Williams; Industrial and Engineering Chemistry, Analytical Edition; vol. 15; (1943); p. 659,687, View in Reaxys Mass Spectrometry (1)

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

26/162

2018-02-22 00:03:45


Description (Mass References Spectrometry) fragmentation pattern; chemical ionization (CI); spectrum

Tu, Ya-Ping; Zou, Da-Peng; Tang, Ming-Sheng; Xin, Bao-Min; Jia, Wei-Ping; Liu, Shu-Ying; Organic Mass Spectrometry; vol. 28; nb. 12; (1993); p. 1435 - 1439, View in Reaxys

UV/VIS Spectroscopy (23) 1 of 23

Description (UV/VIS Spectroscopy)

Spectrum

Solvent (UV/VIS Spectroscopy)

tetrahydrofuran

Location

supporting information

Zhao, Baodong; Zhao, Weidong; Yu, Liujian; Li, Jie; Zhao, Yuming; Wang, Tao; New Journal of Chemistry; vol. 41; nb. 21; (2017); p. 13156 - 13165, View in Reaxys 2 of 23

Description (UV/VIS Spectroscopy)

Spectrum

Solvent (UV/VIS Spectroscopy)

N,N-dimethyl-formamide

Location

supporting information

Absorption Maxima (UV/ 294 VIS) [nm] Li, Qingrui; Zhao, Xiuli; Li, Yabo; Huang, Mengmeng; Kim, Jung Keun; Wu, Yangjie; Organic and Biomolecular Chemistry; vol. 15; nb. 46; (2017); p. 9775 - 9778, View in Reaxys 3 of 23

Description (UV/VIS Spectroscopy)

Spectrum

Absorption Maxima (UV/ 195 VIS) [nm] He, Minghui; Jiang, Shun; Xu, Ruixin; Yang, Jianwen; Zeng, Zhaohua; Chen, Guangxue; Journal of Polymer Science, Part A: Polymer Chemistry; vol. 52; nb. 11; (2014); p. 1560 - 1569, View in Reaxys 4 of 23

Description (UV/VIS Spectroscopy)

Spectrum

Solvent (UV/VIS Spectroscopy)

ethanol

Location

supporting information

Ouchi, Akihiko; Liu, Chuanxiang; Kaneda, Masayuki; Hyugano, Takeshi; European Journal of Organic Chemistry; nb. 18; (2013); p. 3807 - 3816, View in Reaxys 5 of 23

Description (UV/VIS Spectroscopy)

Spectrum

Solvent (UV/VIS Spectroscopy)

various solvents

Xie, Hui; Wang, Huai You; Ma, Li Ying; Xiao, Yan; Han, Juan; Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy; vol. 62; nb. 1-3; (2005); p. 197 - 202, View in Reaxys 6 of 23

Description (UV/VIS Spectroscopy)

Spectrum

Solvent (UV/VIS Spectroscopy)

CHCl3

Mosnacek, Jaroslav; Weiss, Richard G.; Lukac, Ivan; Macromolecules; vol. 35; nb. 10; (2002); p. 3870 - 3875, View in Reaxys 7 of 23

Description (UV/VIS Spectroscopy)

Spectrum

Solvent (UV/VIS Spectroscopy)

CCl4

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

27/162

2018-02-22 00:03:45


Comment (UV/VIS Spectroscopy)

2500 - 714.29 nm

Grinevich, Oleg; Snavely; Chemical Physics Letters; vol. 267; nb. 3-4; (1997); p. 313 - 317, View in Reaxys 8 of 23

Description (UV/VIS Spectroscopy)

Absorption maxima

Solvent (UV/VIS Spectroscopy)

benzene

Absorption Maxima (UV/ 254 VIS) [nm] Ext./Abs. Coefficient [l·mol-1cm-1]

21000

Owen, David J.; O'Donnell, Jennifer; Schutt, Wendy; Morrow, Jeffrey; Li, Yuzhuo; Journal of Organic Chemistry; vol. 58; nb. 23; (1993); p. 6203 - 6207, View in Reaxys 9 of 23

Description (UV/VIS Spectroscopy)

Spectrum

Comment (UV/VIS Spectroscopy)

200 - 300 nm

Malkin, Ya. N.; Shepelin, E. V.; J. Gen. Chem. USSR (Engl. Transl.); vol. 57; nb. 5; (1987); p. 1176 - 1182,1052 1058, View in Reaxys 10 of 23

Description (UV/VIS Spectroscopy)

Spectrum

Solvent (UV/VIS Spectroscopy)

benzene

Comment (UV/VIS Spectroscopy)

400 - 600 nm

Al-Abidin, Kusai M. Z.; Jones, Richard G.; Journal of the Chemical Society, Faraday Transactions 1: Physical Chemistry in Condensed Phases; vol. 78; (1982); p. 513 - 518, View in Reaxys 11 of 23

Description (UV/VIS Spectroscopy)

Spectrum

Solvent (UV/VIS Spectroscopy)

CH2Cl2

Comment (UV/VIS Spectroscopy)

400 - 600 nm

Al-Abidin, Kusai M. Z.; Jones, Richard G.; Journal of the Chemical Society, Faraday Transactions 1: Physical Chemistry in Condensed Phases; vol. 78; (1982); p. 513 - 518, View in Reaxys 12 of 23

Description (UV/VIS Spectroscopy)

Absorption maxima

Solvent (UV/VIS Spectroscopy)

benzene

Absorption Maxima (UV/ 500 VIS) [nm] Al-Abidin, Kusai M. Z.; Jones, Richard G.; Journal of the Chemical Society, Faraday Transactions 1: Physical Chemistry in Condensed Phases; vol. 78; (1982); p. 513 - 518, View in Reaxys 13 of 23

Description (UV/VIS Spectroscopy)

Absorption maxima

Solvent (UV/VIS Spectroscopy)

CH2Cl2

Absorption Maxima (UV/ 500 VIS) [nm] Al-Abidin, Kusai M. Z.; Jones, Richard G.; Journal of the Chemical Society, Faraday Transactions 1: Physical Chemistry in Condensed Phases; vol. 78; (1982); p. 513 - 518, View in Reaxys 14 of 23

Description (UV/VIS Spectroscopy)

UV/VIS

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

28/162

2018-02-22 00:03:45


Kuhnert-Brandstaetter et al.; Scientia Pharmaceutica; vol. 38; (1970); p. 154,156,162, View in Reaxys; McBride; Gisler; Molecular Crystals and Liquid Crystals (1969-1991); vol. 52; (1979); p. 121,125-127, View in Reaxys; Fayat; Foucaud; Bulletin de la Societe Chimique de France; (1971); p. 3747, View in Reaxys 15 of 23

Description (UV/VIS Spectroscopy)

Absorption maxima

Polumbrik et al.; J. Anal. Chem. USSR (Engl. Transl.); vol. 31; (1976); p. 2436,1792,1793, View in Reaxys 16 of 23

Description (UV/VIS Spectroscopy)

Spectrum

Cohen et al.; Journal of Polymer Science; vol. 3; (1948); p. 278, View in Reaxys; Lebourgeois et al.; Journal de Chimie Physique et de Physico-Chimie Biologique; vol. 69; (1972); p. 1633,1634-1637, 1639-1641, View in Reaxys 17 of 23

Description (UV/VIS Spectroscopy)

Spectrum

Solvent (UV/VIS Spectroscopy)

ethyl acetate

Comment (UV/VIS Spectroscopy)

250 - 350 nm

Kinell; Arkiv foer Kemi; vol. 14; (1959); p. 353,366, View in Reaxys 18 of 23

Description (UV/VIS Spectroscopy)

Spectrum

Solvent (UV/VIS Spectroscopy)

ethanol

Comment (UV/VIS Spectroscopy)

240 - 460 nm; nach Bestrahlung mit UV-Licht (λ: 253.7 nm) bei 77 K.

Symons; Townsend; Journal of the Chemical Society; (1959); p. 263,265, View in Reaxys 19 of 23

Description (UV/VIS Spectroscopy)

Spectrum

Solvent (UV/VIS Spectroscopy)

CHCl3

Comment (UV/VIS Spectroscopy)

260 - 300 nm

Takayama; Japan Analyst; vol. 4; (1955); p. 290,291; Chem.Abstr.; (1956); p. 12756, View in Reaxys 20 of 23

Description (UV/VIS Spectroscopy)

Spectrum

Solvent (UV/VIS Spectroscopy)

CHCl3

Comment (UV/VIS Spectroscopy)

220 - 330 nm

Breitenbach; Derkosch; Monatshefte fuer Chemie; vol. 81; (1950); p. 530,531, 532, View in Reaxys 21 of 23

Description (UV/VIS Spectroscopy)

Spectrum

Solvent (UV/VIS Spectroscopy)

light petroleum

Comment (UV/VIS Spectroscopy)

220 - 290 nm

Breitenbach; Derkosch; Monatshefte fuer Chemie; vol. 81; (1950); p. 530,531, 532, View in Reaxys 22 of 23

Description (UV/VIS Spectroscopy)

Spectrum

Solvent (UV/VIS Spectroscopy)

cyclohexane

Comment (UV/VIS Spectroscopy)

200 - 390 nm

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

29/162

2018-02-22 00:03:45


Melville; Valentine; Proceedings of the Royal Society of London, Series A: Mathematical, Physical and Engineering Sciences; vol. 200; (1950); p. 358,360, 361, View in Reaxys 23 of 23

Description (UV/VIS Spectroscopy)

Spectrum

Solvent (UV/VIS Spectroscopy)

ethanol

Purvis; Journal of the Chemical Society; (1927); p. 782; Journal of the Chemical Society; vol. 127; (1925); p. 2773, View in Reaxys ESR Spectroscopy (5) 1 of 5

Description (ESR Spectroscopy)

Spectrum

Temperature (ESR Spectroscopy) [°C]

-196.2

Comment (ESR Spectroscopy)

Solvent(s): further solvent(s)

Kupfer, Michael; Stoesser, Reinhard; Proesch, Ullrich; Kolditz, Lothar; Journal of Fluorine Chemistry; vol. 43; (1989); p. 1 - 14, View in Reaxys 2 of 5

Description (ESR Spectroscopy)

g-factor

Yamauchi, Seigo; Hirota, Noboru; Journal of the American Chemical Society; vol. 107; nb. 17; (1985); p. 5021 5022, View in Reaxys; Kupfer, Michael; Stoesser, Reinhard; Proesch, Ullrich; Kolditz, Lothar; Journal of Fluorine Chemistry; vol. 43; (1989); p. 1 - 14, View in Reaxys 3 of 5

Description (ESR Spectroscopy)

Spectrum

Solvents (ESR Spectroscopy)

CCl4

Yamauchi, Seigo; Hirota, Noboru; Journal of the American Chemical Society; vol. 107; nb. 17; (1985); p. 5021 5022, View in Reaxys 4 of 5

Description (ESR Spectroscopy)

ESR

McBride; Gisler; Molecular Crystals and Liquid Crystals (1969-1991); vol. 52; (1979); p. 121,125-127, View in Reaxys; Box et al.; Journal of the American Chemical Society; vol. 92; (1970); p. 5305,5306, View in Reaxys 5 of 5

Description (ESR Spectroscopy)

Spectrum

Shapiro et al.; Doklady Chemistry; vol. 195; (1970); p. 794; Dokl. Akad. Nauk SSSR Ser. Khim.; vol. 195; (1970); p. 104, View in Reaxys NQR Spectroscopy (1) Description (NQR References Spectroscopy) Nuclear quadrupole resonance

Cheng; Brown; Journal of the American Chemical Society; vol. 101; (1979); p. 2327,2329, View in Reaxys

Raman Spectroscopy (8) Description (Ram- Comment (Raman Spectroscopy) an Spectroscopy) Spectrum; Bands

References Wang, Xiaobin; Huang, Wenqian; Wang, Qingyan; Liu, Chen; Wang, Chaopeng; Yang, Guiyan; Zhao, Chunjiang; Journal of Molecular Structure; vol. 1138; (2017); p. 6 - 11, View in Reaxys

Spectrum

neat (no solvent)

Vacque; Sombret; Huvenne; Legrand; Suc; Spectrochimica Acta - Part A Molecular Spectroscopy; vol. 53; nb. 1; (1997); p. 55 - 66, View in Reaxys

Bands

CH2Cl2

Kosnikov, A. Yu.; Antonovskii, V. L.; Lindeman, S. V.; Struchkov, Yu. T.; Zyat'kov, I. P.; et al.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); vol. 34; nb. 4; (1985); p. 855 - 857; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; nb. 4; (1985); p. 937 - 940, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

30/162

2018-02-22 00:03:45


Raman

Fayat; Foucaud; Bulletin de la Societe Chimique de France; (1971); p. 3747, View in Reaxys

Spectrum

der Krystalle

Susz; Berenstein; C. r. Soc. Phys. Geneve; vol. 59; (1942); p. 182,184, View in Reaxys

Spectrum

von Loesungen in Beresowskaja; Kurnosowa; Zhurnal Fizicheskoi Khimii; vol. 6; (1935); p. 125, Chloroform View in Reaxys

Spectrum

von Loesungen in Beresowskaja; Kurnosowa; Zhurnal Fizicheskoi Khimii; vol. 6; (1935); p. 125, Tetrachlormethan View in Reaxys

Spectrum

einer Loesung in Chloroform

Kohlrausch; Pongratz; Seka; Chemische Berichte; vol. 66; (1933); p. 9, View in Reaxys

Luminescence Spectroscopy (2) Description (LuReferences minescence Spectroscopy) Luminescence quantum yield

Thijs et al.; Journal of Organic Chemistry; vol. 44; (1979); p. 4123,4124, 4125, 4127, View in Reaxys

Luminescence

Hercules; Spectrochimica Acta; vol. 19; (1963); p. 788, View in Reaxys; Panasenko et al.; Bulletin of the Academy of Sciences of the USSR, Division of Chemical Science (English Translation); vol. 26; (1977); p. 425; Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya; vol. 26; (1977); p. 470, View in Reaxys; Ivanchev; Selivanov; Journal of Applied Spectroscopy; vol. 19; (1973); p. 1504; ; p. 920, View in Reaxys; Rychly; Andrasik; Staudner; Beniska; Journal of Luminescence; vol. 11; nb. 3-4; (1976); p. 173 - 183, View in Reaxys; Lloyd; Transactions of the Faraday Society; vol. 61; (1965); p. 2182,2187, View in Reaxys

Phosphorescence Spectroscopy (1) Description References (Phosphorescence Spectroscopy) Phosphorescence Hercules; Spectrochimica Acta; vol. 19; (1963); p. 788, View in Reaxys Abiotic Degradation, Photolysis (1) 1 of 1

Type (Abiotic Degradation, Photolysis)

thermolysis

Temperature (Abiotic 91 Degradation, Photolysis) [°C] Rate Constant

0.245 per hour

Method, Remarks (Abio- title comp. in polystyrene film (10 wtpercent); heated in air up to 8 h; FT-IR analysis; neartic Degradation, Photol- ly complete degradation after 8 h; figure ysis) Mosnacek, Jaroslav; Weiss, Richard G.; Lukac, Ivan; Macromolecules; vol. 35; nb. 10; (2002); p. 3870 - 3875, View in Reaxys Use (740) Laboratory Use and Handling

Use Pattern

Location

References

Cosmetics/dental/ Page/Page colPatent; Tagra Biotechnologies Ltd.; Goldstein, Danny; Sade, Tal; toilet umn title page; 27 Yasman, Yuri; Privalova, Olga; Benaltabet, Lior; (39 pag.); US9682031; (2017); (B2) English, View in Reaxys microcapsule for treatment of acne

Page/Page colPatent; Tagra Biotechnologies Ltd.; Goldstein, Danny; Sade, Tal; umn title page; 27 Yasman, Yuri; Privalova, Olga; Benaltabet, Lior; (39 pag.); US9682031; (2017); (B2) English, View in Reaxys

Pharmaceuticals

Page/Page column title page; 34-35

Patent; DR. REDDY'S LABORATORIES LTD; PATIL, Sushil Kumar; SONI, Rajeev; VAISHNAV, Kaushalesh Kumar; (43 pag.); WO2017/109761; (2017); (A1) English, View in Reaxys

acne

Page/Page column title page; 34-35

Patent; DR. REDDY'S LABORATORIES LTD; PATIL, Sushil Kumar; SONI, Rajeev; VAISHNAV, Kaushalesh Kumar; (43 pag.); WO2017/109761; (2017); (A1) English, View in Reaxys

acne scars

Page/Page column title page; 34-35

Patent; DR. REDDY'S LABORATORIES LTD; PATIL, Sushil Kumar; SONI, Rajeev; VAISHNAV, Kaushalesh Kumar; (43 pag.); WO2017/109761; (2017); (A1) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

31/162

2018-02-22 00:03:45


inflammatory skin disorder

Page/Page column title page; 34-35

Patent; DR. REDDY'S LABORATORIES LTD; PATIL, Sushil Kumar; SONI, Rajeev; VAISHNAV, Kaushalesh Kumar; (43 pag.); WO2017/109761; (2017); (A1) English, View in Reaxys

skin moisture by minimizing transepidermal water loss

Page/Page column title page; 34-35

Patent; DR. REDDY'S LABORATORIES LTD; PATIL, Sushil Kumar; SONI, Rajeev; VAISHNAV, Kaushalesh Kumar; (43 pag.); WO2017/109761; (2017); (A1) English, View in Reaxys

topical composition in combination with one or more silicone and zinc compounds

Page/Page column title page; 34-35

Patent; DR. REDDY'S LABORATORIES LTD; PATIL, Sushil Kumar; SONI, Rajeev; VAISHNAV, Kaushalesh Kumar; (43 pag.); WO2017/109761; (2017); (A1) English, View in Reaxys

Explosive

He, Benzhao; Wu, Yongwei; Qin, Anjun; Tang, Ben Zhong; Macromolecules; vol. 50; nb. 15; (2017); p. 5719 - 5728, View in Reaxys

Explosive

supporting information

Qian, Bo; Xiong, Haigen; Zhu, Nengbo; Ye, Changqing; Jian, Wujun; Bao, Hongli; Tetrahedron Letters; vol. 57; nb. 30; (2016); p. 3400 - 3403, View in Reaxys

Page/Page column 6-7

Patent; Koenig, David William; Hoffman, Douglas Robert; Huang, Yang; He, Aimin; US2015/110893; (2015); (A1) English, View in Reaxys

water insoluble Page/Page coloxidant for a spor- umn 6-7 icidal formulation

Patent; Koenig, David William; Hoffman, Douglas Robert; Huang, Yang; He, Aimin; US2015/110893; (2015); (A1) English, View in Reaxys

Pharmaceuticals

Page/Page column 43; 46

Patent; GALDERMA RESEARCH and DEVELOPMENT; AUDIBERT, Fabien; KERROUCHE, Nabil; SOTO, Pascale; WO2015/91828; (2015); (A1) English, View in Reaxys

inhibiting or treating severe acne related diseases in combination with the retinoid and the antibiotic

Page/Page column 43; 46

Patent; GALDERMA RESEARCH and DEVELOPMENT; AUDIBERT, Fabien; KERROUCHE, Nabil; SOTO, Pascale; WO2015/91828; (2015); (A1) English, View in Reaxys

Pharmaceuticals

Page/Page column 31; 32

Patent; RANBAXY LABORATORIES LIMITED; DUBEY, Vaibhav; JENA, Simon Santosh; MADAN, Sumit; ARORA, Vinod Kumar; WO2015/92602; (2015); (A1) English, View in Reaxys

component in free-form, in form of microcapsules or in form of microspheres in pharmaceutical composition comprising microspheres and microcapsules of retinoid coated with a polymeric layer

Page/Page column 31; 32

Patent; RANBAXY LABORATORIES LIMITED; DUBEY, Vaibhav; JENA, Simon Santosh; MADAN, Sumit; ARORA, Vinod Kumar; WO2015/92602; (2015); (A1) English, View in Reaxys

in combination with retinoid

Page/Page column 31; 32

Patent; RANBAXY LABORATORIES LIMITED; DUBEY, Vaibhav; JENA, Simon Santosh; MADAN, Sumit; ARORA, Vinod Kumar; WO2015/92602; (2015); (A1) English, View in Reaxys

Polymers/polymer Page/Page colapplications umn 11

Patent; Premier Dental Products Company; Gross, Stephen M.; Latta, Mark A.; US9119774; (2015); (B2) English, View in Reaxys

radical initiator suitable for preparing a dental restorative formulation

Patent; Premier Dental Products Company; Gross, Stephen M.; Latta, Mark A.; US9119774; (2015); (B2) English, View in Reaxys

Detergents/disinfections

Page/Page column 11

Cosmetics/dental/ Page/Page coltoilet umn title page; 13; 14

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

Patent; Weisenfluh, Scott Alan; Desai, Ketan; Kroposky, Sandra; US9138446; (2015); (B2) English, View in Reaxys

32/162

2018-02-22 00:03:45


as active ingredient of composition in combination with Emu oil for treating skin imperfections

Page/Page column title page; 13; 14

Patent; Weisenfluh, Scott Alan; Desai, Ketan; Kroposky, Sandra; US9138446; (2015); (B2) English, View in Reaxys

for treating acne

Page/Page column title page; 13; 14

Patent; Weisenfluh, Scott Alan; Desai, Ketan; Kroposky, Sandra; US9138446; (2015); (B2) English, View in Reaxys

for treating hair loss

Page/Page column title page; 13; 14

Patent; Weisenfluh, Scott Alan; Desai, Ketan; Kroposky, Sandra; US9138446; (2015); (B2) English, View in Reaxys

for treating wrinkles

Page/Page column title page; 13; 14

Patent; Weisenfluh, Scott Alan; Desai, Ketan; Kroposky, Sandra; US9138446; (2015); (B2) English, View in Reaxys

Pharmaceuticals

Page/Page column 33-36

Patent; SOL-GEL TECHNOLOGIES LTD.; SERTCHOOK, Hanan; TOLEDANO, Ofer; BAR-SIMANTOV, Haim; WO2014/83557; (2014); (A1) English, View in Reaxys

acne-rosacea type of rosacea

Page/Page column 33-36

Patent; SOL-GEL TECHNOLOGIES LTD.; SERTCHOOK, Hanan; TOLEDANO, Ofer; BAR-SIMANTOV, Haim; WO2014/83557; (2014); (A1) English, View in Reaxys

alone or in combi- Page/Page colnation with antibi- umn 33-36 otic agent

Patent; SOL-GEL TECHNOLOGIES LTD.; SERTCHOOK, Hanan; TOLEDANO, Ofer; BAR-SIMANTOV, Haim; WO2014/83557; (2014); (A1) English, View in Reaxys

alone or in combi- Page/Page colnation with antimi- umn 33-36 crobial agent

Patent; SOL-GEL TECHNOLOGIES LTD.; SERTCHOOK, Hanan; TOLEDANO, Ofer; BAR-SIMANTOV, Haim; WO2014/83557; (2014); (A1) English, View in Reaxys

alone or in combi- Page/Page colnation with retiumn 33-36 noid

Patent; SOL-GEL TECHNOLOGIES LTD.; SERTCHOOK, Hanan; TOLEDANO, Ofer; BAR-SIMANTOV, Haim; WO2014/83557; (2014); (A1) English, View in Reaxys

alone or in combi- Page/Page colnation with tetra- umn 33-36 cycline agent

Patent; SOL-GEL TECHNOLOGIES LTD.; SERTCHOOK, Hanan; TOLEDANO, Ofer; BAR-SIMANTOV, Haim; WO2014/83557; (2014); (A1) English, View in Reaxys

papularpostular rosacea

Page/Page column 33-36

Patent; SOL-GEL TECHNOLOGIES LTD.; SERTCHOOK, Hanan; TOLEDANO, Ofer; BAR-SIMANTOV, Haim; WO2014/83557; (2014); (A1) English, View in Reaxys

rosacea

Page/Page column 33-36

Patent; SOL-GEL TECHNOLOGIES LTD.; SERTCHOOK, Hanan; TOLEDANO, Ofer; BAR-SIMANTOV, Haim; WO2014/83557; (2014); (A1) English, View in Reaxys

Pharmaceuticals

Page/Page column 7; 8

Patent; CADILA HEALTHCARE LIMITED; Mittal, Ravindra; Roy, Sunilendu Bhushan; Kothari, Jay Shantilal; Sheikh, Shafiq; Patel, Jitendra Dasharathlal; Pancholi, Jinesh Suresh; US2013/337016; (2013); (A1) English, View in Reaxys

anti-acne agent

Page/Page column 7; 8

Patent; CADILA HEALTHCARE LIMITED; Mittal, Ravindra; Roy, Sunilendu Bhushan; Kothari, Jay Shantilal; Sheikh, Shafiq; Patel, Jitendra Dasharathlal; Pancholi, Jinesh Suresh; US2013/337016; (2013); (A1) English, View in Reaxys

for treating acne

Page/Page column 7; 8

Patent; CADILA HEALTHCARE LIMITED; Mittal, Ravindra; Roy, Sunilendu Bhushan; Kothari, Jay Shantilal; Sheikh, Shafiq; Patel, Jitendra Dasharathlal; Pancholi, Jinesh Suresh; US2013/337016; (2013); (A1) English, View in Reaxys

inflammatory lesions

Page/Page column 7; 8

Patent; CADILA HEALTHCARE LIMITED; Mittal, Ravindra; Roy, Sunilendu Bhushan; Kothari, Jay Shantilal; Sheikh, Shafiq; Patel, Jitendra Dasharathlal; Pancholi, Jinesh Suresh; US2013/337016; (2013); (A1) English, View in Reaxys

non-inflammatory lesions

Page/Page column 7; 8

Patent; CADILA HEALTHCARE LIMITED; Mittal, Ravindra; Roy, Sunilendu Bhushan; Kothari, Jay Shantilal; Sheikh, Shafiq; Patel, Jitendra Dasharathlal; Pancholi, Jinesh Suresh; US2013/337016; (2013); (A1) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

33/162

2018-02-22 00:03:45


reducing dryness

Page/Page column 7; 8

Patent; CADILA HEALTHCARE LIMITED; Mittal, Ravindra; Roy, Sunilendu Bhushan; Kothari, Jay Shantilal; Sheikh, Shafiq; Patel, Jitendra Dasharathlal; Pancholi, Jinesh Suresh; US2013/337016; (2013); (A1) English, View in Reaxys

reducing erythema

Page/Page column 7; 8

Patent; CADILA HEALTHCARE LIMITED; Mittal, Ravindra; Roy, Sunilendu Bhushan; Kothari, Jay Shantilal; Sheikh, Shafiq; Patel, Jitendra Dasharathlal; Pancholi, Jinesh Suresh; US2013/337016; (2013); (A1) English, View in Reaxys

reducing itching

Page/Page column 7; 8

Patent; CADILA HEALTHCARE LIMITED; Mittal, Ravindra; Roy, Sunilendu Bhushan; Kothari, Jay Shantilal; Sheikh, Shafiq; Patel, Jitendra Dasharathlal; Pancholi, Jinesh Suresh; US2013/337016; (2013); (A1) English, View in Reaxys

reducing local irri- Page/Page coltation umn 7; 8

Patent; CADILA HEALTHCARE LIMITED; Mittal, Ravindra; Roy, Sunilendu Bhushan; Kothari, Jay Shantilal; Sheikh, Shafiq; Patel, Jitendra Dasharathlal; Pancholi, Jinesh Suresh; US2013/337016; (2013); (A1) English, View in Reaxys

reducing photosensitivity

Page/Page column 7; 8

Patent; CADILA HEALTHCARE LIMITED; Mittal, Ravindra; Roy, Sunilendu Bhushan; Kothari, Jay Shantilal; Sheikh, Shafiq; Patel, Jitendra Dasharathlal; Pancholi, Jinesh Suresh; US2013/337016; (2013); (A1) English, View in Reaxys

reducing the inci- Page/Page coldence and severi- umn 7; 8 ty of acne lesions on the skin

Patent; CADILA HEALTHCARE LIMITED; Mittal, Ravindra; Roy, Sunilendu Bhushan; Kothari, Jay Shantilal; Sheikh, Shafiq; Patel, Jitendra Dasharathlal; Pancholi, Jinesh Suresh; US2013/337016; (2013); (A1) English, View in Reaxys

reducing total number of acne lesions on the skin

Page/Page column 7; 8

Patent; CADILA HEALTHCARE LIMITED; Mittal, Ravindra; Roy, Sunilendu Bhushan; Kothari, Jay Shantilal; Sheikh, Shafiq; Patel, Jitendra Dasharathlal; Pancholi, Jinesh Suresh; US2013/337016; (2013); (A1) English, View in Reaxys

supporting information

Lifchits, Olga; Demoulin, Nicolas; List, Benjamin; Angewandte Chemie - International Edition; vol. 50; nb. 41; (2011); p. 9680 9683, View in Reaxys

avoid contact with heat harmful

Caravano, Audrey; Field, Robert A.; Percy, Jonathan M.; Rinaudo, Giuseppe; Roig, Ricard; Singh, Kuldip; Organic and Biomolecular Chemistry; vol. 7; nb. 5; (2009); p. 996 - 1008, View in Reaxys Bactericidal

Patent; TopoTarget Germany AG; EP1839656; (2007); (A1) English, View in Reaxys; Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

Dermatological conditions

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

Anti-inflammatory/ antipyretic/analgetic drug

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

keratolytic

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

dermatological conditions associated with a keratinization disorder

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

comedonal acne

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

polymorphous acne

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

rosacea acne

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

nodulocystic acne

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

acne conglobara

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

34/162

2018-02-22 00:03:45


senile acne

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

secondary acne

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

solar acne

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

drug acne

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

occupational acne

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

keratinization disorders

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

ichthyosiform states

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

Carrier' s disease

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

palmoplantar keratoderma

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

leukoplakia state

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

leucoplakiform state

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

cutaneous lichen

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

mucous (buccal) lichen

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

dermatological conditions associated with a keratinization disorder having an inflammatory component

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

dermatological conditions associated with a keratinization disorder having immunoallergic component

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

cutaneous psoriasis

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

mucous psoriasis

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

ungula psoriasis

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

psoriatic rheumatism

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

cutaneous atopy

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

respiratory atopy

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

gingival hypertrophy

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

inflammatory conditions that do not

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

35/162

2018-02-22 00:03:45


exhibit keratinization disorders dermal proliferation

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

epidermal proliferation

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

benign dermal proliferation

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

malignant dermal proliferation

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

benign epidermal proliferation

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

malignant epidermal proliferation

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

verrucas

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

plane warts

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

epidermodysplasia verruciformis

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

oral papillomatoses

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

floride papillomatoses

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

proliferations induced by ultraviolet light

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

actinic keratose

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

skin aging

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

light-induced skin aging

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

chronological skin aging

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

skin pigmentation

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

pathologies associated with chronological aging

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

pathologies associated with actinic aging

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

wound-healing disorders

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

striae atrophicae

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

wound healing

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

sebaceous gland disorders

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

hyperseborrhea of acne

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

36/162

2018-02-22 00:03:45


simple seborrhea

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

skin condition of fungal origin

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

tinea pedis

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

tinea versicolor

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

skin disorders due to exposure to UV radiation

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

dermatological conditions associated with an inflammation of the tissues surrounding the hair follicle

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

microbial colonization

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

microbial infection

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

sycosis barbae

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

body hygiene

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

hair hygiene

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

acne-prone skin

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

hair regrowth

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

greasy appearance of the skin

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

greasy appearance of the hair

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

damaging effects of the sun

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

light-induced aging

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

chronological aging

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys

Acne lesions

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys

Non-inflammatory lesions

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys

Open comedones

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys

Closed comedones

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys

Inflammatory lesions

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys

Papules

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

37/162

2018-02-22 00:03:45


Pustules

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys

Nodules

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys

Cysts

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys

Common acne

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys

Comedones

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys

Polymorphs

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys

Nodulocystic acne

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys

Acne conglobata

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys

Secondary acne

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys

Solar acne

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys

Medicational acne

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys

Occupational acne

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys

Dermatoses sensitive to retinoids

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys

Non-inflammatory acne lesions

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys

drug deliver system

Patent; STIEFEL LABORATORIES, INC.; US2008/26039; (2008); (A1) English, View in Reaxys

Skin disoders

Patent; STIEFEL LABORATORIES, INC.; US2008/26039; (2008); (A1) English, View in Reaxys

active ingredient of an antiacne topical preparation

Patent; AHUMADA AYALA, Fernando; WO2008/17914; (2008); (A2) English, View in Reaxys

keratolytic agent

Patent; AHUMADA AYALA, Fernando; WO2008/17914; (2008); (A2) English, View in Reaxys

Initiator for hair treatment

Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys

Initiator for producing desired hair characteristics

Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys

Initiator for improving hair strength

Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys

Initiator for improving hair shine

Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

38/162

2018-02-22 00:03:45


Initiator for improving hair color

Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys

Initiator for improving hair elasticity

Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys

Initiator for improving hair optical properties

Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys

Initiator for generating a particular hairstyle

Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys

Initiator for preserving a particular hairstyle

Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys

Initiator for improving hair luster

Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys

Initiator for improving hair smoothness

Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys

Initiator for improving hair slip

Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys

Initiator for improving hair static control

Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys

Initiator for improving hair distinct feel

Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys

Initiator for styling hair

Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys

Initiator for restoring damaged hair

Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys

Initiator for curling hair

Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys

Initiator for giving hair a wave

Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys

Initiator for giving hair a body

Patent; Anderson, Daniel Griffith; Puerta, David Thomas; Akcasu, Bryan Scott; DeRosa, Mitchell John; Nashat, Amir; Williams, Susan Alice; Ramirez, Richard Matthew; Bedford, Susan Eilidh; US2008/66773; (2008); (A1) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

39/162

2018-02-22 00:03:45


initiator

Patent; Pulpdent Corporation; US7371782; (2008); (B2) English, View in Reaxys

dermatological disorders

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

disturbed keratinization

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

defective syntheses of dermal components

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

xerosis

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

palmar hyperkeratoses

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

plantar hyperkeratoses

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

Darier's disease

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

keratoses

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

eczema

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys; Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

pruritus

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

herpes

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

lentigines

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

melasmas

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

hyperkeratoses

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

hyperpigmented skin

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

diminished syntheses of collagen

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

Abnormal syntheses of collagen

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

Abnormal syntheses of glycosatinoglycans

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

Abnormal syntheses of proteoglycans

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

Abnormal syntheses of elastin

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

diminished levels of components in the dermis

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

Irritation

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

Erythema

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

40/162

2018-02-22 00:03:45


cosmetic conditions

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

changes associated with aging of skin

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

changes associated with aging of nail

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

changes associated with aging of hair

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

Dryness of skin

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

Dryness of nails

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

Dryness of hair

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

rough surface of skin

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

rough surface of nail

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

rough surface of hair

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

dandruff

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

itchy scalp

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

itchy skin

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

age spots

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

blemished skin

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

stretch marks

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

skin lines

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

fine lines

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

thinning of skin

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

nail plate and hair

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

skin thickening due to elastosis of photoaging

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

skin thickening due to reduction of skin

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

skin thickening due to reduction of nail

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

hair resiliency

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

41/162

2018-02-22 00:03:45


elasticity

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

lack of skin

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

nail and hair lubricants and luster

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

dull and olderlooking skin

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

dull and olderlooking nail

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

dull and olderlooking hair

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

fragility

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

splitting of nail

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

splitting of hair

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

recoilability

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

Dryness

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

Damage of skin

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys

anti-acne

Patent; Watson, Dana M.; US2006/19935; (2006); (A1) English, View in Reaxys; Patent; SKINVISIBLE PHARMACEUTICALS, INC.; WO2008/51461; (2008); (A2) English, View in Reaxys

anti-seborrhoeic agent

Patent; Galderma Research and Development, S.N.C.; US2007/269524; (2007); (A1) English, View in Reaxys; Patent; L'OREAL; US2008/119527; (2008); (A1) English, View in Reaxys

disorders associated with greasiness of a dark skin

Patent; L'OREAL; US2008/119527; (2008); (A1) English, View in Reaxys

skin disorders associated with hyperseborrhoea of dark skin

Patent; L'OREAL; US2008/119527; (2008); (A1) English, View in Reaxys

greasy skin

Patent; L'OREAL; US2008/119527; (2008); (A1) English, View in Reaxys

hyperseborrhoea

Patent; L'OREAL; US2008/119527; (2008); (A1) English, View in Reaxys

acne lesions

Patent; L'OREAL; US2008/119527; (2008); (A1) English, View in Reaxys

aesthetic disorders associated with the overproduction of sebum

Patent; L'OREAL; US2008/119527; (2008); (A1) English, View in Reaxys

imperfections associated with the overproduction of sebum

Patent; L'OREAL; US2008/119527; (2008); (A1) English, View in Reaxys

reducing the number of comedones, inflammatory papules, pus-

Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

42/162

2018-02-22 00:03:45


tules, cysts and lesions; reducing the microbial count associated with the secondary infection skin disorders

Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys

perioral dermatitis

Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys

impetigo

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys; Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys

secondary skin infections

Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys

seborrhea

Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys; Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys

skin lesions

Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys

inflammatory skin conditions

Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys

oxidizing agent

Patent; Hofmann, Robert F.; US2006/14732; (2006); (A1) English, View in Reaxys; Patent; Watson, Dana M.; US2006/19935; (2006); (A1) English, View in Reaxys; Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys

Anti-acne agent in composition with extract of Primula denticulata

Patent; Johnson and Johnson Consumer Companies, Inc.; US7381433; (2008); (B1) English, View in Reaxys

cosmetic dermatological preparation

Patent; Brunese, Maria Rosaria; Brunese, Julie; Brunese, Roberto; US2008/63737; (2008); (A1) English, View in Reaxys

in combination with α2-adrenoceptor agonists and anti-muscarinic agent for treatment of condition associated with excess sebum production or excretion

Patent; DANIOLABS LTD.; WO2008/59190; (2008); (A1) English, View in Reaxys

bacteriostatic effect on Corynebacterium acnes, reduces the level of free fatty acids in sebaceous secretions; has keratolytic and strong oxidizing properties

Patent; GALDERMA S.A.; US2008/153901; (2008); (A1) English, View in Reaxys

manufacture of a medicament for treating skin conditions

Patent; GALDERMA S.A.; US2008/153901; (2008); (A1) English, View in Reaxys

common acne

Patent; GALDERMA S.A.; US2008/153901; (2008); (A1) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

43/162

2018-02-22 00:03:45


anti-infectious agent

Patent; Galderma Research and Development, S.N.C.; US2007/269524; (2007); (A1) English, View in Reaxys; Patent; GALDERMA S.A.; US2008/153901; (2008); (A1) English, View in Reaxys

dermatological composition

Patent; GALDERMA S.A.; US2008/153901; (2008); (A1) English, View in Reaxys

composition comprising a hydroxycinnamic acid or methoxycinnamic acid, or mixtures thereof, useful for the treating aging human skin to maintain or improve at least visible indicia of aging

Patent; LIPO CHEMICALS INC.; WO2008/73684; (2008); (A1) English, View in Reaxys

exfoliation promoter for cosmetic nanocomposite pigment composition effective in improving aesthetic and natural appearance of skin and other biological surfaces

Patent; AVON PRODUCTS, INC.; WO2008/79760; (2008); (A2) English, View in Reaxys

composition comprising colloidal metals suitable for the treatment and prevention of skin diseases

Patent; PHARMWEST, INC.; WO2008/79898; (2008); (A1) English, View in Reaxys

composition comprising colloidal metals suitable for the treatment and prevention of skin conditions

Patent; PHARMWEST, INC.; WO2008/79898; (2008); (A1) English, View in Reaxys

Personal care composition

Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys

Color cosmetic

Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys

Lipstick

Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys

Foundation

Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys

Shampoo

Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys

Hair conditioner

Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys

Hair fixative

Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys

Shower gel

Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys

Skin moisturizer

Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys

Skin conditioner

Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

44/162

2018-02-22 00:03:45


Body conditioner

Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys

Sun protection product

Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys

Antiperspirant

Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys

Deodorant

Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys

Insect repellants

Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys

Sunscreens

Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys

Acne vulgaris

Patent; ASPEN BENEFITS GROUP, LLC; WO2007/53422; (2007); (A1) English, View in Reaxys; Patent; Abram, Albert Zorko; Fuchshuber, Lilian; US2007/237724; (2007); (A1) English, View in Reaxys; Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/92911; (2008); (A1) English, View in Reaxys

Disorders of keratinisation

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/92911; (2008); (A1) English, View in Reaxys

Disorders of proliferation

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/92911; (2008); (A1) English, View in Reaxys

Disorders of differentiation

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/92911; (2008); (A1) English, View in Reaxys

Retinoid-sensitive dermatoses

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/92911; (2008); (A1) English, View in Reaxys

Treating a surface condition

Patent; SOL-GEL TECHNOLOGIES LTD.; WO2008/93346; (2008); (A2) English, View in Reaxys

Acne

Patent; ALPHARX INC.; US2005/255133; (2005); (A1) English, View in Reaxys; Patent; MIDWEST RESEARCH LABORATORIES, LLC; WO2005/112872; (2005); (A1) English, View in Reaxys; Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys; Patent; ASPEN BENEFITS GROUP, LLC; WO2007/53422; (2007); (A1) English, View in Reaxys; Patent; Imaginative Research Associates, Inc.; EP1813277; (2007); (A1) English, View in Reaxys; Patent; Abram, Albert Zorko; Fuchshuber, Lilian; US2007/237724; (2007); (A1) English, View in Reaxys; Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys; Patent; STIEFEL LABORATORIES, INC.; US2008/26039; (2008); (A1) English, View in Reaxys; Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys; Patent; DOW CORNING CORPORATION; WO2008/85360; (2008); (A2) English, View in Reaxys; Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/92911; (2008); (A1) English, View in Reaxys; Patent; SOL-GEL TECHNOLOGIES LTD.; WO2008/93346; (2008); (A2) English, View in Reaxys

Rosacea

Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys; Patent; SOL-GEL TECHNOLOGIES LTD.; WO2008/93346; (2008); (A2) English, View in Reaxys

Psoriasis

Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys; Patent; SOL-GEL TECHNOLOGIES LTD.; WO2008/93346; (2008); (A2) English, View in Reaxys

Photoaging skin

Patent; SOL-GEL TECHNOLOGIES LTD.; WO2008/93346; (2008); (A2) English, View in Reaxys

Hyperpigmented skin

Patent; SOL-GEL TECHNOLOGIES LTD.; WO2008/93346; (2008); (A2) English, View in Reaxys

Mucosal infected areas

Patent; SOL-GEL TECHNOLOGIES LTD.; WO2008/93346; (2008); (A2) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

45/162

2018-02-22 00:03:45


Inflamed dermatitis

Patent; SOL-GEL TECHNOLOGIES LTD.; WO2008/93346; (2008); (A2) English, View in Reaxys

free radical initiator of polymerization

Patent; Godwin, Allen D.; Buturla, Kenneth J.; Colle, Karla S.; Kiss, Gabor; Nadler, Kirk C.; Patil, Abhimanyu O.; Pike, Edris Eileen; Saleh, Ramzi Y.; Stanat, Jon E.; Varma-Nair, Manika; Zushma, Stephen; US2008/242895; (2008); (A1) English, View in Reaxys

in combination with a retinoid receptor agonist as active ingredients of a composition suitable for treating acne

Patent; ALMIRALL HERMAL GMBH; WO2008/107193; (2008); (A1) English, View in Reaxys

polymerisation initiator for preparing a cross-linked gelatin suitable for the prepation of controlled release compositions

Patent; FUJIFILM Manufacturing Europe B.V.; EP1961411; (2008); (A1) English, View in Reaxys

greasy seborrhoea

Patent; CARDON PHAMACEUTICALS NV; US2008/103117; (2008); (A1) English, View in Reaxys

ingredient of a composition suitable for the treatment of animals

Patent; CARDON PHAMACEUTICALS NV; US2008/103117; (2008); (A1) English, View in Reaxys

seborrheic dermatitis

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

lichen simplex chronicus

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

pseudofolliculitis barbae

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

antimicrobial agent

Patent; ECOLAB, INC.; EP1738758; (2007); (A1) English, View in Reaxys; Patent; Lane, Jonathan Douglas; US2008/269222; (2008); (A1) English, View in Reaxys

photosensitizer of dental composition for making dental prostheses and for dental restoration

Patent; RHODIA CHIMIE; US2008/287562; (2008); (A1) English, View in Reaxys

acne

Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys; Patent; Shanler, Stuart D.; Ondo, Andrew; US2005/165079; (2005); (A1) English, View in Reaxys; Patent; Medpak LLC; US2005/208153; (2005); (A1) English, View in Reaxys; Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys; Patent; JR CHEM, LLC; US2006/204530; (2006); (A1) English, View in Reaxys; Patent; Lane, Jonathan Douglas; US2008/269222; (2008); (A1) English, View in Reaxys; Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

46/162

2018-02-22 00:03:45


bacterial skin infections

Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

folliculitis

Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys; Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys; Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys; Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

hidradenitis suppurativa

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

warts

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

molluscum contagiosum

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

psoriasis

Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys; Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys; Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys; Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

ichthyosis

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys; Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

skin ulcers

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

atopic dermatitis

Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

rosacea

Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys; Patent; Shanler, Stuart D.; Ondo, Andrew; US2005/165079; (2005); (A1) English, View in Reaxys; Patent; Galderma Research and Development, S.N.C.; US2007/269524; (2007); (A1) English, View in Reaxys; Patent; STIEFEL LABORATORIES, INC.; WO2008/57411; (2008); (A1) English, View in Reaxys; Patent; GALDERMA S.A.; US2008/153901; (2008); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

hair loss

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys; Patent; Phar-

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

47/162

2018-02-22 00:03:45


macia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys wrinkles

Patent; Green, Barbara A.; Milora, David J.; US2008/113037; (2008); (A1) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

acne vulgaris

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6848; (2008); (A1) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

initiator for preparation of bone cement

Patent; DISC-O-TECH MEDICAL TECHNOLOGIES LTD.; WO2008/32322; (2008); (A2) English, View in Reaxys

Skin disorders

Patent; ALPHARX INC.; US2005/255133; (2005); (A1) English, View in Reaxys; Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys

radical initiator

Patent; Sumitomo Chemical Company, Limited; EP1683777; (2006); (A1) English, View in Reaxys; Patent; UNIVERSITY OF SOUTH CAROLINA; WO2007/8927; (2007); (A2) English, View in Reaxys; Patent; Solvay SA; EP1757570; (2007); (A1) English, View in Reaxys

oxygen component of antimicrobial composition

Patent; ECOLAB, INC.; EP1738758; (2007); (A1) English, View in Reaxys

auto cure initiator used to create a two-part system that cures when the components are mixed together

Patent; Pulpdent Corporation; US7157502; (2007); (B2) English, View in Reaxys

Microbial infections

Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys

Inflammation of tissue

Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys

P. acnes

Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys

Strep. pyogenes

Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys

E. coli

Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys

Pseudomonas aeruginosa

Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys

Staph. aureus

Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys

Impetigo

Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys

Dermatitis

Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys

Secondary skin infectionss

Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys

Responsive dermatoses

Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys

Seborrhea

Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys

Skin lesions

Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

48/162

2018-02-22 00:03:45


Atopic dermatitis

Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys

Bacterial skin infections

Patent; STIEFEL LABORATORIES, INC.; US2007/3585; (2007); (A1) English, View in Reaxys

tablets with reinforcement depressions on the upper side

Patent; Holderbaum, Thomas; Pegelow, Ulrich; Nitsch, Christian; Steffen-Holderbaum, Uta; US2007/9561; (2007); (A1) English, View in Reaxys

compressed particulate washing or cleaning composition

Patent; Holderbaum, Thomas; Pegelow, Ulrich; Nitsch, Christian; Steffen-Holderbaum, Uta; US2007/9561; (2007); (A1) English, View in Reaxys

organic bleache

Patent; Holderbaum, Thomas; Pegelow, Ulrich; Nitsch, Christian; Steffen-Holderbaum, Uta; US2007/9561; (2007); (A1) English, View in Reaxys

antibacterial composition for skin infection

Patent; Jones, George; US2007/9607; (2007); (A1) English, View in Reaxys

anti-inflammatory composition for skin infection

Patent; Jones, George; US2007/9607; (2007); (A1) English, View in Reaxys

manufacture of biodegradable and crosslinkable polymer

Patent; UNIVERSITY OF SOUTH CAROLINA; WO2007/8927; (2007); (A2) English, View in Reaxys

polymerization initiator for dental material

Patent; Dodiuk-Kenig, Hanna; Zalsman, Barry; Lisenboim, Kira; McHale, William A.; US2007/43142; (2007); (A1) English, View in Reaxys

radiopaque acrylic bone cement for orthopaedic use

Patent; Tecres, S.p.A.; US7186761; (2007); (B2) English, View in Reaxys

pharmaceutical composition comprising alkanolamine, soy and/or feverfew for mitigating redness or inflammation of skin

Patent; Tierney, Neena; Martin, Katharine; Mitchell, Phyllis; Southall, Michael; US2007/59259; (2007); (A1) English, View in Reaxys

Therapeutic agent for an orally-dissolvable, edible film

Patent; Maibach, Todd; US2007/59346; (2007); (A1) English, View in Reaxys

Dermatological agent

Patent; Maibach, Todd; US2007/59346; (2007); (A1) English, View in Reaxys

Crosslinking agent

Patent; Sumitomo Rubber Industries, Ltd.; US2007/78218; (2007); (A1) English, View in Reaxys

skin care agent

Patent; ENGINEERED RELEASE SYSTEMS, INC.; WO2007/9023; (2007); (A2) English, View in Reaxys

Reduces side effects associated with the ingredients used

Patent; ASPEN BENEFITS GROUP, LLC; WO2007/53422; (2007); (A1) English, View in Reaxys

Symptoms associated with acne

Patent; ASPEN BENEFITS GROUP, LLC; WO2007/53422; (2007); (A1) English, View in Reaxys

Propionibacterium acnes

Patent; ASPEN BENEFITS GROUP, LLC; WO2007/53422; (2007); (A1) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

49/162

2018-02-22 00:03:45


Acne causation factors due to oxidative effect

Patent; ASPEN BENEFITS GROUP, LLC; WO2007/53422; (2007); (A1) English, View in Reaxys

Anti-acne

Patent; Liegeois, Nanette; US2007/207115; (2007); (A1) English, View in Reaxys; Patent; THE BOOTS COMPANY PLC; WO2006/51246; (2006); (A1) English, View in Reaxys

free-radical polymerization initiator

Patent; Li, Zhi; Iqbal, Rifat; Wang, Jun; US2006/241220; (2006); (A1) English, View in Reaxys; Patent; Tecres, S.p.A.; US7186761; (2007); (B2) English, View in Reaxys

Initiator for BaylisHillman reaction for prudusing coating materials containing α-(1'hydroxyalkyl)acrylates

Patent; Schwalm, Reinhold; Beck, Erich; Heischkel, Yvonee; Gruber, Nick; Larbig, Harald; US2007/135556; (2007); (A1) English, View in Reaxys

initiator for manufacturing an ionomeric resin suitable for manufacturing a flexible wound dressing

Patent; Den-Mat Corporation; US2007/154528; (2007); (A1) English, View in Reaxys

Crosslinking initiator in an injectable bone cement for fixing bone fractures

Patent; Goupil, Dennis W.; Asfaw, Bruktawit T.; US2007/149641; (2007); (A1) English, View in Reaxys

Crosslinking initiator in an injectable bone cement to treat porous bone

Patent; Goupil, Dennis W.; Asfaw, Bruktawit T.; US2007/149641; (2007); (A1) English, View in Reaxys

Crosslinking initiator in an injectable bone cement to treat osteoporotic bone

Patent; Goupil, Dennis W.; Asfaw, Bruktawit T.; US2007/149641; (2007); (A1) English, View in Reaxys

Temporary dental restorative

Patent; Tiba, Amer; Charlton, David G.; Ragain, James C.; US2007/173559; (2007); (A1) English, View in Reaxys

Oxidizing agent for solid biocide composition

Patent; SANDERSON, William, D.; WO2007/78838; (2007); (A2) English, View in Reaxys

Comedonalbased acne

Patent; Liegeois, Nanette; US2007/207115; (2007); (A1) English, View in Reaxys

Acne/rosacea combination

Patent; Liegeois, Nanette; US2007/207115; (2007); (A1) English, View in Reaxys

Pustular variants of acne

Patent; Liegeois, Nanette; US2007/207115; (2007); (A1) English, View in Reaxys

Severe acne

Patent; Liegeois, Nanette; US2007/207115; (2007); (A1) English, View in Reaxys

Anti-inflammatory

Patent; Liegeois, Nanette; US2007/207115; (2007); (A1) English, View in Reaxys

Follicular based beard acne

Patent; Liegeois, Nanette; US2007/207115; (2007); (A1) English, View in Reaxys

anti-acne medicament

Patent; LUBRIZOL ADVANCED MATERIALS, INC.; WO2007/101059; (2007); (A2) English, View in Reaxys

Dermatological condition

Patent; Abram, Albert Zorko; Fuchshuber, Lilian; US2007/237724; (2007); (A1) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

50/162

2018-02-22 00:03:45


Rashes

Patent; Abram, Albert Zorko; Fuchshuber, Lilian; US2007/237724; (2007); (A1) English, View in Reaxys

Eczema

Patent; Abram, Albert Zorko; Fuchshuber, Lilian; US2007/237724; (2007); (A1) English, View in Reaxys

Contact dermatitis

Patent; Abram, Albert Zorko; Fuchshuber, Lilian; US2007/237724; (2007); (A1) English, View in Reaxys

Acne rosacea

Patent; Abram, Albert Zorko; Fuchshuber, Lilian; US2007/237724; (2007); (A1) English, View in Reaxys

Fungal infections

Patent; Abram, Albert Zorko; Fuchshuber, Lilian; US2007/237724; (2007); (A1) English, View in Reaxys

Bacterial infections

Patent; Abram, Albert Zorko; Fuchshuber, Lilian; US2007/237724; (2007); (A1) English, View in Reaxys

Anti-acne agent

Patent; AMCOL INTERNATIONAL CORPORATION; WO2007/114904; (2007); (A2) English, View in Reaxys

Skin treatment

Patent; AMCOL INTERNATIONAL CORPORATION; WO2007/114904; (2007); (A2) English, View in Reaxys

Controlling excess skin oil

Patent; AMCOL INTERNATIONAL CORPORATION; WO2007/114904; (2007); (A2) English, View in Reaxys

Adsorption of moisture

Patent; AMCOL INTERNATIONAL CORPORATION; WO2007/114904; (2007); (A2) English, View in Reaxys

heat cure initiator of polymeric matrix of dental material

Patent; Jia, Weitao; Jin, Shuhua; US2007/232718; (2007); (A1) English, View in Reaxys

fibrosis inhibitor; inflammation inhibitor; acute inflammatory response inhibitor; migration or proliferation of connective tissue cells inhibitor; angiogenesis inhibitor; tissue remodelling inhibitor; reduces extracellular matrix (ECM) production; promotes ECM breakdown; collagen production inhibitor; collagen release inhibitor

Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys

Excessive scarring

Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys

Surgical adhesion

Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys

Fibrosis

Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys

Hypertrophic scar

Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys

Abdominal surgery

Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys

gynecological surgery

Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys

Hysterectomies

Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

51/162

2018-02-22 00:03:45


Suture granulomas

Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys

Stitch abscess

Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys

Local irritation

Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys

Tissue necrosis

Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys

Side effects of surgical adhesion

Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys

Scarring

Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys

Tissue irritation

Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys

Improving skin retention time

Patent; CRODA, INC; WO2007/127158; (2007); (A2) English, View in Reaxys

Decreasing flux

Patent; CRODA, INC; WO2007/127158; (2007); (A2) English, View in Reaxys

keloid

Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

Polymerization initiator

Patent; Toumi, Beatrice; US2005/281769; (2005); (A1) English, View in Reaxys; Patent; ROHMAX ADDITIVES GMBH; US2007/191238; (2007); (A1) English, View in Reaxys; Patent; Great Lakes Chemical (Europe) GmbH; EP1124787; (2003); (B1) English, View in Reaxys; Patent; QUICK-MED TECHNOLOGIES, INC.; WO2005/84436; (2005); (A1) English, View in Reaxys

Anti-microbial agent for cosmetic compositions

Page/Page column 9; 12

Patent; General Electric Company; US2007/134283; (2007); (A1) English, View in Reaxys

anti-acne agent

Patent; Estanislao, Roderico B.; Lambino, Danilo L.; Lim, Connie; Sugimoto, Maki; US2005/74484; (2005); (A1) English, View in Reaxys; Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/8537; (2006); (A1) English, View in Reaxys; Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys; Patent; Or-Le-Or Ltd.; EP1685824; (2006); (A1) English, View in Reaxys; Patent; REVANCE THERAPEUTICS, INC.; WO2006/105450; (2006); (A2) English, View in Reaxys; Patent; Bhatnagar, Rajendra S.; US2006/293227; (2006); (A1) English, View in Reaxys; Patent; Bhatnagar, Rajendra S.; US2006/293228; (2006); (A1) English, View in Reaxys

papulo-pustular inflammatory acne

Patent; Watson, Dana M.; US2006/19935; (2006); (A1) English, View in Reaxys

Oxidizing agent for cracking hydrocarbon feedstock

Patent; Keusenkothen, Paul F.; US2006/14994; (2006); (A1) English, View in Reaxys

thermal free radical initiator

Patent; Pearson, Jason Clay; Weaver, Max Allen; Fleischer, Jean Carroll; King, Gregory Allan; US2006/115516; (2006); (A1) English, View in Reaxys

radical polymerization initiator

Patent; ASAHI GLASS COMPANY LTD.; EP1679311; (2006); (A1) English, View in Reaxys

halogenation of aralkyl compounds

Patent; Sumitomo Chemical Company, Limited; EP1683777; (2006); (A1) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

52/162

2018-02-22 00:03:45


Free radical initiator

Patent; THE GOODYEAR TIRE and RUBBER COMPANY; EP1681293; (2006); (A1) English, View in Reaxys

Topical acne drug

Patent; Leonard, Todd; US2006/122282; (2006); (A1) English, View in Reaxys

Skin and mucous membrane miscellaneous antiinfective

Patent; Leonard, Todd; US2006/122282; (2006); (A1) English, View in Reaxys

thermal radical initiator for synthesis of carbon-isotope labeled compounds

Patent; Langstrom, Bengt; Itsenko, Oleksiy; Kihlberg, Tor; US2006/171882; (2006); (A1) English, View in Reaxys

ingredient of topical composition beneficial for skin care

Patent; Or-Le-Or Ltd.; EP1685824; (2006); (A1) English, View in Reaxys

chemical initiator of polymerization

Patent; Abels, Norbert; Fischer, Dan E.; Backes, Claus-H; US2006/189707; (2006); (A1) English, View in Reaxys

Initiator of polymerization for dental sealant composition

Patent; DENTSPLY DE TREY GMBH; WO2006/10631; (2006); (A1) English, View in Reaxys

Antidandruff

Patent; L'OREAL; US2006/159730; (2006); (A1) English, View in Reaxys

topical application to the skin

Patent; JR CHEM, LLC; US2006/204530; (2006); (A1) English, View in Reaxys

Acne Vulgaris

Patent; JR CHEM, LLC; US2006/204530; (2006); (A1) English, View in Reaxys

Polymerization initiator for dental self-curing resin cement composition

Patent; Dentkist, Inc.; US7115674; (2006); (B2) English, View in Reaxys

Component for skin lotions of invention

Patent; HY-GENE BIOMEDICAL CORPORATION; WO2006/31230; (2006); (A1) English, View in Reaxys

Initiator of radical polymerisation

Patent; CELANESE EMULSIONS GMBH; WO2006/34762; (2006); (A2) German, View in Reaxys

keratolytic agent that removes the dead and damaged skin cells

Patent; TARO PHARMACEUTICALS U.S.A., INC.; RAO, Srinivasa; DIXIT, Suresh; OBE, Folusho; GOYAL, Sandhya; YACOBI, Avraham; WO2006/102004; (2006); (A2) English, View in Reaxys

anti-acne drug

Patent; ZYMES, LLC; WO2006/107825; (2006); (A2) English, View in Reaxys

Component of skin-health-improving formulations

Patent; ZYMES, LLC; WO2006/107825; (2006); (A2) English, View in Reaxys

Polymerization initiator for an uncured dental composition

Patent; Anton, Douglas Robert; Jaycox, Gary Delmar; US2006/258771; (2006); (A1) English, View in Reaxys

free radical crosslinker

Patent; Pluyter, Johan Gerwin Lodewijk; anastasiou, Theodore James; US2006/248665; (2006); (A1) English, View in Reaxys

Oxygen component for preparation of the antimi-

Patent; ECOLAB INC.; US2006/257498; (2006); (A1) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

53/162

2018-02-22 00:03:45


crobial composition Oil control agent

Patent; Bissett, Donald Lynn; Mitra, Shekhar; US2006/275237; (2006); (A1) English, View in Reaxys

cosmetic composition comprising transforming growth factor-β (TGF-β) mimic used for treatment of skin

Patent; Bhatnagar, Rajendra S.; US2006/293227; (2006); (A1) English, View in Reaxys

in combination with peptide useful for teatment of dermatitis, psoriasis, acne, urticaria, mucositis, and a wound

Patent; Bhatnagar, Rajendra S.; US2006/293228; (2006); (A1) English, View in Reaxys

chemical initiator

Patent; KANCA, John, III; WO2006/91855; (2006); (A1) English, View in Reaxys

Tooth whitening agent

Patent; CORIUM INTERNATIONAL, INC.; A.V. TOPCHIEV INSTITUTE OF PETROCHEMICAL SYNTHESIS; WO2006/69236; (2006); (A2) English, View in Reaxys

organic peroxide initiator for the peroxide curing system

Patent; 3M INNOVATIVE PROPERTIES COMPANY; WO2006/55220; (2006); (A1) English, View in Reaxys; Patent; 3M INNOVATIVE PROPERTIES COMPANY; WO2006/55274; (2006); (A1) English, View in Reaxys

Reducing agent for skin cleansing system

Patent; Kimberly-Clark Worldwide, Inc.; US2006/140899; (2006); (A1) English, View in Reaxys

topical acne drug for adhesive skin patch

Patent; NU-TEIN CO., INC.; LEONARD, Todd; WO2006/62740; (2006); (A2) English, View in Reaxys

mucous membrane miscellaneous anti-infective

Patent; NU-TEIN CO., INC.; LEONARD, Todd; WO2006/62740; (2006); (A2) English, View in Reaxys

skin miscellaneous anti-infective

Patent; NU-TEIN CO., INC.; LEONARD, Todd; WO2006/62740; (2006); (A2) English, View in Reaxys

Antibacterial drug

Patent; THE BOOTS COMPANY PLC; WO2006/51246; (2006); (A1) English, View in Reaxys

Antimicrobial agent

Patent; THE BOOTS COMPANY PLC; WO2006/51246; (2006); (A1) English, View in Reaxys

Initiator

Patent; Myung, David; Noolandi, Jaan; Smith, Alan J.; Frank, Curtis W.; Ta, Christopher; Hu, Yin; Koh, Won-Gun; Carrasco, Michael R.; US2006/83773; (2006); (A1) English, View in Reaxys

producing a hydrogel composition comprising crosslinked poly(ethylene oxide) useful for wound dressing

Patent; DePuy Products, Inc.; EP1642595; (2006); (A1) English, View in Reaxys

crosslinking agent

Patent; DePuy Products, Inc.; EP1642595; (2006); (A1) English, View in Reaxys

component comosition for the treating mammalian skin and hair

Patent; LIPO CHEMICALS, INC.; WO2006/36557; (2006); (A1) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

54/162

2018-02-22 00:03:45


polymerization initiator for transparent resin matrix for temporary cosmetic dental coating

Patent; Hurwitz, Mami Markell; Narasimhan, Dave; US2006/63853; (2006); (A1) English, View in Reaxys

curable composition

Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys

restorative material

Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys

prosthesis

Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys

cement

Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys

cavity liner

Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys

varnish

Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys

sealer

Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys

hip prostheses

Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys

dental fissure sealers

Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys

temporary or permanent crowns

Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys

temporary or permanent bridges

Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys

cemented orthodontic appliances

Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys

veneer

Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys

bonding material

Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys

diseased tooth

Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys

cavity

Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys

caries

Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys

broken tooth

Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys

discolored tooth

Patent; Orlowski, Jan A.; Butler, David V.; Chin, Alice; US2006/35997; (2006); (A1) English, View in Reaxys

follicular diseases

Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys

follicular rash

Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys

follicular infections

Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys

psudofolliculitis barbe

Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys

follicular ketarosis

Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

55/162

2018-02-22 00:03:45


phrynoderma

Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys

ichthyosis follicularis

Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys

follicular dysplasia

Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys

antimicrobial agent of cleansing composition

Patent; L'OREAL; US2006/18865; (2006); (A1) English, View in Reaxys

formulation for resolve scar tissue

Patent; Hofmann, Robert F.; US2006/14732; (2006); (A1) English, View in Reaxys

scar tissue resulting from a burn

Patent; Hofmann, Robert F.; US2006/14732; (2006); (A1) English, View in Reaxys

burn-related injuries

Patent; Hofmann, Robert F.; US2006/14732; (2006); (A1) English, View in Reaxys

hypertrichosis

Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

hirsutism

Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

polymerization initiator

Patent; BASF AKTIENGESELLSCHAFT; US2005/196444; (2005); (A1) English, View in Reaxys; Patent; Ahn, Sung Hee; Yang, Jae Ho; Hong, Sang Hyun; Bae, Su Hak; Ryu, Young Sik; US2006/183825; (2006); (A1) English, View in Reaxys

keratosis pilaris

Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

alopecia

Patent; Wu, Jeffrey M.; Liu, Jue-Chen; Chantalat, Jeannette; Sun, Ying; US2006/9499; (2006); (A1) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

free radical polymerization initiator

Patent; Farcet, Celine; US2006/8431; (2006); (A1) English, View in Reaxys

free-radical polymerization initiator

Page/Page column 11

Patent; Mougin, Nathalie; US2006/88487; (2006); (A1) English, View in Reaxys

polymerization ini- Page/Page coltiator umn 14

Patent; L'OREAL; WO2006/106487; (2006); (A1) English, View in Reaxys

source of peroxide for conducting a chemiluminescent assay of detecting complexbound microorganisms

Patent; Olstein, Alan D.; Feirtag, Joellen; US2005/26813; (2005); (A1) English, View in Reaxys

component of emulsion for topical application to the skin

Patent; Hy-Gene Biomedical Corporation; US2005/36972; (2005); (A1) English, View in Reaxys

component of spray for application to surfaces

Patent; Hy-Gene Biomedical Corporation; US2005/36972; (2005); (A1) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

56/162

2018-02-22 00:03:45


treatment of blemishes

Patent; Fusco, Normajean; US2005/53595; (2005); (A1) English, View in Reaxys

anti-acne agent for medicinal compositions

Patent; GALDERMA RESEARCH and DEVELOPMENT, S.N.C.; WO2005/58312; (2005); (A1) English, View in Reaxys

polymerization thermal initiator

Patent; Burtscher, Peter; Madler, Lutz; Moszner, Nobert; Pratsinis, Sotiris E.; Rheinberger, Volker M.; US2005/176843; (2005); (A1) English, View in Reaxys

chlorination catalyst

Patent; Central Glass Co., Ltd; JP2005/200396; (2005); (A) Japanese, View in Reaxys

Component for pharmaceutical composition for the treatment of acne vulgaris

Patent; Bernstein, Joel E.; US2005/169948; (2005); (A1) English, View in Reaxys

Component for pharmaceutical composition for the treatment of acne rosacea

Patent; Bernstein, Joel E.; US2005/169948; (2005); (A1) English, View in Reaxys

bleach solution

Patent; Brennen Medical, Inc.; Carbon Medical Technologies, Inc.; US6933103; (2005); (B1) English, View in Reaxys

medicament

Patent; Medpak LLC; US2005/208153; (2005); (A1) English, View in Reaxys

therapy

Patent; Medpak LLC; US2005/208153; (2005); (A1) English, View in Reaxys

dental material

Patent; Ivoclar Vivadent AG; US6953832; (2005); (B2) English, View in Reaxys

thermal initiator

Patent; Ivoclar Vivadent AG; US6953832; (2005); (B2) English, View in Reaxys

elimination of allergen(s) from the skin's surface

Patent; ALPHARX INC.; US2005/255133; (2005); (A1) English, View in Reaxys

viral infection

Patent; ALPHARX INC.; US2005/255133; (2005); (A1) English, View in Reaxys

Microbial infection

Patent; ALPHARX INC.; US2005/255133; (2005); (A1) English, View in Reaxys

Radical initiator in the reactions of chlorination

Patent; SOLVAY FLUOR GMBH; WO2005/123636; (2005); (A1) German, View in Reaxys

Initiator of a freeradical polymerization reaction

Patent; Lemoine, Guy; Youssef, Boulos; Bunel, Claude; Jolivet, Yannick; Pinoche, Jean-Marie; US2005/256350; (2005); (A1) English, View in Reaxys

oxidizing agent for removing a biocompatible hydrogel from a patient

Patent; Pritchard, Wilson; Flowers, Cedric; Prescott, Tony; Mendius, Rick; Hallam, Clive; US2005/220882; (2005); (A1) English, View in Reaxys

sexual dysfunction

Patent; MIDWEST RESEARCH LABORATORIES, LLC; WO2005/112872; (2005); (A1) English, View in Reaxys

Human sexual dysfunction

Patent; MIDWEST RESEARCH LABORATORIES, LLC; WO2005/112872; (2005); (A1) English, View in Reaxys

sexual arousal

Patent; MIDWEST RESEARCH LABORATORIES, LLC; WO2005/112872; (2005); (A1) English, View in Reaxys

whitening agent

Patent; Hassan, Mahmoud; Xu, Guofeng; Viscio, David; Gaffar, Abdul; US2005/249678; (2005); (A1) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

57/162

2018-02-22 00:03:45


Oxidizing agent for sinthesis of drug for effectively stimulate bone regeneration and increase osteoblastic activity

Patent; Hofmann, Robert F.; US2005/250755; (2005); (A1) English, View in Reaxys

Oxidizing agent for sinthesis of drug against agerelated macular degeneration

Patent; Hofmann, Robert F.; US2005/250756; (2005); (A1) English, View in Reaxys

Oxidizing agent for sinthesis of drug against lymphoma

Patent; Hofmann, Robert F.; US2005/250757; (2005); (A1) English, View in Reaxys

initiator for preparing silver/polymer composite nanospheres for preservation of cosmetics

Patent; AMOREPACIFIC CORPORATION; WO2005/77329; (2005); (A1) English, View in Reaxys

antiacne component of treatment composition

Patent; Shanler, Stuart D.; Ondo, Andrew; US2005/165079; (2005); (A1) English, View in Reaxys

discreet erythema of the skin

Patent; Shanler, Stuart D.; Ondo, Andrew; US2005/165079; (2005); (A1) English, View in Reaxys

skin redness

Patent; Shanler, Stuart D.; Ondo, Andrew; US2005/165079; (2005); (A1) English, View in Reaxys

chronic sun damage

Patent; Shanler, Stuart D.; Ondo, Andrew; US2005/165079; (2005); (A1) English, View in Reaxys

allergic rhinitis

Patent; Shanler, Stuart D.; Ondo, Andrew; US2005/165079; (2005); (A1) English, View in Reaxys

skin exfoliant as component of the topical preparation for reducing an occurrence of irritation and/or inflammatory reaction in human skin

Patent; PCR TECHNOLOGY HOLDINGS, LC; WO2005/79775; (2005); (A1) English, View in Reaxys

antibacterial agent

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

dermatological or mucosal disorder

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

disorder of the skin, mucosal membrane, vagina and rectum

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

Pain

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

nummular dermatitis

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

chronic dermatitis of the hands and feet

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

generalized exfoliative dermatitis

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

58/162

2018-02-22 00:03:45


stasis dermatitis

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

diaper rash

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

bacterial infections

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

staphylococcal scalded skin syndrome

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

fungal infections

Patent; ALPHARX INC.; US2005/255133; (2005); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

dermatophyte infections

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

yeast infections

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

parasitic infections

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

viral infections

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

disorders of hair follicles and sebaceous glands

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

peroral dermatitis

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

male pattern baldness

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

alopecia areata

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

alopecia universalis

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

alopecia totalis

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

keratinous cyst

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

scaling papular diseases

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

benign tumors

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

dysplastic nevi

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

skin tags

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

lipomas

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

angiomas

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

pyogenic granuloma

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

seborrheic keratoses

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

dermatofibroma

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

59/162

2018-02-22 00:03:45


keratoacanthoma

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

malignant tumors

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

Paget's disease of the nipples

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

reactions to sunlight

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

bullous diseases

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

linear immunoglobulin A disease

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

vitiligo

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

albinism

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

postinflammatory hypopigmentation

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

hyperpigmentation

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

melasma

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

chloasma

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

drug-induced hyperpigmentation

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

postinflammatory hyperpigmentation

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

calluses

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

actinic keratosis

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

pressure sores

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

disorders of sweating

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

granuloma annulare

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

non-dermatological disorders, which respond to topical/ transdermal delivery of an active agent

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

localized pain

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

joint pain

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

muscle pain

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

back pain

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

60/162

2018-02-22 00:03:45


rheumatic pain

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

arthritis

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

ostheoarthritis

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

acute soft tissue injuries and sports injuries

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

conditions, which respond to hormone therapy

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

hormone replacement therapy

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

transdermal nicotine administration

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

pelvic pain

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

premenstrual syndrome (PMS)

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

mittelschmerz

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

dysmenorrhea

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

endometriosis

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

ectopic pregnancy

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

ovarian cysts and masses

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

acute pelvic inflammatory disease

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

pelvic congestion syndrome

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

vulvodynia

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

vulvovaginal infections

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

bacterial vaginosis

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

candidal vaginitis

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

trichomonas vaginalis

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

herpes simplex

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

genital ulcers and warts

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

pelvic inflammatory disease (PID)

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

cervicitis

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

61/162

2018-02-22 00:03:45


acute and chronic salpingitis

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

gynecological neoplasms

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

endometrial cancer

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

ovarian cancer

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

cervical cancer

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

vulvar cancer

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

vaginal cancer

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

fallopian tube cancer

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

gestational trophoblastic disease

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

sexually transmitted diseases

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

sexual dysfunction disorders that respond to pharmacological therapy

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

sexual arousal disorder

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

female orgasmic disorder

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

dyspareunia

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

vaginismus

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

anal abscess/ fistula

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

anal cancer

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

anal warts

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

Crohn's disease

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

haemorrhoids

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

perianal thrush

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

anal fissures

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

fecal incontinence

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

constipation

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

polyps of the colon and rectum

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

62/162

2018-02-22 00:03:45


sexually-transmitted disease

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

non-sexuallytransmitted vaginal and genital infectious disease

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

wounds

Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

burns

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

cuts

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

ulcers

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys

photosensitizer in a dental composition

Patent; RHODIA CHIMIE; US2005/59752; (2005); (A1) English, View in Reaxys

decellularizing agent

Patent; DEPUY SPINE, INC.; WO2005/32473; (2005); (A2) English, View in Reaxys

sequential decellurization of an isolated tissue

Patent; DEPUY SPINE, INC.; WO2005/32473; (2005); (A2) English, View in Reaxys

tissue regeneration

Patent; DEPUY SPINE, INC.; WO2005/32473; (2005); (A2) English, View in Reaxys

biocompatible tissue implant

Patent; DEPUY SPINE, INC.; WO2005/32473; (2005); (A2) English, View in Reaxys

injured or diseased joints

Patent; DEPUY SPINE, INC.; WO2005/32473; (2005); (A2) English, View in Reaxys

creation artificial tissue (kidney, liver, bladder, skin, and the like)

Patent; DEPUY SPINE, INC.; WO2005/32473; (2005); (A2) English, View in Reaxys

dermatological disorders and dermatological disorder-related complications

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

comedones

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

papules, pustules

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

inflamed nodules

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

superficial pus-filled cysts

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

skin lesions and dermal inflammation

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

dermal scarring

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

disfigurement, cellulitis

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

dermal abscesses

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

63/162

2018-02-22 00:03:45


secondary bacterial infection (impetigo)

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

herpes simplex or zoster

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

dermatological pain

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

dermatological inflammation

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

dermatitis

Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

fungal skin infections

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

skin neoplasia

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

viral skin infections

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

parasitic skin infections

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

skin neoplasms

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

pruritis

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

cellulitis

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

acute lymphangitis

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

lymphadenitis

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

erysipelas

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

cutaneous abscesses

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

necrotizing subcutaneous infections

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

scalded skin syndrome

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

furuncles

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

carbuncles

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

paronychial infections

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

64/162

2018-02-22 00:03:45


rashes

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

erythrasma

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

ecthyma

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

yeast skin infections

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

trauma or injury to the skin

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

post-operative or post-surgical skin conditions

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

scabies

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

pediculosis

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

creeping eruption

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

eczemas

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

pityriasis rosea

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

lichen planus

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

pityriasis rubra pilaris

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

edematous

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

erythema multiforme

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

erythema nodosum

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

grannuloma annulare

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

epidermal necrolysis

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

sunburn

Patent; Shanler, Stuart D.; Ondo, Andrew; US2005/165079; (2005); (A1) English, View in Reaxys; Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

photosensitivity

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

pemphigus

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

65/162

2018-02-22 00:03:45


bullous pemphigoid

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

dermatitis herpetiformis

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

callouses

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

corns

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

ischemic necrosis

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

miliaria

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

hyperhidrosis

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

moles

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

Kaposi's sarcoma

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

melanoma

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

malignant melanoma

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

basal cell carcinoma

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

squamous cell carcinoma

Patent; FOAMIX LTD.; WO2005/18530; (2005); (A2) English, View in Reaxys; Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

poison ivy

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

poison oak

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

contact dermatitis

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

purpura

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

moniliasis

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

candidiasis

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

baldness

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

Behcet's syndrome

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

cholesteatoma

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

Dercum disease

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

66/162

2018-02-22 00:03:45


ectodermal dysplasia

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

gustatory sweating

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

nail patella syndrome

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

lupus

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

hives

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

Hailey-Hailey disease

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

chemical or thermal skin burns

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

scleroderma

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

aging skin

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

sun spots

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

necrotizing fasciitis

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

necrotizing myositis

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

gangrene

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

scarring and vitiligo

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

inflammatory acne

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

non-inflammatory acne

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

acne fulminans

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

nodular papulopustular acne

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

acne conglobata

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

dermatological treatment agent

Patent; Pharmacia Corporation; US2005/14729; (2005); (A1) English, View in Reaxys

keratoplastic effect

Patent; CIBA SPECIALTY CHEMICALS HOLDING INC.; WO2005/40284; (2005); (A1) English, View in Reaxys

Ingredient of cosmetics

Patent; CIBA SPECIALTY CHEMICALS HOLDING INC.; WO2005/40284; (2005); (A1) English, View in Reaxys

radical generator

Patent; TAISHO PHARMACEUTICAL CO., LTD; Sato, Fumie; EP1598335; (2005); (A1) English, View in Reaxys

initiator for polymerization of MIP for reducing dietary phosphate

Patent; Ross, Edward Allan; Batich, Christopher D.; US2005/276781; (2005); (A1) English, View in Reaxys

Initiator of radical polymerization

Patent; ASAHI GLASS COMPANY, LIMITED; WO2005/121118; (2005); (A1) Japanese, View in Reaxys

inhibition of anaerobotic microbial

Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

67/162

2018-02-22 00:03:45


growth and establishment of a healthier membrane microflora; enhanced tissue immunological activity reduction the visible signs of skin aging

Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys

pseudo-folliculitis barbae

Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys

lesions

Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys

sebum regulations

Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys

pigmentation regulation

Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys

hair growth retardation

Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys

hair stimulation

Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys

vaginal candidiasis

Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys

vaginosis

Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys

genital herpes

Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys

blood vasoconstriction

Patent; Sun, Ying; Liu, Jue-Chen; Wu, Jeffrey M.; US2004/265395; (2004); (A1) English, View in Reaxys

oxidation of iron(II) to iron(III), which precipitates.

Patent; BP CORPORATION NORTH AMERICA INC.; WO2003/91195; (2003); (A1) English, View in Reaxys

Removal of dissolved iron from liquid streams during aromatic acid manufacture

Patent; BP CORPORATION NORTH AMERICA INC.; WO2003/91195; (2003); (A1) English, View in Reaxys

polymerization ini- Page/Page coltiator umn 22

Patent; Mitsubishi Rayon Co., Ltd.; EP1352904; (2003); (A1) English, View in Reaxys

Medchem (289) 1 of 289

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |transport Bioassay : control: without title comp. hydrated nail clippings incubated with title comp. for 20 h; excess moisture removed; title comp. penetration activity measured as nail swelling and increase in nail weight

Biological Species/NCBI human ID Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title comp. did not significantly increase nail weight; table

Measurement Parameter

Qualitative

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

68/162

2018-02-22 00:03:45


Khengar; Jones; Turner; Forbes; Brown; Pharmaceutical Research; vol. 24; nb. 12; (2007); p. 2207 - 2212, View in Reaxys 2 of 289

Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : T1 cell lineBioassay : in Dulbecco's modified Eagle's medium with 10 percent FCS, HEPES and antibiotics; positive control: 0.5 ng/ml mezerein; 1E4 cells/ml; lowest conc. at which no sign. increase in foci compared to unexposed control determined; compared with Ames and SHE tests bovine papillomavirus DNA-carrying C3H/10T1/2 cell line; 200 cells from T1 passages 26-35 cocultured with 5E4 untransfected C3H/10T1/2 cells passages 16-19; incubated at 37 deg C for 72 hr; prediction of carcinogenicity; foci counted

Substance RN

984320View in Reaxys

Substance Name

230913

Substance Dose

0.00500000 µM

Qualitative Results

title comp. showed positive response; lowest transforming dose: 0.1 μmol/l

Measurement Parameter

Qualitative

Kowalski; Assi; Wee; Madden Vera Genics; Environmental and Molecular Mutagenesis; vol. 37; nb. 3; (2001); p. 231 - 240, View in Reaxys 3 of 289

Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : cutaneous iron levels; increase ofBioassay : control: untreated mice mice pretreated with 7,12-dimethylbenz(a)anthracene and iron-dextran; administered with title comp.; sacrificed at termination of tumor induction; dorsal skin removed; cutaneous iron levels were estimated by dipyridyl method

Biological Species/NCBI Mus musculus ID Substance RN

984320View in Reaxys

Substance Name

230913

Substance Route of Adm.

transdermal administration

Qualitative Results

non-tumor-bearing, tumor-bearing skin of mice treated with title comp. showed increase in cutaneous iron levels

Measurement Parameter

Qualitative

Bhasin, Gayatri; Kauser, Hina; Athar, Mohammad; Archives of Toxicology; vol. 78; nb. 3; (2004); p. 139 - 146, View in Reaxys 4 of 289

Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : tumor-promotingBioassay : mice pretreated with 7,12-dimethylbenz(a)anthracene in presence or absence of iron-dextran; administered with title comp.; carcinomas formed were counted and verified by histopathological examination

Biological Species/NCBI Mus musculus ID Substance RN

984320View in Reaxys

Substance Name

230913

Substance Route of Adm.

transdermal administration

Qualitative Results

tumor size of title comp.-treated mice was 62.3 mm2 and in iron-overloaded mice treated with title comp. was 74 mm2; fig.

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

69/162

2018-02-22 00:03:45


Measurement Parameter

Qualitative

Bhasin, Gayatri; Kauser, Hina; Athar, Mohammad; Archives of Toxicology; vol. 78; nb. 3; (2004); p. 139 - 146, View in Reaxys 5 of 289

Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : tumor-promotingBioassay : DMBA: 7,12-dimethylbenz(a)anthracene mice pretreated with DMBA in presence or absence of iron-dextran; administered with title comp.; carcinomas formed were counted and verified by histopathological examination; percent of malignant conversion of benign papillomas into carcinomas was determined

Biological Species/NCBI Mus musculus ID Substance RN

984320View in Reaxys

Substance Name

230913

Substance Route of Adm.

transdermal administration

Qualitative Results

percent of incidence of carcinomas was 85 and 90 percent in normal and iron-overloaded mice treated with title comp., resp.; fig.

Measurement Parameter

Qualitative

Bhasin, Gayatri; Kauser, Hina; Athar, Mohammad; Archives of Toxicology; vol. 78; nb. 3; (2004); p. 139 - 146, View in Reaxys 6 of 289

Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : tumor-promotingBioassay : DMBA: 7,12-dimethylbenz(a)anthracene mice pretreated with DMBA in presence or absence of iron-dextran; mice administered with title comp.; mice sacrificed at termination of tumor induction; tissues removed; sections were stained with hematoxylin, eosin stains and examined microscopically

Biological Species/NCBI Mus musculus ID Substance RN

984320View in Reaxys

Substance Name

230913

Substance Route of Adm.

transdermal administration

Qualitative Results

epidermal ulceration was observed in tumor samples treated with iron and title comp.; table

Measurement Parameter

Qualitative

Bhasin, Gayatri; Kauser, Hina; Athar, Mohammad; Archives of Toxicology; vol. 78; nb. 3; (2004); p. 139 - 146, View in Reaxys 7 of 289

Substance Effect

Antimicrobial

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : This example illustrates antimicrobial efficacy of topical benzoyl peroxide compositions in accordance with the present disclosure in skin during a three day study. Materials and Methods A split-face, randomized study of 24 patients was conducted. Patients were randomly divided into two groups of 12

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Substance Name

230913

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

70/162

2018-02-22 00:03:45


Qualitative Results

The 5% test compound in accordance with the present disclosure yielded a 0.2 log greater reduction in P. acnes than the 5% benzoyl peroxide gel and a 0.7 log greater reduction in P. acnes that the 5% benzoyl peroxide/1% clindamycin gel after 3 and 8

Measurement Parameter

Qualitative

Patent; JR CHEM, LLC; US2006/204530; (2006); (A1) English, View in Reaxys 8 of 289

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : inflammatory lesion; effect onBioassay : This example illustrates lesion reduction using topical 5% benzoyl peroxide compositions in accordance with the present disclosure. Materials and Methods Subjects were randomly assigned to receive 5% benzoyl peroxide compositions (meeting the U.S. Pharmacopoeia labeling requirements) in accordance with

Biological Species/NCBI human ID Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

inflammatory lesion counts over treatment course: ~55.0% (4 week); ~35% (10week); figure given

Measurement Parameter

Qualitative

Patent; JR CHEM, LLC; US2006/204530; (2006); (A1) English, View in Reaxys 9 of 289

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : non-inflammatory lesion; effect onBioassay : This example illustrates lesion reduction using topical 5% benzoyl peroxide compositions in accordance with the present disclosure. Materials and Methods Subjects were randomly assigned to receive 5% benzoyl peroxide compositions (meeting the U.S. Pharmacopoeia labeling requirements) in accordance with

Biological Species/NCBI human ID Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

non-inflammatory lesion counts over treatment course: 40.0% (4 week); ~38% (10week); figure given

Measurement Parameter

Qualitative

Patent; JR CHEM, LLC; US2006/204530; (2006); (A1) English, View in Reaxys 10 of 289

Target Name

Myeloperoxidase

Target Synonyms

mpo; myeloperoxidase; uncleaved myeloperoxidase

Target, Subunit, Species Myeloperoxidase Target Mutant/Chimera Details

Myeloperoxidase:Wild

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |enzyme; examination of Bioassay : 20 mg in 0.2 ml acetone; applied topically to female mice CD-1; after killing MPO extraction from 22-mm diameter dorsal skin from polymorphonuclear leucocytes (PMNs) spectrophotometrically; MPO accumulation in mouse skin

Substance RN

984320View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

71/162

2018-02-22 00:03:45


11 of 289

Substance Name

230913

Qualitative Results

ability to elicit the accumulation of MPO as MPO activity: 0.04 +/- 0.01 (units/22 mm skin punch); 1 unit of MPO activity is equivalent to 8.6*106 murine PMNs

Measurement Parameter

Qualitative

Substance Effect

Antimicrobial

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

reducing the number of P.acnes, figure 4 is given

Measurement Parameter

Qualitative

Patent; KIM, Jenny; FRIEDMAN, Adam; MODLIN, Robert; WO2007/149868; (A2); (2007), View in Reaxys 12 of 289

Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : TPA-induced ear edema; reduction ofTarget : Balb/c ByJIc mouseBioassay : Example 2 : Evaluation of the anti-inflammatory in ear oedema model on Balb/c miceThe study was carried out with 45 (5 par groups) female9 weeks aged Balb/c ByJIc mice.The Edema was induced by a single application of 20μl of TPA dissolved in acetone at 0.01%.The treatment was administrated by single

Substance RN

984320View in Reaxys

Substance Name

230913

Substance Route of Adm.

cutaneous administration

Qualitative Results

2.5%, 5% and 10% title compound has a slight anti-inflammatory effect, reducing the TPAinduced ear edema by 16%, 24% and 40%, respectively; figure is given

Measurement Parameter

Qualitative

Patent; GROSS, Denis; LOESCHE, Christian; PONCET, Michel; ABOU-CHACRA VERNET, Marie-line; WO2008/6888; (A1); (2008), View in Reaxys 13 of 289

Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : lesions; reduction ofBioassay : Example 1: Clinical study results A clinical study for confirmation of efficacy was performed for a topical gel combining adapalene + benzoyl peroxide (BPO) . <n="13"/>This gel has the following formulation (expressed as % weight/ total weight) :Adapalene 0.10%Benzoyl peroxide 2.50% Copolymer of acrylamide

Biological Species/NCBI human ID Substance RN

984320View in Reaxys

Substance Name

230913

Substance Route of Adm.

cutaneous administration

Qualitative Results

2.5% title compound treatment resulted in 15.4% degree of success, -43.6% number of inflammatory lesions, -36.4% number of non-inflammatory lesions, -35.6% total number of lesions, -13.0 number of inflammatory lesions, -16.0 number of non-inflammatory

Measurement Parameter

Qualitative

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

72/162

2018-02-22 00:03:45


Patent; GROSS, Denis; LOESCHE, Christian; PONCET, Michel; ABOU-CHACRA VERNET, Marie-line; WO2008/6888; (A1); (2008), View in Reaxys 14 of 289

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Substance Name

Bezoyl peroxide

Substance Dose

1.95000 mg/L

Measurement Parameter

MIC

Unit

mg/L

Quantitative value

31.25

Measurement pX

3.89

Patent; ROACH, Alan George; GOLDSMITH, Paul; (12 pag.); WO2007/141530; (2007); (A2), View in Reaxys 15 of 289

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Substance Name

Bezoyl peroxide

Substance Dose

1.95000 mg/L

Measurement Parameter

Concentration

Unit

mg/L

Measurement Object

minimum bactericidal concentration (MBC)

Quantitative value

62.5

Patent; ROACH, Alan George; GOLDSMITH, Paul; (12 pag.); WO2007/141530; (2007); (A2), View in Reaxys 16 of 289

Substance Effect

Antiproliferative

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Bioassay Details

Effect : cell proliferation; inhibition ofEXAMPLE 13SCREENING ASSAY FOR ASSESSING THE EFFECT OF COMPOUNDS ON CELLPROLIFERATIONA screening assay was conducted on numerous compounds to determing their effect on cell proliferation (In vitro toxicol. (1990) 3: 219; Biotech. Histochem. (1993) 68: 29; Anal Biochem. (1993) 213: 426).Fibroblasts at

Biological Species/NCBI human ID Cells/Cell Lines

fibroblast

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

IC50

Unit

nM

Quantitative value

1200 - 10000

Measurement pX

5.92

Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

73/162

2018-02-22 00:03:45


17 of 289

Substance Effect

Antimicrobial

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : anti-microbial

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

reducing the number of P.acnes, figure 4 is given

Measurement Parameter

Qualitative

Patent; SK CHEMICALS CO., LTD.; WO2007/49868; (2007); (A1) English, View in Reaxys 18 of 289

Substance Effect

Antimicrobial

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : anti-microbial

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

reducing the number of P.acnes, figure 4 is given

Measurement Parameter

Qualitative

Patent; KIM, Jenny; FRIEDMAN, Adam; MODLIN, Robert; (43 pag.); WO2007/149868; (A2); (2007), View in Reaxys 19 of 289

Substance Effect

Antimicrobial

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : anti-microbial

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

reducing the number of P.acnes, figure 4 is given

Measurement Parameter

Qualitative

Patent; KIM, Jenny; FRIEDMAN, Adam; MODLIN, Robert; (43 pag.); WO2007/149868; (A2); (2007), View in Reaxys 20 of 289

Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : TPA-induced ear edema; reduction of Example 2 : Evaluation of the anti-inflammatory in ear oedema model on Balb/c miceThe study was carried out with 45 (5 par groups) female9 weeks aged Balb/c ByJIc mice.The Edema was induced by a single application of 20μl of TPA dissolved in acetone at 0.01%.The treatment was administrated by single

Biological Species/NCBI Mus musculus ID Substance RN

984320View in Reaxys

Substance Name

230913

Substance Route of Adm.

cutaneous administration

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

74/162

2018-02-22 00:03:45


Qualitative Results

2.5%, 5% and 10% title compound has a slight anti-inflammatory effect, reducing the TPAinduced ear edema by 16%, 24% and 40%, respectively; figure is given

Measurement Parameter

Qualitative

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys 21 of 289

Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : lesions; reduction of Example 1: Clinical study results A clinical study for confirmation of efficacy was performed for a topical gel combining adapalene + benzoyl peroxide (BPO) . <n="13"/>This gel has the following formulation (expressed as % weight/total weight) :Adapalene 0.10%Benzoyl peroxide 2.50% Copolymer of acrylamide

Biological Species/NCBI human ID Substance RN

984320View in Reaxys

Substance Name

230913

Substance Route of Adm.

cutaneous administration

Qualitative Results

2.5% title compound treatment resulted in 15.4% degree of success, -43.6% number of inflammatory lesions, -36.4% number of non-inflammatory lesions, -35.6% total number of lesions, -13.0 number of inflammatory lesions, -16.0 number of non-inflammatory

Measurement Parameter

Qualitative

Patent; GALDERMA RESEARCH and DEVELOPMENT; WO2008/6888; (2008); (A1) English, View in Reaxys 22 of 289

Substance Effect

Antiproliferative

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : fibroblasts of humanBioassay : EXAMPLE 13SCREENING ASSAY FOR ASSESSING THE EFFECT OF COMPOUNDS ON CELLPROLIFERATIONA screening assay was conducted on numerous compounds to determing their effect on cell proliferation (In vitro toxicol. (1990) 3: 219; Biotech. Histochem. (1993) 68: 29; Anal Biochem. (1993) 213: 426).Fibroblasts at

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

IC50

Unit

nM

Quantitative value

1200 - 10000

Measurement pX

5.92

Patent; ANGIOTECH PHARMACEUTICALS, INC.; WO2007/89878; (2007); (A2) English, View in Reaxys 23 of 289

Substance Effect

Antiacne

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : with Grade 2-3 facial acne of humanBioassay : B. Acne Clinical Trial Using Inventive FormulationFifteen panelists exhibiting Grade 2-3 facial acne were recruited for participation in this study. Panelists were randomized into three equal groups corresponding to the three different products they were using: Lotion 1, 2, and 3.Lotion 1 contained

Substance RN

984320View in Reaxys

Substance Name

230913

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

75/162

2018-02-22 00:03:45


Qualitative Results

title compound treatment resulted in a significant reduction in the acne lesion counts; title compound demonstrated a decrease in the total number of lesions observed on days 3(10%), 7(18%), 14(37%), 28(55%); title compound performed better in reducing

Measurement Parameter

Qualitative

Patent; CONCERT, LLC; US2008/139518; (2008); (A1) English, View in Reaxys 24 of 289

Substance Effect

Sensitizing

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : CBA mouseBioassay : 6-12 wk old animals; housed under standard conitions with food and tap water ad libitum; international interlaboratory trial (5 participants) local lymph node assay; exposed on dorsum of both ears to 25 μl of 1 of 5 conc.; 5 d after the start of treatment injected i.v. with PSB cont. 20 μCi of <3H>methylthymidine (spec. act. 2 Ci/ mmol); proliferative act. of draining auricular LNC measured

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

elicited strong LLNA respnses in each participating laboratory; dpm: 658-9110 to 715-8595 (acetone: 27-463), SI: 14.6-24.4 to 16.1 to 26.5

Measurement Parameter

Qualitative

Kimber; Hilton; Dearman; Gerberick; Ryan; Basketter; Lea; House; Ladics; Loveless; Hastings; Journal of Toxicology and Environmental Health; vol. 53; nb. 7; (1998); p. 563 - 579, View in Reaxys 25 of 289

Substance Effect

Mutagenic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : preincubation protocol; in the absence and presence of Aroclor 1254-induced male Fischer 344 rat or male B6C3F1 mouse liver S9 mix

Biological Species/NCBI Salmonella enterica serovar Typhimurium ID Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

Qualitative

Qualitative value

NA

Measurement pX

1

Dillon, Deborah; Combes, Robert; Zeiger, Errol; Mutagenesis; vol. 13; nb. 1; (1998); p. 19 - 26, View in Reaxys 26 of 289

Substance Effect

Mutagenic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : Salmonella typhimurium TA102Bioassay : preincubation protocol; in the absence and presence of Aroclor 1254-induced male Fischer 344 rat or male B6C3F1 mouse liver S9 mix

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

Qualitative

Qualitative value

NA

Measurement pX

1

Dillon, Deborah; Combes, Robert; Zeiger, Errol; Mutagenesis; vol. 13; nb. 1; (1998); p. 19 - 26, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

76/162

2018-02-22 00:03:45


27 of 289

Substance Effect

Mutagenic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : Salmonella typhimurium TA104Bioassay : preincubation protocol; in the absence and presence of Aroclor 1254-induced male Fischer 344 rat or male B6C3F1 mouse liver S9 mix

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

Qualitative

Qualitative value

NA

Measurement pX

1

Dillon, Deborah; Combes, Robert; Zeiger, Errol; Mutagenesis; vol. 13; nb. 1; (1998); p. 19 - 26, View in Reaxys 28 of 289

Substance Effect

Mutagenic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : Salmonella typhimurium TA97aBioassay : preincubation protocol; in the absence and presence of Aroclor 1254-induced male Fischer 344 rat or male B6C3F1 mouse liver S9 mix

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

Qualitative

Qualitative value

NA

Measurement pX

1

Dillon, Deborah; Combes, Robert; Zeiger, Errol; Mutagenesis; vol. 13; nb. 1; (1998); p. 19 - 26, View in Reaxys 29 of 289

Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : control: 1 percent ethanol cells cult. in 75 cm2 plastic flask in DMEM med. with 10 percent FCS, antibiotics at 37 deg C; 5 percent CO2; seeded 75E3 cell/cm2 in 6-well plates for 24 h; confluent 90 percent; treat. for 24 h; Neutral red assay; neutral red dye uptake as measure of cell viablity

Biological Species/NCBI human ID Cells/Cell Lines

HaCat

Substance RN

984320View in Reaxys

Substance Name

230913

Substance Dose

100 µM

Qualitative Results

min. cytotoxicity at doses from 100 to 200 μmol/l ( cell viability ca. 99 percent); significant cytotoxicity at doses 250 and 300 μmol/l (cell viability 70 and 50 percent resp.) (fig.)

Measurement Parameter

Qualitative

Valacchi, Giuseppe; Rimbach, Gerald; Saliou, Claude; Weber, Stefan U; Packer, Lester; Toxicology; vol. 165; nb. 2-3; (2001); p. 225 - 234, View in Reaxys 30 of 289

Substance Effect

Genotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

77/162

2018-02-22 00:03:45


Bioassay Details

Bioassay : control: untreated and 1 percent ethanol treated cells cells cult. in 75 cm2 plastic flask in DMEM medium with 10 percent FCS, antibiotics at 37 deg C; 5 percent CO2; seeded 75E3 cell/cm2 in 6-well plates for 24 h; confluent 90 percent; treat. for 24 h; flow cytometry, with propidium iodide (PI) staining; DNA fragmentat.

Biological Species/NCBI human ID Cells/Cell Lines

HaCat

Substance RN

984320View in Reaxys

Substance Name

230913

Substance Dose

100 µM

Qualitative Results

little dose dependent DNA fragmentation from 1.1 to 4.9 percent

Measurement Parameter

Qualitative

Valacchi, Giuseppe; Rimbach, Gerald; Saliou, Claude; Weber, Stefan U; Packer, Lester; Toxicology; vol. 165; nb. 2-3; (2001); p. 225 - 234, View in Reaxys 31 of 289

Target Name

cytokine

Target Synonyms

cytokine

Target, Subunit, Species cytokine Target Mutant/Chimera Details

cytokine:Wild

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : cytokines; expression ofBioassay : EPh: electrophoresis; internal control: β-actin cells cult. in 75 cm2 pl. flask in DMEM med. with 10 percent FCS, antibiot. at 37 deg C; 5 percent CO2; seeded 2E5 cell/cm2 in 12-well plates for 24 h; confl. 90 percent; treat. for 6, 12, 24 h; total RNA extr.; rev. transcrip.; IL-1α, IL-8, β-actin PCR ampl.; EPh

Biological Species/NCBI human ID Cells/Cell Lines

HaCat

Substance RN

984320View in Reaxys

Substance Name

230913

Substance Dose

50 µM

Qualitative Results

dose-dependent increase of IL-1α mRNA steady state levels; more significant after 6 h incubation 2.8, 3.8 and 5-fold at doses 50, 100 and 200 μmol/l resp.; no effect on IL-8 mRNA level (fig.)

Measurement Parameter

Qualitative

Valacchi, Giuseppe; Rimbach, Gerald; Saliou, Claude; Weber, Stefan U; Packer, Lester; Toxicology; vol. 165; nb. 2-3; (2001); p. 225 - 234, View in Reaxys 32 of 289

Target Name

NF-kappaB

Target Synonyms

nf-kappab

Target, Subunit, Species NF-kappaB Target Mutant/Chimera Details

NF-kappaB:Wild

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

78/162

2018-02-22 00:03:45


Bioassay Details

Effect : NF-κB activationBioassay : pGL3-4κB-Luc and pRL-TK plasmids; dual-luciferase reporter assay system; positive control: TNFα (5 and 20 ng/ml) treatment cells cult. in 75 cm2 plastic flask in DMEM med. with 10 percent FCS, antibiot. at 37 deg C; 5 percent CO2; seeded 2E5 cell/cm2 in 12-well plates for 24 h; confl. 90 percent; co-transfect.; incub. for 18 h; treat. for 24 h; cell lysis 12 h after tr.; luciferase act.

Biological Species/NCBI human ID Cells/Cell Lines

HaCat

Substance RN

984320View in Reaxys

Substance Name

230913

Substance Dose

10 µM

Measurement Parameter

Qualitative

Qualitative value

NA

Measurement pX

1

Valacchi, Giuseppe; Rimbach, Gerald; Saliou, Claude; Weber, Stefan U; Packer, Lester; Toxicology; vol. 165; nb. 2-3; (2001); p. 225 - 234, View in Reaxys 33 of 289

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |metabolic Bioassay : GSH: reduced glutathione; GSSG: oxidized glutathione; control: untreated and 1 percent ethanol treated cells cells cult. in 75 cm2 plastic flask in DMEM med. with 10 percent FCS, antibiot. at 37 deg C; 5 percent CO2; seeded 75E3 cell/cm2 in 6-well plates for 24 h; confluent 90 percent; treat. for 24 h and from 30 min to 6 h at dose 300 μmol/l; HPLC; GSH, GSSG, vit. E lev.

Biological Species/NCBI human ID Cells/Cell Lines

HaCat

Substance RN

984320View in Reaxys

Substance Name

230913

Substance Dose

100 µM

Qualitative Results

dose-dependent decrease of vit. E and GSH levels from 8 to 4 pmol/E6 cells and from 10.7 to 0.4 nmol/E6 cells; increase of GSSG/GSH ratio from 2.3 to 90.4 percent; time course study: 50 percent decrease of vit. E and GSH level at 30 min and 6 h resp.

Measurement Parameter

Qualitative

Valacchi, Giuseppe; Rimbach, Gerald; Saliou, Claude; Weber, Stefan U; Packer, Lester; Toxicology; vol. 165; nb. 2-3; (2001); p. 225 - 234, View in Reaxys 34 of 289

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : smooth muscle cell proliferation; effect onBioassay : SCREENING ASSAY FOR ASSESSING THE EFFECT OF COMPOUNDS ON SMOOTHMUSCLE CELL PROLIFERATIONThis example describes a screening assay for assessing the effect of an agent on smooth muscle cell proliferation (In vitro toxicol. (1990) 3: 219; Biotech. Histochem. (1993) 68: 29; Anal. Biochem. (1993) 213: 426).

Cells/Cell Lines

smooth muscle cell

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

IC50

Unit

nM

Quantitative value

0.01

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

79/162

2018-02-22 00:03:45


Measurement pX

11

Patent; HUNTER, William, L.; TOLEIKIS, Philip, M.; GRAVETT, David, M.; MAITI, Arpita; LIGGINS, Richard T.; TAKACS-COX, Aniko; AVELAR, Rui; SIGNORE, Pierre, E.; LOSS, Troy, A. E.; HUTCHINSON, Anne; MCDONALD-JONES, Gaye; LAKHANI, Fara; (2278 pag.); WO2006/121518; (A2); (2006), View in Reaxys 35 of 289

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

no mutagenicity in test on Salmonella typhimurium TA 98 and TA 100

Measurement Parameter

Qualitative

Yamaguchi; Yamashita; Agricultural and Biological Chemistry; vol. 44; nb. 7; (1980); p. 1675 - 1678, View in Reaxys 36 of 289

Substance Effect

Keratolytic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Bioassay : SC: stratum corneum randomized, blinded and placebo-controlled study; TEWL measurements taken using closed-chamber evaporimeter; 25 tape stripping and protein assay

Biological Species/NCBI human ID Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

mean SC removed (μg/cm2) after 3 h of treatment: 1.46 (control: 1.01), after 6 h: 1.64 (control: 1.31); mean TEWL taken 5 times over 30 min at 3 h after stripping: 30.08 and at 6 h: 28.76 (control: 9.68 and 11.65)

Measurement Parameter

Qualitative

Waller; Dreher; Behnam; Ford; Lee; Tiet; Weinstein; Maibach; Skin Pharmacology and Physiology; vol. 19; nb. 5; (2006); p. 283 - 289, View in Reaxys 37 of 289

Substance Effect

Mutagenic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : Escherichia coli IC188Bioassay : parent WP2 uvrA/pKM101 bacterial strain in vitro; plate incorporation assay; Difco agar; minimal ET4 plates; 37 deg C; 2 d; number of revertants per plates counted

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

Qualitative

Qualitative value

NA

Measurement pX

1

Martinez, A.; Urios, A.; Blanco, M.; Mutation research; vol. 467; nb. 1; (2000); p. 41 - 53, View in Reaxys 38 of 289

Substance Effect

Mutagenic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : Escherichia coli IC203Bioassay : WP2 uvrA/pKM101 bacterial strain deficient in OxyR in vitro; plate incorporation assay; Difco agar; minimal ET4 plates; 37 deg C; 2 d; number of revertants per plates counted

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

80/162

2018-02-22 00:03:45


Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

Qualitative

Qualitative value

NA

Measurement pX

1

Martinez, A.; Urios, A.; Blanco, M.; Mutation research; vol. 467; nb. 1; (2000); p. 41 - 53, View in Reaxys 39 of 289

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |DNA; examination of Target : supercoiled pBR 322 DNA (form I, MW of 2.9E6 Da, 4365 bp)Bioassay : Reactivity of benzoyloxyl versus tert-butoxyl radicals was assessed by comparison with tert-butyl perbenzoate; ssb=single-strand breaks The title comp. in water with DNA in KH2PO4 buffer (pH 7.4) were irradiated (UV, λ=300 nm); 0 deg C; 2 min or 10 min; the DNA-cleaving activity of the title comp. assessed; gel electrophoresis analysis

Substance RN

984320View in Reaxys

Substance Name

230913

Substance Dose

1 mM

Qualitative Results

The blank value of open circular DNA: without irrad. 0.04 ssb, after 10 min irrad. 0.06 ssb per DNA molecule 4E3 bp; irradiation with the title comp.: 0.06 ssb (2 min) and 0.09 ssb (10 min) per DNA molecule; the moderate activity of title comp.

Measurement Parameter

Qualitative

Adam, Waldemar; Grimm, Guenther N.; Saha-Moeller, Chantu R.; Dall'Acqua, Francesco; Miolo, Gorgia; Vedaldi, Daniela; Chemical Research in Toxicology; vol. 11; nb. 9; (1998); p. 1089 - 1097, View in Reaxys 40 of 289

Substance Effect

Antiacne

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : anti-acneExample 27; Inhibition of Propionibacterium acnes Growth; [00308] The present example demonstrates that certain AFC complexes of the present invention exhibit superior or similar anti-microbial activity when compared to benzoyl peroxide, a wellknown anti-microbial and anti-acne agent. The assay for

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

IC50

Unit

µg/mL

Quantitative value

161

Measurement pX

3.18

Patent; SIGNUM BIOSCIENCES, INC.; VORONKOV, Michael; STOCK, Jeffry, B.; STOCK, Maxwell; LEE, Seung-Yub; PEREZ, Eduardo; GORDON, Joel, S.; WO2010/90845; (2010); (A1) English, View in Reaxys 41 of 289

Substance Effect

Antiacne

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : anti-acneExample 27; Inhibition of Propionibacterium acnes Growth; [00308] The present example demonstrates that certain AFC complexes of the present invention exhibit superior or similar anti-microbial activity when compared to benzoyl peroxide, a wellknown anti-microbial and anti-acne agent. The assay for

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

81/162

2018-02-22 00:03:45


Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

IC50

Unit

µg/mL

Quantitative value

161

Measurement pX

3.18

Patent; VORONKOV, Michael; STOCK, Jeffry, B.; STOCK, Maxwell; LEE, Seung-Yub; PEREZ, Eduardo; GORDON, Joel, S.; (135 pag.); WO2010/90845; (A1); (2010), View in Reaxys 42 of 289

Substance Effect

Antiacne

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : anti-acneExample 27; Inhibition of Propionibacterium acnes Growth; [00308] The present example demonstrates that certain AFC complexes of the present invention exhibit superior or similar anti-microbial activity when compared to benzoyl peroxide, a wellknown anti-microbial and anti-acne agent. The assay for

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

IC50

Unit

µg/mL

Quantitative value

161

Measurement pX

3.18

Patent; VORONKOV, Michael; STOCK, Jeffry, B.; STOCK, Maxwell; LEE, Seung-Yub; PEREZ, Eduardo; GORDON, Joel, S.; (135 pag.); WO2010/90845; (A1); (2010), View in Reaxys 43 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATC 25577 of Propionibacterium avidumBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in 25.83 mm in disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 44 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 12600 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combina-

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

82/162

2018-02-22 00:03:45


tions of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in a 11.99 mm disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 45 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 12600-U of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in a 12.20 mm disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 46 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 12601 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in a 11.68 mm disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 47 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 12602 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in a 12.73 mm disc diffusion assay (DDA)

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

83/162

2018-02-22 00:03:45


Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 48 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 12604 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in a 12.52 mm disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 49 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 12605 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in a 12.20 mm disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 50 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 12606 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in a 11.68 mm disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 51 of 289

Substance Effect

Antibiotic

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

84/162

2018-02-22 00:03:45


Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 12607 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in a 12.31 mm disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 52 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 25923 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in a 10.86 mm disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 53 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 27836 of Staphylococcus warneriBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in a 12.04 mm disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 54 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 27848 of Staphylococcus capitisBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

85/162

2018-02-22 00:03:45


with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in a 12.46 mm disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 55 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 27848 of Staphylococcus hominisBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in a 11.83 mm disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 56 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 27848 of Staphylococcus simulansBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in a 9.94 mm disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 57 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 29212 of Enterococcus faecalisBioassay : Example 10 - activity against E. faecalisThe activities of BP, TBHQ and combinations of the two were tested against E. faecalis ATCC 29212, using MIC, MBC and (S)DDA assays as described above.For the (S)DDA assays, 200 μg of each compound was loaded onto each disc. The solvents used were DMSO for

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

Qualitative

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

86/162

2018-02-22 00:03:45


Qualitative value

NA

Measurement pX

1

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 58 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 29213 of Staphylococcus aureusBioassay : Example 1 - activity against S. aureus -MIC, MBC & (S)DDA assaysThe following experiments all used S. aureus ATCC 29213 as the test organism.MIC, MBC and DDA assays, as described above, were carried out using the test compound benzoyl peroxide (BP) and a range of different benzoquinones and hydroquinones.

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in a 11.03 mm disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 59 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 29213 of Staphylococcus aureusBioassay : Example 3 - activity against S. aureus - TTK assaysTTK assays were then conducted, as described above, on samples of BP, TBHQ and a BP/TBHQ mixture, using S. aureus ATCC 29213 as the test organism. The solvents used were DMSO for the BP and ethanol for the TBHQ. The results are shown in Table 3. cfu

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

125 μg/ml of title compound resulted in a 3.67E4-7.63E5 CFU/ml t=0-1.0 wherein time to kill was >1 h

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 60 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 29213 of Staphylococcus aureusBioassay : Example 4 - activity against S aureus - MTTK assaysSamples containing BP, TBHQ and BP/TBHQ mixtures were also subjected to MTTK assays as described above, using S. aureus ATCC 29213 as the test organism The BP was dissolved in DMSO and the TBHQ in ethanolThe results, after 24 hours, are shown in Table

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

mixture of BP and TBHQ showed reduction in microbial activity greater (after 24 hours) than that obtained using title compound alone

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

87/162

2018-02-22 00:03:45


61 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 29970 of Staphylococcus haemolyticusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in a 11.10 mm disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 62 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 29971 of Staphylococcus xylosusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in a 10.99 mm disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 63 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 29974 of Staphylococcus cohniiBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in a 11.51 mm disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 64 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 33753 of Staphylococcus auricularisBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

88/162

2018-02-22 00:03:45


with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in a 21.56 mm disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 65 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : CPHL EMRSA 15 of Staphylococcus aureus methicillin (Met)/β-lactams resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in a 10.17 mm disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 66 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : CPHL EMRSA 16 of Staphylococcus aureus methicillin (Met)/β-lactams resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in a 10.80 mm disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 67 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : CPHL EMRSA 17 of Staphylococcus simulans methicillin (Met)/β-lactams resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in a 11.74 mm disc diffusion assay (DDA)

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

89/162

2018-02-22 00:03:45


Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 68 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : CPHL GISA HO41340156 of Staphylococcus aureus vancomycin (Van)/teicoplanin (Tec)-resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in a 12.16 mm disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 69 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : CPHL VISA Mu3 of Staphylococcus aureus vancomycin (Van)-resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in a 10.90 mm disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 70 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : CPHL VISA Mu50 of Staphylococcus aureus vancomycin (Van)-resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in a 11.64 mm disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 71 of 289

Substance Effect

Antibiotic

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

90/162

2018-02-22 00:03:45


Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : NCTC 11047 of Staphylococcus epidermidisBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in a 10.65 mm disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 72 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : NCTC 11865 of Propionibacterium granulosumBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in 24.19 mm in disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 73 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : NCTC 7292 of Staphylococcus saprophyticusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in a 11.38 mm disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 74 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : NCTC 737 of Propionibacterium acnesBioassay : Example 6 - activity against P. acnes -MIC, MBC & (S)DDA assaysThe following experiments all used P. acnes NCTC 737 as the test organism.MIC, MBC and DDA assays, as described above, were carried

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

91/162

2018-02-22 00:03:45


out using BP and a range of different benzoquinones and hydroquinones. Supplemented DDA assays, in the presence Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in a 24.25 mm disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 75 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : NCTC 737 of Propionibacterium acnesBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in 19.25 mm in disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 76 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-002 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamidestreptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in 25.69 mm in disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 77 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-003 of Propionibacterium acnes tetracycline (Tet)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in 25.69 mm in disc diffusion assay (DDA)

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

92/162

2018-02-22 00:03:45


Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 78 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-004 of Propionibacterium acnes tetracycline (Tet)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in 31.17 mm in disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 79 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-005 of Propionibacterium granulosum macrolide-lincosamide-streptograminketolide (MLSK)-resistantBioassay : Example 8 - activity against other propionibacteria MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in 22.95 mm in disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 80 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-007 of Propionibacterium acnes clindamycin (Clin)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in 23.88 mm in disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 81 of 289

Substance Effect

Antibiotic

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

93/162

2018-02-22 00:03:45


Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-008 of Propionibacterium acnes clindamycin (Clin)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in 27.80 mm in disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 82 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-010 of Propionibacterium acnes macrolide-lincosamide-streptogramin-ketolide (MLSK)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in 30.39 mm in disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 83 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-017 of Propionibacterium acnes macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in 23.28 mm in disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 84 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-023 of Propionibacterium acnes macrolide-lincosamide-streptogramin-ketolide (MLSK)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tes-

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

94/162

2018-02-22 00:03:45


ted against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in 24.11 mm in disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 85 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-026 of Propionibacterium acnes macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in 26.52 mm in disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 86 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-043 of Propionibacterium granulosum macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in 22.48 mm in disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 87 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-044 of Propionibacterium granulosum macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in 29.31 mm in disc diffusion assay (DDA)

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

95/162

2018-02-22 00:03:45


Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 88 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-046 of Propionibacterium acnesBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in 24.36 mm in disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 89 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-053 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamidestreptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in 29.72 mm in disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 90 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-055 of Propionibacterium granulosumBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in 21.52 mm in disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 91 of 289

Substance Effect

Antibiotic

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

96/162

2018-02-22 00:03:45


Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-059 of Propionibacterium acnes macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in 23.49 mm in disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 92 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-068 of Propionibacterium acnes erythromycin (Ery)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in 28.79 mm in disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 93 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-101 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamidestreptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in 25.73 mm in disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 94 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-102 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamidestreptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

97/162

2018-02-22 00:03:45


were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

title compound resulted in 29.62 mm in disc diffusion assay (DDA)

Measurement Parameter

Qualitative

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 95 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATC 25577 of Propionibacterium avidumBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

62.5

Measurement pX

3.59

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 96 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 12600 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 97 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 12600-U of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

98/162

2018-02-22 00:03:45


with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 98 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 12601 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 99 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 12602 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

125

Measurement pX

3.29

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 100 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

99/162

2018-02-22 00:03:45


Bioassay Details

Target : ATCC 12604 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 101 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 12605 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 102 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 12606 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 103 of 289 Substance Effect Bioassay Category

Antibiotic In Vitro (Efficacy)

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

100/162

2018-02-22 00:03:45


Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 12607 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 104 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 25923 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 105 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 27836 of Staphylococcus warneriBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 106 of 289 Substance Effect

Antibiotic

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

101/162

2018-02-22 00:03:45


Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 27840 of Staphylococcus capitisBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 107 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 27844 of Staphylococcus hominisBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 108 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 27848 of Staphylococcus simulansBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

102/162

2018-02-22 00:03:45


109 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 29213 of Staphylococcus aureusBioassay : Example 1 - activity against S. aureus -MIC, MBC & (S)DDA assaysThe following experiments all used S. aureus ATCC 29213 as the test organism.MIC, MBC and DDA assays, as described above, were carried out using the test compound benzoyl peroxide (BP) and a range of different benzoquinones and hydroquinones.

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 110 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 29970 of Staphylococcus haemolyticusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 111 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 29971 of Staphylococcus xylosusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

103/162

2018-02-22 00:03:45


Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 112 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 29974 of Staphylococcus cohniiBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

125

Measurement pX

3.29

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 113 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 33753 of Staphylococcus auricularisBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

62.5

Measurement pX

3.59

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 114 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : CPHL EMRSA 16 of Staphylococcus aureus methicillin (Met)/β-lactams resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

250

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

104/162

2018-02-22 00:03:45


Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 115 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : CPHL GISA HO42340156 of Staphylococcus aureus vancomycin (Van)/teicoplanin (Tec)-resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 116 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : CPHL VISA Mu50 of Staphylococcus aureus vancomycin (Van)-resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 117 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : NCTC 11047 of Staphylococcus epidermidisBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

105/162

2018-02-22 00:03:45


Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 118 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : NCTC 11865 of Propionibacterium granulosumBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

15.6

Measurement pX

4.19

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 119 of 289

Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : NCTC 7292 of Staphylococcus saprophyticusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 120 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : NCTC 737 of Propionibacterium acnesBioassay : Example 6 - activity against P. acnes -MIC, MBC & (S)DDA assaysThe following experiments all used P. acnes NCTC 737 as the test organism.MIC, MBC and DDA assays, as described above, were carried out using BP and a range of different benzoquinones and hydroquinones. Supplemented DDA assays, in the presence

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

106/162

2018-02-22 00:03:45


Unit

µg/mL

Quantitative value

62.5

Measurement pX

3.59

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 121 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : NCTC 737 of Propionibacterium acnesBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

31.25

Measurement pX

3.89

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 122 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-002 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamidestreptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

31.25

Measurement pX

3.89

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 123 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-003 of Propionibacterium acnes tetracycline (Tet)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

107/162

2018-02-22 00:03:45


Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

31.25

Measurement pX

3.89

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 124 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-004 of Propionibacterium acnes tetracycline (Tet)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

15.6

Measurement pX

4.19

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 125 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-005 of Propionibacterium granulosum macrolide-lincosamide-streptograminketolide (MLSK)-resistantBioassay : Example 8 - activity against other propionibacteria MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

15.6

Measurement pX

4.19

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 126 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-007 of Propionibacterium acnes clindamycin (Clin)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

108/162

2018-02-22 00:03:45


Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

62.5

Measurement pX

3.59

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 127 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-008 of Propionibacterium acnes clindamycin (Clin)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

31.25

Measurement pX

3.89

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 128 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-010 of Propionibacterium acnes macrolide-lincosamide-streptogramin-ketolide (MLSK)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

31.25

Measurement pX

3.89

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 129 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-017 of Propionibacterium acnes macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

109/162

2018-02-22 00:03:45


Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

62.5

Measurement pX

3.59

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 130 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-023 of Propionibacterium acnes macrolide-lincosamide-streptogramin-ketolide (MLSK)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

62.5

Measurement pX

3.59

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 131 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-026 of Propionibacterium acnes macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

31.25

Measurement pX

3.89

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 132 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-043 of Propionibacterium granulosum macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

110/162

2018-02-22 00:03:45


against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

62.5

Measurement pX

3.59

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 133 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-044 of Propionibacterium granulosum macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

31.25

Measurement pX

3.89

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 134 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-046 of Propionibacterium acnesBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

62.5

Measurement pX

3.59

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 135 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

111/162

2018-02-22 00:03:45


Bioassay Details

Target : PRP-053 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamidestreptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

62.5

Measurement pX

3.59

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 136 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-055 of Propionibacterium granulosumBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

15.6

Measurement pX

4.19

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 137 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-059 of Propionibacterium acnes macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

125

Measurement pX

3.29

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 138 of 289 Substance Effect Bioassay Category

Antibiotic In Vitro (Efficacy)

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

112/162

2018-02-22 00:03:45


Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-068 of Propionibacterium acnes erythromycin (Ery)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

125

Measurement pX

3.29

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 139 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-101 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamidestreptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

31.25

Measurement pX

3.89

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 140 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-102 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamidestreptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

62.5

Measurement pX

3.59

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 141 of 289 Substance Effect

Antibiotic

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

113/162

2018-02-22 00:03:45


Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATC 25577 of Propionibacterium avidumBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

31.25

Measurement pX

3.89

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 142 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 12600 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

125

Measurement pX

3.29

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 143 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 12600-U of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

114/162

2018-02-22 00:03:45


144 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 12601 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 145 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 12602 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

125

Measurement pX

3.29

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 146 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 12604 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

125

Measurement pX

3.29

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

115/162

2018-02-22 00:03:45


Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 147 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 12605 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 148 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 12606 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 149 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 12607 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

250

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

116/162

2018-02-22 00:03:45


Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 150 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 25923 of Staphylococcus aureusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 151 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 27836 of Staphylococcus warneriBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 152 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 27840 of Staphylococcus capitisBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

117/162

2018-02-22 00:03:45


Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 153 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 27844 of Staphylococcus hominisBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 154 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 27848 of Staphylococcus simulansBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 155 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 29212 of Enterococcus faecalisBioassay : Example 10 - activity against E. faecalisThe activities of BP, TBHQ and combinations of the two were tested against E. faecalis ATCC 29212, using MIC, MBC and (S)DDA assays as described above.For the (S)DDA assays, 200 μg of each compound was loaded onto each disc. The solvents used were DMSO for

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

118/162

2018-02-22 00:03:45


Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 156 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 29213 of Staphylococcus aureusBioassay : Example 1 - activity against S. aureus -MIC, MBC & (S)DDA assaysThe following experiments all used S. aureus ATCC 29213 as the test organism.MIC, MBC and DDA assays, as described above, were carried out using the test compound benzoyl peroxide (BP) and a range of different benzoquinones and hydroquinones.

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 157 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 29970 of Staphylococcus haemolyticusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 158 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 29971 of Staphylococcus xylosusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

119/162

2018-02-22 00:03:45


Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 159 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 29974 of Staphylococcus cohniiBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

62.5

Measurement pX

3.59

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 160 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : ATCC 33753 of Staphylococcus auricularisBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

15.6

Measurement pX

4.19

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 161 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : CPHL EMRSA 15 of Staphylococcus aureus methicillin (Met)/β-lactams resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

120/162

2018-02-22 00:03:45


Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

125

Measurement pX

3.29

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 162 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : CPHL EMRSA 16 of Staphylococcus aureus methicillin (Met)/β-lactams resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

125

Measurement pX

3.29

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 163 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : CPHL EMRSA 17 of Staphylococcus aureus methicillin (Met)/β-lactams resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

125

Measurement pX

3.29

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 164 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : CPHL GISA HO41340156 of Staphylococcus aureus vancomycin (Van)/teicoplanin (Tec)-resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

121/162

2018-02-22 00:03:45


Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

125

Measurement pX

3.29

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 165 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : CPHL VISA Mu3 of Staphylococcus aureus vancomycin (Van)-resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

125

Measurement pX

3.29

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 166 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : CPHL VISA Mu50 of Staphylococcus aureus vancomycin (Van)-resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

125

Measurement pX

3.29

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 167 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : NCTC 11047 of Staphylococcus epidermidisBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, includ-

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

122/162

2018-02-22 00:03:45


ing some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 168 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : NCTC 11865 of Propionibacterium granulosumBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

15.6

Measurement pX

4.19

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 169 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : NCTC 7292 of Staphylococcus saprophyticusBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

250

Measurement pX

2.99

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 170 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

123/162

2018-02-22 00:03:45


Bioassay Details

Target : NCTC 737 of Propionibacterium acnesBioassay : Example 6 - activity against P. acnes -MIC, MBC & (S)DDA assaysThe following experiments all used P. acnes NCTC 737 as the test organism.MIC, MBC and DDA assays, as described above, were carried out using BP and a range of different benzoquinones and hydroquinones. Supplemented DDA assays, in the presence

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

31.25

Measurement pX

3.89

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 171 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : NCTC 737 of Propionibacterium acnesBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

15.6

Measurement pX

4.19

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 172 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-002 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamidestreptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

15.6

Measurement pX

4.19

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 173 of 289 Substance Effect Bioassay Category

Antibiotic In Vitro (Efficacy)

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

124/162

2018-02-22 00:03:45


Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-003 of Propionibacterium acnes tetracycline (Tet)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

31.25

Measurement pX

3.89

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 174 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-004 of Propionibacterium acnes tetracycline (Tet)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

7.8

Measurement pX

4.49

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 175 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-005 of Propionibacterium granulosum macrolide-lincosamide-streptograminketolide (MLSK)-resistantBioassay : Example 8 - activity against other propionibacteria MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

15.6

Measurement pX

4.19

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 176 of 289 Substance Effect

Antibiotic

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

125/162

2018-02-22 00:03:45


Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-007 of Propionibacterium acnes clindamycin (Clin)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

31.25

Measurement pX

3.89

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 177 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-008 of Propionibacterium acnes clindamycin (Clin)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

31.25

Measurement pX

3.89

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 178 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-010 of Propionibacterium acnes macrolide-lincosamide-streptogramin-ketolide (MLSK)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

31.25

Measurement pX

3.89

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

126/162

2018-02-22 00:03:45


179 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-017 of Propionibacterium acnes macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

31.25

Measurement pX

3.89

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 180 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-023 of Propionibacterium acnes macrolide-lincosamide-streptogramin-ketolide (MLSK)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

31.25

Measurement pX

3.89

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 181 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-026 of Propionibacterium acnes macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

15.6

Measurement pX

4.19

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

127/162

2018-02-22 00:03:45


Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 182 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-043 of Propionibacterium granulosum macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

62.5

Measurement pX

3.59

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 183 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-044 of Propionibacterium granulosum macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

31.25

Measurement pX

3.89

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 184 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-046 of Propionibacterium acnesBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

31.25

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

128/162

2018-02-22 00:03:45


Measurement pX

3.89

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 185 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-053 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamidestreptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

31.25

Measurement pX

3.89

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 186 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-055 of Propionibacterium granulosumBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

15.6

Measurement pX

4.19

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 187 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-059 of Propionibacterium acnes macrolide-lincosamide-streptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

129/162

2018-02-22 00:03:45


Quantitative value

62.5

Measurement pX

3.59

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 188 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-068 of Propionibacterium acnes erythromycin (Ery)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

62.5

Measurement pX

3.59

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 189 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-101 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamidestreptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Unit

µg/mL

Quantitative value

15.6

Measurement pX

4.19

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 190 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : PRP-102 of Propionibacterium acnes tetracycline (Tet)/macrolide-lincosamidestreptogramin (MLS)-resistantBioassay : Example 8 - activity against other propionibacteria - MIC MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other Propionibacteriiim spp strains, including some with known antibiotic resistance. MIC, MBC and (S)DDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MIC

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

130/162

2018-02-22 00:03:45


Unit

µg/mL

Quantitative value

62.5

Measurement pX

3.59

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 191 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : CPHL EMRSA 15 of Staphylococcus aureus methicillin (Met)/β-lactams resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

125 - 150

Measurement pX

3.29

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 192 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : CPHL EMRSA 17 of Staphylococcus aureus methicillin (Met)/β-lactams resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

125 - 250

Measurement pX

3.29

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 193 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : CPHL VISA Mu3 of Staphylococcus aureus vancomycin (Van)-resistantBioassay : Example 5 - activity against other staphylococci -MIC, MBC & (S)DDA assaysThe activities of BP, TBHQ and combinations of the two were tested against other staphylococcal bacterial strains, including some with known antibiotic resistance. MIC, MBC and (S)DJDA assays were carried out as described above

Substance RN

984320View in Reaxys

Substance Name

230913

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

131/162

2018-02-22 00:03:45


Measurement Parameter

MBC

Unit

µg/mL

Quantitative value

125 - 250

Measurement pX

3.29

Patent; EADY, Elizabeth, Anne; FITZGERALD, Daniel, James; COVE, Jonathan, Howard; SEVILLE, Scott; WO2006/100495; (A1); (2006), View in Reaxys 194 of 289 Substance Effect

Antiinflammatory

Bioassay Category

In Vivo (Animal models)

Bioassay Name

In vivo Measurement

Bioassay Details

Effect : anti-inflammatoryBioassay : TPA-induced ear oedemic animalEvaluation of the anti-inflammatory activity of the peroxides after a single topical administration in TPA- induced ear oedema.Principle of the test: the aim is to evaluate the anti¬ inflammatory activity of the peroxides by measuring the thickness of mouse ear after TPA topical application.

Substance RN

984320View in Reaxys

Substance Name

230913

Substance Route of Adm.

transdermal administration

Measurement Parameter

MIC

Unit

mg/mL

Quantitative value

80

Patent; GALDERMA RESEARCH and DEVELOPMENT; BOUIX-PETER, Claire; PASCAL, Jean-Claude; RODEVILLE, Nicolas; WO2011/70170; (2011); (A1) English, View in Reaxys 195 of 289 Target Name Target Synonyms

enzyme catalytic; enzyme

Target, Subunit, Species enzyme Target Mutant/Chimera Details

enzyme:Wild

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |enzyme; inhib. of Bioassay : protein kinase C (PKC) activity measured after 24 h of exposure; immunoblot analysis cultured cells from adult breast skin were grown and maintained in serum-free medium with var. Ca(2+) conc.; cells treated with soln. of title comp. in acetone; cell proliferation, phorbol ester-induced differentiation determined using <3H>-thymidine

Substance RN

984320View in Reaxys

Substance Name

230913

Substance Dose

100 nM

Qualitative Results

title comp. does not downregulate subcellular levels of PKC activity after 24 h expos.; does not significantly antagonize phorbol ester-induced inhib. of prolife. and differentiation; inhibits both human and murine PKC activity in vitro

Measurement Parameter

Qualitative

Matsui; Mintz; DeLeo; Skin Pharmacology; vol. 8; nb. 3; (1995); p. 130 - 138, View in Reaxys 196 of 289 Target Name Target Synonyms

enzyme catalytic; enzyme

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

132/162

2018-02-22 00:03:45


Target, Subunit, Species enzyme Target Mutant/Chimera Details

enzyme:Wild

Target Transfection

Non Transfected

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Effect : |enzyme; examination of Bioassay : in PBS; compared to untreated control in vitro; cells maintained with or without pretreatment CDNB (chlorodinitrobenzene) for 1 h; treated title comp.; exposed; measured cellular reduced glutathione (GSH) spectrophotometrically at 412 nm according to Anderson

Substance RN

984320View in Reaxys

Substance Name

230913

Substance Dose

0.0100000 mM

Qualitative Results

title comp. reduced intracellular GSH level at conc. 0.5 mM and higher (75, 54, 31, 31 percent at 0.5, 1.0, 1.5, 2.0 mM); pretreatment with CDNB lowered intracellular level of GSH to 15 percent of control cells and enhanced their subsequent sensitivity

Measurement Parameter

Qualitative

Babich; Zuckerbraun; Wurzburger; Rubin; Borenfreund; Blau; Toxicology; vol. 106; nb. 1-3; (1996); p. 187 196, View in Reaxys 197 of 289 Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : human keratinocyte cell line, RHEK-1Bioassay : exposure medium: DMEM, 10 percent Serum Plus, 2 percent EBS and antibiotics; compared to untreated control in vitro; cells incubated with growth medium 24 or 48 h; treated title comp.; exposed; assessed cell proliferation using quantitative determination of DNA with the fluorochrome, bisbenzimidazole

Substance RN

984320View in Reaxys

Substance Name

230913

Substance Dose

0.0200000 mM

Qualitative Results

time required for the DNA content to double, h: 20 (control), 23, 24, 38, 48 at 0.02, 0.04, 0.06, 0.08 mM title comp., respect; after 7 d of exposure cell population, percent of control: 86, 76, 69, 61 at 0.02, 0.04, 0.06, 0.08 mM title comp., respect.

Measurement Parameter

Qualitative

Babich; Zuckerbraun; Wurzburger; Rubin; Borenfreund; Blau; Toxicology; vol. 106; nb. 1-3; (1996); p. 187 196, View in Reaxys 198 of 289 Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : human keratinocyte cell line, RHEK-1Bioassay : exposure medium: DMEM, 10 percent Serum Plus, 2 percent EBS and antibiotics; compared to untreated control in vitro; cells incubated with growth medium 48-72 h; treated varied conc. title comp.; exposed: for 24 h, or 1 h followed by 48 h in title comp.-free medium; fixed; stained with Giemsa's solut.; examined miroscopically for cellular aberrations

Substance RN

984320View in Reaxys

Substance Name

230913

Qualitative Results

at all tested conditions title comp. resulted in an increase in multinucleation and in extensive vacuolization; initially appeared vacuolization then spread throughout the cytoplasm

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

133/162

2018-02-22 00:03:45


Measurement Parameter

Qualitative

Babich; Zuckerbraun; Wurzburger; Rubin; Borenfreund; Blau; Toxicology; vol. 106; nb. 1-3; (1996); p. 187 196, View in Reaxys 199 of 289 Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : human keratinocyte cell line, RHEK-1Bioassay : exposure medium: DMEM, 10 percent Serum Plus, 2 percent EBS and antibiotics; incubated cells with NR 3 h at 37 deg C; calculated NR50 (reduced uptake NR by 50 percent); compared to untreated control in vitro; cells incubated with growth medium 24 or 48 h; treated exposure medium amended with varied conc. title comp.; exposed; assessed cytotoxicity with neutral red (NR), which is based on the uptake and lysosomal accumulation of supravital dye, NR

Substance RN

984320View in Reaxys

Substance Name

230913

Substance Dose

0.0500000 mM

Qualitative Results

NR50 0.11 mmol/l

Measurement Parameter

Qualitative

Babich; Zuckerbraun; Wurzburger; Rubin; Borenfreund; Blau; Toxicology; vol. 106; nb. 1-3; (1996); p. 187 196, View in Reaxys 200 of 289 Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : human keratinocyte cell line, RHEK-1Bioassay : exposure medium: DMEM, 10 percent Serum Plus, 2 percent EBS and antibiotics; incubated cells with NR 3 h at 37 deg C; compared to untreated control in vitro; cells incubated with growth medium 24 or 48 h; treated title comp.; exposed for 1 h or 1 h followed by 48 h in title comp.-free medium; assessed cytotoxicity with neutral red (NR): uptake and lysosomal accumulation of supravital dye, NR

Substance RN

984320View in Reaxys

Substance Name

230913

Substance Dose

0.0100000 mM

Qualitative Results

title comp. caused irreversible damage for cells exposed 1-h at conc. > 0.15 mM; response cells to 1-h exposure followed by 48 h in title comp.-free medium 20 percent of control, while to only 1 h exposure - ca. 42 percent of control

Measurement Parameter

Qualitative

Babich; Zuckerbraun; Wurzburger; Rubin; Borenfreund; Blau; Toxicology; vol. 106; nb. 1-3; (1996); p. 187 196, View in Reaxys 201 of 289 Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : human keratinocyte cell line, RHEK-1Bioassay : in PBS in vitro; cells incubated with growth medium 24 or 48 h; treated title comp.; exposed; determined lactic acid dehydrogenase (LDH) release in supernatant using the CytoTox 96<R> Nonradiactive Cytotoxicity Assay Kit

Substance RN

984320View in Reaxys

Substance Name

230913

Substance Dose

0.0100000 mM

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

134/162

2018-02-22 00:03:45


Qualitative Results

title comp. evoked signif. LDH release in supernatant at conc. 0.5 mM and higher; presented as graph

Measurement Parameter

Qualitative

Babich; Zuckerbraun; Wurzburger; Rubin; Borenfreund; Blau; Toxicology; vol. 106; nb. 1-3; (1996); p. 187 196, View in Reaxys 202 of 289 Substance Effect

Cytotoxic

Bioassay Category

In Vitro (Efficacy)

Bioassay Name

In Vitro (others)

Bioassay Details

Target : human keratinocyte cell line, RHEK-1Bioassay : in PBS; lipid peroxidation by conc. malondialdehyde and thiobarbituric acid reactive substances (TBARS); LDH reliase using CytoTox 96<R> Nonradioactive Cytotoxicity Assay Kit in vitro; cells maintained or not in vitamin E 24; treated title comp.; with or without 1 mM Fe(2+); exposed; estimated lipid peroxidation in supernatant and lactic acid dehydrogenase (LDH) release; compared to untreated control

Substance RN

984320View in Reaxys

Substance Name

230913

Substance Dose

2 mM

Qualitative Results

title comp. or Fe(2+) alone did not exhibit peroxidation; title comp.+Fe(2+) caused formation 0.7 or 2.3 nmol TBARS/mg cellular protein in cells maintained or not in vitamin E; LDH release: 71 percent and 74 percent without and with Fe(2+) and title

Measurement Parameter

Qualitative

Babich; Zuckerbraun; Wurzburger; Rubin; Borenfreund; Blau; Toxicology; vol. 106; nb. 1-3; (1996); p. 187 196, View in Reaxys 203 of 289 Bioassay Category Bioassay Details

Metabolism/Transport Percutaneous penetration of benzoyl peroxide in monkey is low

Biological Species/NCBI Cercopithecidae ID Substance RN

984320View in Reaxys

Qualitative Results

Low

Measurement Parameter

Absorption

Qualitative value

NA

Measurement pX

1

Galderma Laboratories, L.P., Benzac¿ (benzoyl peroxide) Gel & AC wash, Product Leaflet, View in Reaxys 204 of 289 Bioassay Category Bioassay Details

Pharmacokinetic In vivo, benzoic acid recovered from urine following topical administration of small amounts of 14C-benzoyl peroxide

Biological Species/NCBI Cercopithecidae ID Substance RN

984320View in Reaxys

Substance Route of Adm.

topical administration

Qualitative Results

45

Measurement Parameter

Ue (%)

Unit

%

Measurement Object

Excretion

Quantitative value

45

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

135/162

2018-02-22 00:03:45


Nacht; Yeung; Beasley Jr.; Anjo; Maibach; Journal of the American Academy of Dermatology; vol. 4; nb. 1; (1981); p. 31 - 37, View in Reaxys 205 of 289 Target Name Target Synonyms

protein kinase C atp:protein phosphotransferase (diacylglycerol-dependent); diacylglycerol-activated phospholipid-dependent pkc; diacylglycerol-activated phospholipid-dependent protein kinase c; pkc (protein kinase c); pkc1 (protein kinase c); protein kinase c

Target, Subunit, Species protein kinase C Target Mutant/Chimera Details

protein kinase C:Wild

Substance Action on Target

Inhibitor

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Inhibitory concentration of the compound against Protein Kinase C

Substance RN

984320View in Reaxys

Measurement Parameter

IC50

Unit

nM

Qualitative value

=

Quantitative value

500

Measurement pX

6.3

206 of 289 Bioassay Category Bioassay Details

Metabolism/Transport Percutaneous absorption in rhesus monkey in a 24 Hr period study

Biological Species/NCBI Cercopithecidae ID Substance RN

984320View in Reaxys

Qualitative Results

45

Measurement Parameter

Absorption

Unit

%

Quantitative value

45

Galderma Laboratories, L.P., Benzac¿ (benzoyl peroxide) Gel & AC wash, Product Leaflet, View in Reaxys 207 of 289 Bioassay Category Bioassay Details

Metabolism/Transport Percutaneous penetration of benzoyl peroxide in rat is low

Biological Species/NCBI Rattus norvegicus ID Substance RN

984320View in Reaxys

Qualitative Results

Low

Measurement Parameter

Absorption

Qualitative value

NA

Measurement pX

1

Galderma Laboratories, L.P., Benzac¿ (benzoyl peroxide) Gel & AC wash, Product Leaflet, View in Reaxys 208 of 289 Bioassay Category Bioassay Details

Metabolism/Transport Percutaneous penetration of benzoyl peroxide in rabbit is low

Biological Species/NCBI rabbit ID Substance RN

984320View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

136/162

2018-02-22 00:03:45


Qualitative Results

Low

Measurement Parameter

Absorption

Qualitative value

NA

Measurement pX

1

Galderma Laboratories, L.P., Benzac¿ (benzoyl peroxide) Gel & AC wash, Product Leaflet, View in Reaxys 209 of 289 Bioassay Category Bioassay Details

Metabolism/Transport Percutaneous penetration of benzoyl peroxide in man is low

Biological Species/NCBI human ID Substance RN

984320View in Reaxys

Qualitative Results

Low

Measurement Parameter

Absorption

Qualitative value

NA

Measurement pX

1

Galderma Laboratories, L.P., Benzac¿ (benzoyl peroxide) Gel & AC wash, Product Leaflet, View in Reaxys 210 of 289 Bioassay Category Bioassay Details

Pharmacokinetic In vivo, benzoic acid recovered from urine following intramuscular administration of small amounts of 14C-benzoyl peroxide

Biological Species/NCBI Cercopithecidae ID Substance RN

984320View in Reaxys

Substance Route of Adm.

intramuscular administration

Qualitative Results

98

Measurement Parameter

Ue (%)

Unit

%

Measurement Object

Excretion

Quantitative value

98

Nacht; Yeung; Beasley Jr.; Anjo; Maibach; Journal of the American Academy of Dermatology; vol. 4; nb. 1; (1981); p. 31 - 37, View in Reaxys 211 of 289

Substance Action on Target

Inhibitor

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

In vitro inhibitory concentration against mouse ehrlich ascites tumor (EAT) cells upon incubation at 37 degree C for 3 h 45 min and pH 7.4 with compound dissolved in DMSO (0.25) using MTT assay

Biological Species/NCBI Mus musculus ID Cells/Cell Lines

Ehrlich ascites carcinoma cell line

Substance RN

984320View in Reaxys

Measurement Parameter

IC80

Unit

µM

Qualitative value

=

Quantitative value

415

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

137/162

2018-02-22 00:03:45


Deviation

9

Measurement pX

3.98

Woerdenbag; Moskal; Pras; Malingre; El-Feraly; Kampinga; Konings; Journal of Natural Products (Lloydia); vol. 56; nb. 6; (1993); p. 849 - 856, View in Reaxys 212 of 289 Substance Action on Target

Inhibitor

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

In vitro inhibitory concentration against mouse ehrlich ascites tumor (EAT) cells upon incubation at 37 degree C for 3 h 45 min and pH 7.4 with compound dissolved in DMSO (0.25) using MTT assay

Biological Species/NCBI Mus musculus ID Cells/Cell Lines

Ehrlich ascites carcinoma cell line

Substance RN

984320View in Reaxys

Measurement Parameter

IC50

Unit

µM

Qualitative value

=

Quantitative value

337

Deviation

43

Measurement pX

3.47

Woerdenbag; Moskal; Pras; Malingre; El-Feraly; Kampinga; Konings; Journal of Natural Products (Lloydia); vol. 56; nb. 6; (1993); p. 849 - 856, View in Reaxys 213 of 289 Bioassay Category Bioassay Details

In Vitro (Efficacy) Percent increase in serum production on the forehead in human with localized acne on face determined upon administration of the compound

Biological Species/NCBI human ID Substance RN

984320View in Reaxys

Measurement Parameter

Activity

Unit

%

Measurement Object

Percent increase in serum production on the forehead in human

Qualitative value

=

Quantitative value

10.5

Stinco, Guiseppe; Bragadin; Trotter; Pillon; Patrone; Journal of the European Academy of Dermatology and Venereology; vol. 21; nb. 3; (2007); p. 320 - 325, View in Reaxys 214 of 289 Bioassay Category Bioassay Details

In Vitro (Efficacy) Percent increase in serum production on the cheek in human with localized acne on face determined upon administration of the compound

Biological Species/NCBI human ID Substance RN

984320View in Reaxys

Measurement Parameter

Activity

Unit

%

Measurement Object

Percent increase in serum production on the cheek in human

Qualitative value

=

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

138/162

2018-02-22 00:03:45


Quantitative value

25.4

Stinco, Guiseppe; Bragadin; Trotter; Pillon; Patrone; Journal of the European Academy of Dermatology and Venereology; vol. 21; nb. 3; (2007); p. 320 - 325, View in Reaxys 215 of 289 Bioassay Category Bioassay Details

In Vitro (Efficacy) Percent increase in serum production on the chin in human with localized acne on face determined upon administration of the compound

Biological Species/NCBI human ID Substance RN

984320View in Reaxys

Measurement Parameter

Activity

Unit

%

Measurement Object

Percent increase in serum production on the chin in human

Qualitative value

=

Quantitative value

10.3

Stinco, Guiseppe; Bragadin; Trotter; Pillon; Patrone; Journal of the European Academy of Dermatology and Venereology; vol. 21; nb. 3; (2007); p. 320 - 325, View in Reaxys 216 of 289 Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Details

Lethal dose (LD50) in mammal after application on skin

Substance RN

984320View in Reaxys

Qualitative Results

> 1000

Measurement Parameter

LD50

Unit

mg/kg

Quantitative value

1000

Material Safety Data Sheet, View in Reaxys 217 of 289 Bioassay Category Bioassay Details

Toxicity/Safety Pharmacology Intraperitoneal lethal dose in mouse

Biological Species/NCBI Mus musculus ID Substance RN

984320View in Reaxys

Measurement Parameter

LD50

Unit

mg/kg

Qualitative value

=

Quantitative value

250

Material Safety Data Sheet, View in Reaxys 218 of 289 Bioassay Category Bioassay Details

Toxicity/Safety Pharmacology Oral lethal dose in mouse

Biological Species/NCBI Mus musculus ID Substance RN

984320View in Reaxys

Substance Route of Adm.

oral administration

Measurement Parameter

LD50

Unit

mg/kg

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

139/162

2018-02-22 00:03:45


Qualitative value

=

Quantitative value

5700

Material Safety Data Sheet, View in Reaxys 219 of 289 Bioassay Category Bioassay Details

Toxicity/Safety Pharmacology Oral lethal dose in rats

Biological Species/NCBI Rattus norvegicus ID Substance RN

984320View in Reaxys

Measurement Parameter

LD50

Unit

mg/kg

Qualitative value

=

Quantitative value

7710

Material Safety Data Sheet, View in Reaxys 220 of 289 Bioassay Category Bioassay Details

Toxicity/Safety Pharmacology Intraperitoneal lethal dose (LD50) in mouse

Biological Species/NCBI Mus musculus ID Substance RN

984320View in Reaxys

Qualitative Results

250

Measurement Parameter

LD50

Unit

mg/kg

Quantitative value

250

Material Safety Data Sheet, View in Reaxys 221 of 289 Bioassay Category Bioassay Details

Toxicity/Safety Pharmacology Oral lethal dose (LD50) in mouse

Biological Species/NCBI Mus musculus ID Substance RN

984320View in Reaxys

Qualitative Results

5700

Measurement Parameter

LD50

Unit

mg/kg

Quantitative value

5700

Material Safety Data Sheet, View in Reaxys 222 of 289 Bioassay Category Bioassay Details

Toxicity/Safety Pharmacology Lethal dose in mammal after application on skin; Value is >1000;Dermal

Biological Species/NCBI mammal ID Substance RN

984320View in Reaxys

Substance Route of Adm.

topical administration

Measurement Parameter

LD50

Unit

mg/kg

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

140/162

2018-02-22 00:03:45


Qualitative value

=

Quantitative value

1000

Material Safety Data Sheet, View in Reaxys 223 of 289 Bioassay Category Bioassay Details

Toxicity/Safety Pharmacology Oral lethal dose (LD50) in rats

Biological Species/NCBI Rattus norvegicus ID Substance RN

984320View in Reaxys

Substance Route of Adm.

oral administration

Qualitative Results

7710

Measurement Parameter

LD50

Unit

mg/kg

Quantitative value

7710

Material Safety Data Sheet, View in Reaxys 224 of 289 Substance Effect

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Minimum inhibitory concentration of compound against Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.01 mg/mL 15-Hydroxyeicosa-8(Z),11(Z),13(E)-trienoic acid (15-HETrE)

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

Experiment 1

Measurement Parameter

MIC

Unit

mg/mL

Measurement Object

Growth inhibition

Qualitative value

>

Quantitative value

0.6

Measurement pX

1

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 225 of 289 Substance Effect

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Minimum inhibitory concentration of compound against Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.01 mg/mL 15-Hydroxyeicosa-8(Z),11(Z),13(E)-trienoic acid (15-HETrE)

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

Experiment 2

Measurement Parameter

MIC

Unit

mg/mL

Measurement Object

Growth inhibition

Qualitative value

<=

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

141/162

2018-02-22 00:03:45


Quantitative value

0.8

Measurement pX

2.48

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 226 of 289 Substance Effect

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Minimum inhibitory concentration of compound against Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.05 mg/mL 15-Hydroxyeicosa-8(Z),11(Z),13(E)-trienoic acid (15-HETrE)

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Measurement Parameter

MIC

Unit

mg/mL

Measurement Object

Growth inhibition

Qualitative value

<

Quantitative value

0.2

Measurement pX

3.08

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 227 of 289 Substance Effect

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Minimum inhibitory concentration of compound against Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 1.0 mg/mL Dihomo-gamma-linolenic acid (DGLA)

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

Experiment 1

Measurement Parameter

MIC

Unit

mg/mL

Measurement Object

Growth inhibition

Qualitative value

>

Quantitative value

0.2

Measurement pX

1

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 228 of 289 Substance Effect

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Minimum inhibitory concentration of compound against Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 1.0 mg/mL Dihomo-gamma-linolenic acid (DGLA)

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

Experiment 2

Measurement Parameter

MIC

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

142/162

2018-02-22 00:03:45


Unit

mg/mL

Measurement Object

Growth inhibition

Qualitative value

<=

Quantitative value

0.4

Measurement pX

2.78

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 229 of 289 Substance Effect

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Minimum inhibitory concentration of compound against Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.4 mg/mL Dihomo-gamma-linolenic acid (DGLA)

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

Experiment 1

Measurement Parameter

MIC

Unit

mg/mL

Measurement Object

Growth inhibition

Qualitative value

>

Quantitative value

0.2

Measurement pX

1

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 230 of 289 Substance Effect

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Minimum inhibitory concentration of compound against Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.4 mg/mL Dihomo-gamma-linolenic acid (DGLA)

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

Experiment 2

Measurement Parameter

MIC

Unit

mg/mL

Measurement Object

Growth inhibition

Qualitative value

<=

Quantitative value

0.4

Measurement pX

2.78

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 231 of 289 Substance Effect

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Minimum inhibitory concentration of compound against Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.1 mg/mL 15-Hydroxyeicosa-5,8,11,13,17-pentaenoic acid

Biological Species/NCBI Propionibacterium acnes ID

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

143/162

2018-02-22 00:03:45


Substance RN

984320View in Reaxys

Measurement Parameter

MIC

Unit

mg/mL

Measurement Object

Growth inhibition

Qualitative value

<

Quantitative value

0.2

Measurement pX

3.08

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 232 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.2 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.4 mg/mL Dihomo-gamma-linolenic acid (DGLA)

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

+++ = Confluent growth

Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

@

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 233 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.4 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.4 mg/mL Dihomo-gamma-linolenic acid (DGLA)

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

- = No growth present

Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

NA

Measurement pX

1

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 234 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.6 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.4 mg/mL Dihomo-gamma-linolenic acid (DGLA)

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

- = No growth present

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

144/162

2018-02-22 00:03:45


Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

NA

Measurement pX

1

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 235 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.6 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.05 mg/mL 15-Hydroxyeicosa-5,8,11,13,17-pentaenoic acid

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

+ = Marked reduction in growth to multiple tiny, single colonies

Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

@

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 236 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.8 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.05 mg/mL 15-Hydroxyeicosa-5,8,11,13,17-pentaenoic acid

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

- = No growth present

Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

NA

Measurement pX

1

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 237 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 1.0 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.05 mg/mL 15-Hydroxyeicosa-5,8,11,13,17-pentaenoic acid

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

- = No growth present

Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

NA

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

145/162

2018-02-22 00:03:45


Measurement pX

1

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 238 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.2 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.1 mg/mL 15-Hydroxyeicosa-5,8,11,13,17-pentaenoic acid

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

- = No growth present

Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

NA

Measurement pX

1

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 239 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.2 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

+++ = Confluent growth

Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

@

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 240 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.2 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.05 mg/mL 15-Hydroxyeicosa-8(Z),11(Z),13(E)-trienoic acid (15-HETrE)

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

- = No growth present

Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

NA

Measurement pX

1

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 241 of 289 Substance Effect Bioassay Category

Antibiotic In Vitro (Efficacy)

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

146/162

2018-02-22 00:03:45


Bioassay Details

Antibacterial activity of 1.0 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.05 mg/mL 15-Hydroxyeicosa-8(Z),11(Z),13(E)-trienoic acid (15-HETrE)

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

- = No growth present

Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

NA

Measurement pX

1

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 242 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.6 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

++ = Less confluent growth

Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

@

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 243 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.8 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

+ = Marked reduction in growth to multiple tiny, single colonies

Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

@

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 244 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.4 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

+++ = Confluent growth

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

147/162

2018-02-22 00:03:45


Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

@

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 245 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.4 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.1 mg/mL 15-Hydroxyeicosa-5,8,11,13,17-pentaenoic acid

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

- = No growth present

Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

NA

Measurement pX

1

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 246 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.6 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.1 mg/mL 15-Hydroxyeicosa-5,8,11,13,17-pentaenoic acid

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

- = No growth present

Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

NA

Measurement pX

1

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 247 of 289 Substance Effect

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Minimum inhibitory concentration of compound against Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.05 mg/mL 15-Hydroxyeicosa-5,8,11,13,17-pentaenoic acid

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

Experiment 1

Measurement Parameter

MIC

Unit

mg/mL

Measurement Object

Growth inhibition

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

148/162

2018-02-22 00:03:45


Qualitative value

>

Quantitative value

0.4

Measurement pX

1

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 248 of 289 Substance Effect

Antineoplastic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Minimum inhibitory concentration of compound against Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.05 mg/mL 15-Hydroxyeicosa-5,8,11,13,17-pentaenoic acid

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

Experiment 2

Measurement Parameter

MIC

Unit

mg/mL

Measurement Object

Growth inhibition

Qualitative value

<=

Quantitative value

0.6

Measurement pX

2.61

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 249 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.8 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.4 mg/mL Dihomo-gamma-linolenic acid (DGLA)

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

- = No growth present

Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

NA

Measurement pX

1

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 250 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.2 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 1.0 mg/mL Dihomo-gamma-linolenic acid (DGLA)

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

++ = Less confluent growth

Measurement Parameter

Activity

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

149/162

2018-02-22 00:03:45


Measurement Object

Growth index

Qualitative value

@

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 251 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.4 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 1.0 mg/mL Dihomo-gamma-linolenic acid (DGLA)

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

- = No growth present

Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

NA

Measurement pX

1

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 252 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.6 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 1.0 mg/mL Dihomo-gamma-linolenic acid (DGLA)

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

- = No growth present

Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

NA

Measurement pX

1

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 253 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.8 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 1.0 mg/mL Dihomo-gamma-linolenic acid (DGLA)

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

- = No growth present

Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

NA

Measurement pX

1

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

150/162

2018-02-22 00:03:45


Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 254 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.4 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.01 mg/mL 15-Hydroxyeicosa-8(Z),11(Z),13(E)-trienoic acid (15-HETrE)

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

+++ = Confluent growth

Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

@

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 255 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.6 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.01 mg/mL 15-Hydroxyeicosa-8(Z),11(Z),13(E)-trienoic acid (15-HETrE)

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

++ = Less confluent growth

Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

@

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 256 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.8 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.01 mg/mL 15-Hydroxyeicosa-8(Z),11(Z),13(E)-trienoic acid (15-HETrE)

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

+ = Marked reduction in growth to multiple tiny, single colonies

Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

@

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 257 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.8 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.1 mg/mL 15-Hydroxyeicosa-5,8,11,13,17-pentaenoic acid

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

151/162

2018-02-22 00:03:45


Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

- = No growth present

Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

NA

Measurement pX

1

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 258 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.2 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.01 mg/mL 15-Hydroxyeicosa-8(Z),11(Z),13(E)-trienoic acid (15-HETrE)

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

+++ = Confluent growth

Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

@

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 259 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 1 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.4 mg/mL Dihomo-gamma-linolenic acid (DGLA)

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

- = No growth present

Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

NA

Measurement pX

1

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 260 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 1.0 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.01 mg/mL 15-Hydroxyeicosa-8(Z),11(Z),13(E)-trienoic acid (15-HETrE)

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

- = No growth present

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

152/162

2018-02-22 00:03:45


Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

NA

Measurement pX

1

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 261 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.4 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.05 mg/mL 15-Hydroxyeicosa-8(Z),11(Z),13(E)-trienoic acid (15-HETrE)

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

- = No growth present

Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

NA

Measurement pX

1

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 262 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.6 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.05 mg/mL 15-Hydroxyeicosa-8(Z),11(Z),13(E)-trienoic acid (15-HETrE)

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

- = No growth present

Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

NA

Measurement pX

1

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 263 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.8 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.05 mg/mL 15-Hydroxyeicosa-8(Z),11(Z),13(E)-trienoic acid (15-HETrE)

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

- = No growth present

Measurement Parameter

Activity

Measurement Object

Growth index

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

153/162

2018-02-22 00:03:45


Qualitative value

NA

Measurement pX

1

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 264 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.2 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.05 mg/mL 15-Hydroxyeicosa-5,8,11,13,17-pentaenoic acid

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

+++ = Confluent growth

Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

@

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 265 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Antibacterial activity of 0.4 mg/mL compound towards Propionibacterium acnes growth upon incubation for 72 h at 35-37 degree C in combination with 0.05 mg/mL 15-Hydroxyeicosa-5,8,11,13,17-pentaenoic acid

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

++ = Less confluent growth

Measurement Parameter

Activity

Measurement Object

Growth index

Qualitative value

@

Patent; DIGNITY SCIENCES LIMITED; US2012/232147; (2012); (A1) English, View in Reaxys 266 of 289 Substance Effect

Antimicrobial

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Minimum inhibitory concentration of compound against PROPIONIBACTERIUM ACNES NCTC 737 at pH 7.1 +/- 0.2 using BROTH MICRODILUTION ASSAY

Biological Species/NCBI Propionibacterium acnes ATCC 6919 ID Substance RN

984320View in Reaxys

Measurement Parameter

MIC

Unit

mg/L

Measurement Object

BACTERIAL GROWTH

Qualitative value

=

Quantitative value

31.25

Measurement pX

3.89

Patent; SUMMIT (CAMBRIDGE) LIMITED; US2010/184727; (2010); (A1) English, View in Reaxys 267 of 289 Substance Effect

Antimicrobial

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

154/162

2018-02-22 00:03:45


Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Minimum bactericidal concentration of compound against PROPIONIBACTERIUM ACNES NCTC 737 at pH 7.1 +/- 0.2 using BROTH MICRODILUTION ASSAY

Biological Species/NCBI Propionibacterium acnes ATCC 6919 ID Substance RN

984320View in Reaxys

Measurement Parameter

MBC

Unit

mg/L

Measurement Object

BACTERIAL GROWTH

Qualitative value

=

Quantitative value

62.5

Measurement pX

3.59

Patent; SUMMIT (CAMBRIDGE) LIMITED; US2010/184727; (2010); (A1) English, View in Reaxys 268 of 289 Substance Effect

Antimicrobial

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Minimum bactericidal concentration of compound against PROPIONIBACTERIUM ACNES NCTC 737 at pH 6 using BROTH MICRODILUTION ASSAY

Biological Species/NCBI Propionibacterium acnes ATCC 6919 ID Substance RN

984320View in Reaxys

Measurement Parameter

MBC

Unit

mg/L

Measurement Object

BACTERIAL GROWTH

Qualitative value

=

Quantitative value

62.5

Measurement pX

3.59

Patent; SUMMIT (CAMBRIDGE) LIMITED; US2010/184727; (2010); (A1) English, View in Reaxys 269 of 289 Substance Effect

Antimicrobial

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

Minimum inhibitory concentration of compound against PROPIONIBACTERIUM ACNES NCTC 737 at pH 6 using BROTH MICRODILUTION ASSAY

Biological Species/NCBI Propionibacterium acnes ATCC 6919 ID Substance RN

984320View in Reaxys

Measurement Parameter

MIC

Unit

mg/L

Measurement Object

BACTERIAL GROWTH

Qualitative value

=

Quantitative value

31.25

Measurement pX

3.89

Patent; SUMMIT (CAMBRIDGE) LIMITED; US2010/184727; (2010); (A1) English, View in Reaxys 270 of 289 Substance Effect Bioassay Category

Antibiotic In Vitro (Efficacy)

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

155/162

2018-02-22 00:03:45


Bioassay Details

In vitro minimum bactericidal concentration (MBC90) of compound against growth of Propionibacterium acnes upon incubation at 35 degree C for 72 hours in the presence of 50 sebum by Microtiter assay

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Measurement Parameter

MBC90

Unit

µg/mL

Measurement Object

BACTERIAL GROWTH

Qualitative value

=

Quantitative value

1600

Measurement pX

3.13

Patent; NANOBIO CORPORATION; SUTCLIFFE, Joyce, A.; CIOTTI, Susan, M.; BAKER, James, R., Jr.; WO2010/87964; (2010); (A2) English, View in Reaxys 271 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

In vitro minimum inhibitory concentration (MIC90) of compound against growth of Propionibacterium acnes upon incubation at 35-37 degree C for 48 hours in the presence of 50 sebum by Microtiter assay

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Measurement Parameter

MIC90

Unit

µg/mL

Measurement Object

BACTERIAL GROWTH

Qualitative value

=

Quantitative value

400

Measurement pX

3.74

Patent; NANOBIO CORPORATION; SUTCLIFFE, Joyce, A.; CIOTTI, Susan, M.; BAKER, James, R., Jr.; WO2010/87964; (2010); (A2) English, View in Reaxys 272 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

In vitro minimum bactericidal concentration (MBC50) of compound against growth of Propionibacterium acnes upon incubation at 35 degree C for 72 hours in the absence of 50 sebum by Microtiter assay

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Measurement Parameter

MBC50

Unit

µg/mL

Measurement Object

BACTERIAL GROWTH

Qualitative value

=

Quantitative value

200

Measurement pX

3.08

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

156/162

2018-02-22 00:03:45


Patent; NANOBIO CORPORATION; SUTCLIFFE, Joyce, A.; CIOTTI, Susan, M.; BAKER, James, R., Jr.; WO2010/87964; (2010); (A2) English, View in Reaxys 273 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

In vitro minimum inhibitory concentration (MIC90) of compound against growth of Propionibacterium acnes upon incubation at 35-37 degree C for 48 hours in the absence of 50 sebum by Microtiter assay

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Measurement Parameter

MIC90

Unit

µg/mL

Measurement Object

BACTERIAL GROWTH

Qualitative value

=

Quantitative value

50

Measurement pX

4.64

Patent; NANOBIO CORPORATION; SUTCLIFFE, Joyce, A.; CIOTTI, Susan, M.; BAKER, James, R., Jr.; WO2010/87964; (2010); (A2) English, View in Reaxys 274 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

In vitro minimum inhibitory concentration (MIC) of compound against growth of Propionibacterium acnes upon incubation at 35-37 degree C for 48 hours in the absence of 50 sebum by Microtiter assay

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

Range = <=50 ug/ml to 100 ug/ml

Measurement Parameter

MIC

Unit

µg/ml

Measurement Object

BACTERIAL GROWTH

Qualitative value

<=

Quantitative value

50 - 100

Measurement pX

3.69

Patent; NANOBIO CORPORATION; SUTCLIFFE, Joyce, A.; CIOTTI, Susan, M.; BAKER, James, R., Jr.; WO2010/87964; (2010); (A2) English, View in Reaxys 275 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

In vitro minimum inhibitory concentration (MIC50) of compound against growth of Propionibacterium acnes upon incubation at 35-37 degree C for 48 hours in the absence of 50 sebum by Microtiter assay

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Measurement Parameter

MIC50

Unit

µg/mL

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

157/162

2018-02-22 00:03:45


Measurement Object

BACTERIAL GROWTH

Qualitative value

=

Quantitative value

50

Measurement pX

3.69

Patent; NANOBIO CORPORATION; SUTCLIFFE, Joyce, A.; CIOTTI, Susan, M.; BAKER, James, R., Jr.; WO2010/87964; (2010); (A2) English, View in Reaxys 276 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

In vitro minimum bactericidal concentration (MBC90) of compound against growth of Propionibacterium acnes upon incubation at 35 degree C for 72 hours in the absence of 50 sebum by Microtiter assay

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Measurement Parameter

MBC90

Unit

µg/mL

Measurement Object

BACTERIAL GROWTH

Qualitative value

=

Quantitative value

200

Measurement pX

4.04

Patent; NANOBIO CORPORATION; SUTCLIFFE, Joyce, A.; CIOTTI, Susan, M.; BAKER, James, R., Jr.; WO2010/87964; (2010); (A2) English, View in Reaxys 277 of 289 Substance Effect

Antibiotic

Bioassay Category

In Vitro (Efficacy)

Bioassay Details

In vitro minimum bactericidal concentration (MBC) of compound against growth of Propionibacterium acnes upon incubation at 35 degree C for 72 hours in the absence of 50 sebum by Microtiter assay

Biological Species/NCBI Propionibacterium acnes ID Substance RN

984320View in Reaxys

Qualitative Results

Range = 100 ug/ml to 400 ug/ml

Measurement Parameter

MBC

Unit

µg/ml

Measurement Object

BACTERIAL GROWTH

Quantitative value

100 - 400

Measurement pX

3.38

Patent; NANOBIO CORPORATION; SUTCLIFFE, Joyce, A.; CIOTTI, Susan, M.; BAKER, James, R., Jr.; WO2010/87964; (2010); (A2) English, View in Reaxys 278 of 289 Substance Effect

Antibiotic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Biological Species/NCBI Propionibacterium acnes ATCC 6919 ID Substance RN

984320View in Reaxys

Substance Name

BPO-Table 3, Entry 1; Table 4, Entry 1; Table 5, Entry 1

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

158/162

2018-02-22 00:03:45


Measurement Parameter

MIC

Unit

mg/L

Quantitative value

64

Measurement pX

3.58

Concomitants: Compound RN

1718733; 506008

Concomitants: Compound name

Ethanol; DMSO

Concomitants: Compound role

COM; COM

Desbois, Andrew P.; Lawlor, Keelan C.; Marine Drugs; vol. 11; nb. 11; (2013); p. 4544 - 4557, View in Reaxys 279 of 289 Substance Effect

Antibiotic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Biological Species/NCBI Propionibacterium acnes ATCC 6919 ID Substance RN

984320View in Reaxys

Substance Name

BPO-Table 3, Entry 1; Table 4, Entry 1; Table 5, Entry 1

Measurement Parameter

MBC

Unit

mg/L

Qualitative value

>

Quantitative value

4096

Measurement pX

1

Concomitants: Compound RN

1718733; 506008

Concomitants: Compound name

Ethanol; DMSO

Concomitants: Compound role

COM; COM

Desbois, Andrew P.; Lawlor, Keelan C.; Marine Drugs; vol. 11; nb. 11; (2013); p. 4544 - 4557, View in Reaxys 280 of 289 Substance Effect

Antibiotic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Biological Species/NCBI Staphylococcus aureus subsp. aureus ATCC 43300 ID Substance RN

984320View in Reaxys

Substance Name

BPO-Table 3, Entry 1; Table 4, Entry 1; Table 5, Entry 1

Measurement Parameter

MIC

Unit

mg/L

Quantitative value

512

Measurement pX

2.68

Concomitants: Compound RN

1718733; 506008

Concomitants: Compound name

Ethanol; DMSO

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

159/162

2018-02-22 00:03:45


Concomitants: Compound role

COM; COM

Desbois, Andrew P.; Lawlor, Keelan C.; Marine Drugs; vol. 11; nb. 11; (2013); p. 4544 - 4557, View in Reaxys 281 of 289 Substance Effect

Antibiotic

Bioassay Category

Toxicity/Safety Pharmacology

Bioassay Name

Cell/tumor cell: proliferation/viability/growth

Biological Species/NCBI Staphylococcus aureus subsp. aureus ATCC 43300 ID Substance RN

984320View in Reaxys

Substance Name

BPO-Table 3, Entry 1; Table 4, Entry 1; Table 5, Entry 1

Measurement Parameter

MBC

Unit

mg/L

Quantitative value

512

Measurement pX

2.68

Concomitants: Compound RN

1718733; 506008

Concomitants: Compound name

Ethanol; DMSO

Concomitants: Compound role

COM; COM

Desbois, Andrew P.; Lawlor, Keelan C.; Marine Drugs; vol. 11; nb. 11; (2013); p. 4544 - 4557, View in Reaxys 282 of 289 Substance Effect Bioassay Category

Antibiotic In Vitro (Efficacy)

Biological Species/NCBI Propionibacterium acnes ATCC 6919 ID Substance RN

984320View in Reaxys

Substance Name

dibenzoyl peroxide

Measurement Parameter

MIC

Unit

μM

Quantitative value

62.5

Measurement pX

4.2

Patent; BOARD OF TRUSTEES UNIVERSITY OF ARKANSAS; Song, Peter I.; Armstrong, Cheryl; Ryu, Sunhyo; Park, Yoonkyung; US2014/274879; (2014); (A1) English, View in Reaxys 283 of 289 Substance Effect Bioassay Category

Antibiotic In Vitro (Efficacy)

Biological Species/NCBI Propionibacterium acnes ATCC 11828 ID Substance RN

984320View in Reaxys

Substance Name

dibenzoyl peroxide

Measurement Parameter

MIC

Unit

μM

Quantitative value

62.5

Measurement pX

4.2

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

160/162

2018-02-22 00:03:45


Patent; BOARD OF TRUSTEES UNIVERSITY OF ARKANSAS; Song, Peter I.; Armstrong, Cheryl; Ryu, Sunhyo; Park, Yoonkyung; US2014/274879; (2014); (A1) English, View in Reaxys 284 of 289 Bioassay Category

Pharmacokinetic

Biological Species/NCBI Sprague Dawley rat ID Substance RN

984320View in Reaxys

Substance Name

benzoyl peroxide

Substance Dose

50 mg

Substance Route of Adm.

topical administration

Substance Dosing Regi- Single men Measurement Parameter

Concentration

Unit

μg/g

Quantitative value

146

Patent; DR. REDDY'S LABORATORIES LTD; PATIL, Sushil Kumar; SONI, Rajeev; VAISHNAV, Kaushalesh Kumar; (43 pag.); WO2017/109761; (2017); (A1) English, View in Reaxys 285 of 289 Bioassay Category

Pharmacokinetic

Biological Species/NCBI Sprague Dawley rat ID Substance RN

984320View in Reaxys

Substance Name

benzoyl peroxide

Substance Dose

50 mg

Substance Route of Adm.

topical administration

Substance Dosing Regi- Single men Measurement Parameter

Concentration

Unit

μg/g

Quantitative value

367

Patent; DR. REDDY'S LABORATORIES LTD; PATIL, Sushil Kumar; SONI, Rajeev; VAISHNAV, Kaushalesh Kumar; (43 pag.); WO2017/109761; (2017); (A1) English, View in Reaxys 286 of 289 Substance Effect Bioassay Category

Antibiotic In Vitro (Efficacy)

Biological Species/NCBI Propionibacterium acnes 11827 ID Substance RN

984320View in Reaxys

Substance Name

dibenzoyl peroxide

Measurement Parameter

ZI

Unit

mm

Quantitative value

0-6

Patent; Tagra Biotechnologies Ltd.; Goldstein, Danny; Sade, Tal; Yasman, Yuri; Privalova, Olga; Benaltabet, Lior; (39 pag.); US9682031; (2017); (B2) English, View in Reaxys 287 of 289 Substance Effect Bioassay Category

Antibiotic In Vitro (Efficacy)

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

161/162

2018-02-22 00:03:45


Biological Species/NCBI Propionibacterium acnes 11827 ID Substance RN

984320View in Reaxys

Substance Name

dibenzoyl peroxide

Measurement Parameter

ZI

Unit

mm

Quantitative value

12 - 17

Patent; Tagra Biotechnologies Ltd.; Goldstein, Danny; Sade, Tal; Yasman, Yuri; Privalova, Olga; Benaltabet, Lior; (39 pag.); US9682031; (2017); (B2) English, View in Reaxys 288 of 289 Substance Effect Bioassay Category

Antibiotic In Vitro (Efficacy)

Biological Species/NCBI Propionibacterium acnes 11827 ID Substance RN

984320View in Reaxys

Substance Name

dibenzoyl peroxide

Measurement Parameter

ZI

Unit

mm

Quantitative value

6 - 10

Patent; Tagra Biotechnologies Ltd.; Goldstein, Danny; Sade, Tal; Yasman, Yuri; Privalova, Olga; Benaltabet, Lior; (39 pag.); US9682031; (2017); (B2) English, View in Reaxys 289 of 289 Substance Effect Bioassay Category

Antibiotic In Vitro (Efficacy)

Biological Species/NCBI Propionibacterium acnes 11827 ID Substance RN

984320View in Reaxys

Substance Name

dibenzoyl peroxide

Measurement Parameter

ZI

Unit

mm

Quantitative value

6-8

Patent; Tagra Biotechnologies Ltd.; Goldstein, Danny; Sade, Tal; Yasman, Yuri; Privalova, Olga; Benaltabet, Lior; (39 pag.); US9682031; (2017); (B2) English, View in Reaxys

Copyright © 2018 Reed Elsevier Properties SA. All rights reserved. Authorized use only. Reaxys® and the Reaxys® trademark are owned and protected by Reed Elsevier Properties SA and used under license.

162/162

2018-02-22 00:03:45


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.